

DEPARTMENT OF DEFENSE / NIH NATIONAL CANCER INSTITUTE
CANCER DEMONSTRATION PROJECT

ANALYSIS PLAN: STUDY TO MEASURE THE COST OF
CHAMPUS-ELIGIBLE PARTICIPANTS IN SOUTHWEST ONCOLOGY GROUP
NCI COOPERATIVE PROGRAM
CANCER CLINICAL TRIALS 1988-1996

TECHNICAL REPORT NO. 1


SCOTT A. OPTENBERG, DrPH, GM-15
SANDRA L. SCHNEIDER, DrPH
Center for Healthcare Education and Studies

ARNOLD POTOSKY, PhD
MARY MCCABE, RN
National Cancer Institute

19971230 122

DTIC QUALITY INSPECTED 2

RP 98-002
DECEMBER 1997



UNITED STATES ARMY
MEDICAL DEPARTMENT CENTER AND SCHOOL
FORT SAM HOUSTON, TEXAS 78234-6100

DEPARTMENT OF DEFENSE / NIH NATIONAL CANCER INSTITUTE
CANCER DEMONSTRATION PROJECT

**ANALYSIS PLAN: STUDY TO MEASURE THE COST OF
CHAMPUS-ELIGIBLE PARTICIPANTS IN SOUTHWEST ONCOLOGY GROUP
NCI COOPERATIVE PROGRAM
CANCER CLINICAL TRIALS 1988-1996**

TECHNICAL REPORT NO. 1

SCOTT A. OPTENBERG, DrPH, GM-15
Chief, Analysis Branch

SANDRA L. SCHNEIDER, DrPH
Study Director

Analysis Branch
Center for Healthcare Education and Studies
Academy of Health Sciences

ARNOLD POTOSKY, PhD
Division of Cancer Prevention and Control

MARY MCCABE, RN
Office of Clinical Prevention and Control

National Cancer Institute
Bethesda, Maryland

RP 98-002
DECEMBER 1, 1997

UNITED STATES ARMY
MEDICAL DEPARTMENT CENTER AND SCHOOL
FORT SAM HOUSTON, TEXAS 78234-6100

NOTICE

The findings in this report are
not to be construed as an official
Department of the Defense position
unless so designated by other
authorized documents.

* * * * *

Address of author's organization:

Center for Healthcare Education and Studies (CHES)
ATTN: MCCS-HRN
AMEDDC&S
1608 Stanley Road, Building 2268
Fort Sam Houston, Texas 78234-6125

* * * * *

Reports may be purchased directly from the following:

Defense Technical Information Center (DTIC)
ATTN: DTIC-DDR
Cameron Station
Alexandria, VA 22304-6145

Telephones: DSN 284-7633, 4, or 5
Commercial (703) 274-7633, 4, or 5

U.S. Department of Commerce
National Technical Information Service (NTIS)
5285 Port Royal Road
Springfield, VA 22161

Telephone: Commercial (703) 487-4600

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

| | | | | | |
|---|-------|--|---|---|--------------------------------|
| 1a. REPORT SECURITY CLASSIFICATION Unclassified | | | 1b. RESTRICTIVE MARKINGS | | |
| 2a. SECURITY CLASSIFICATION AUTHORITY | | | 3. DISTRIBUTION / AVAILABILITY OF REPORT Distribution Unlimited; Public Use Authorized. | | |
| 2b. DECLASSIFICATION / DOWNGRADING SCHEDULE | | | | | |
| 4. PERFORMING ORGANIZATION REPORT NUMBER(S) RP 98-002 | | | 5. MONITORING ORGANIZATION REPORT NUMBER(S) | | |
| 6a. NAME OF PERFORMING ORGANIZATION Center for Healthcare Education and Studies (CHES) | | 6b. OFFICE SYMBOL (If applicable) MCCS-HRN | 7a. NAME OF MONITORING ORGANIZATION U. S. Army Medical Department Center and School | | |
| 6c. ADDRESS (City, State, and ZIP Code) Bldg 2268, 1608 Stanley Road Fort Sam Houston, TX 78234-6125 | | | 7b. ADDRESS (City, State, and ZIP Code) Fort Sam Houston, TX 78234-6100 | | |
| 8a. NAME OF FUNDING / SPONSORING ORGANIZATION U. S. Army Medical Department Center and School | | 8b. OFFICE SYMBOL (If applicable) | 9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER | | |
| 8c. ADDRESS (City, State, and ZIP Code) Fort Sam Houston, TX 78234-6100 | | | 10. SOURCE OF FUNDING NUMBERS | | |
| | | PROGRAM ELEMENT NO. | PROJECT NO. | TASK NO. | WORK UNIT ACCESSION NO. |
| 11. TITLE (Include Security Classification) (U) Analysis Plan: Study to Measure the Cost of CHAMPUS-Eligible Participants in Southwest Oncology Group NCI Cooperative Program Cancer Clinical Trials 1988-1996: Technical Report No. 1 | | | | | |
| 12. PERSONAL AUTHOR(S) Scott A. Optenberg, DrPh; Sandra L. Schneider, DrPh; Arnold Potosky, PhD; Mary McCabe, RN | | | | | |
| 13a. TYPE OF REPORT Interim | | 13b. TIME COVERED FROM <u>Oct88</u> TO <u>Sep96</u> | | 14. DATE OF REPORT (Year, Month, Day) 1997 Dec 1 | |
| 15. PAGE COUNT 80 | | | | | |
| 16. SUPPLEMENTARY NOTATION | | | | | |
| 17. COSATI CODES | | | 18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) | | |
| FIELD | GROUP | SUB-GROUP | CHAMPUS, National Cancer Institute, Southwest Oncology, clinical trials, cancer, cost analysis | | |
| | | | | | |
| | | | | | |
| 19. ABSTRACT (Continue on reverse if necessary and identify by block number) The National Cancer Institute's Division of Cancer Treatment, Diagnosis, and Centers (DCTDC) has initiated effort to expand clinical trial participation by proposing coverage agreement of NCI clinical trial participants with various third party payers. An agreement was signed with the Department of Defense (DOD) to allow patients who are beneficiaries of TRICARE/CHAMPUS to participate in, and be reimbursed for, NCI-sponsored clinical cancer treatment trials. This study is a cancer demonstration project pilot study to evaluate the potential cost impact of the NCI/DOD agreement. The initial study phase identified CHAMPUS eligible beneficiaries (CEBs) diagnosed with cancer and enrolled in NCI clinical trials (1988-1996). CEBs treated for cancer of the breast, prostate, colon, lung, leukemia, and lymphoma in phase 2 and 3 adjuvant, advanced/ recurrent disease trials were identified. The second phase of this study will be to determine the cost of the clinical trials by using TRICARE/CHAMPUS claims data from resource utilization of inpatient and outpatient (ambulatory) professional services and institutional costs. CEB enrolled in clinical trials will be compared to a non-trial group disease and clinical matched CEB cancer cases. | | | | | |
| 20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input checked="" type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS | | | 21. ABSTRACT SECURITY CLASSIFICATION Unclassified | | |
| 22a. NAME OF RESPONSIBLE INDIVIDUAL Dr. Scott A. Optenberg | | | 22b. TELEPHONE (Include Area Code) (210) 221-9333 | | 22c. OFFICE SYMBOL MCCS-HRN |

TABLE OF CONTENTS

| SECTION | PAGE |
|---|-------|
| DISCLAIMER..... | ii |
| REPORT DOCUMENTATION PAGE (DD FORM 1473)..... | iii |
| TABLE OF CONTENTS..... | v |
| LIST OF TABLES..... | vi |
| LIST OF FIGURES..... | vii |
| EXECUTIVE SUMMARY..... | 1 |
| METHODS..... | 2 |
| •Study Population..... | 2 |
| •Identification of NCI Clinical Trials..... | 2 |
| •CHAMPUS Eligible Beneficiaries Cancer Classification..... | 2 |
| •CHAMPUS Eligible Beneficiaries Case and Cost Analysis Files..... | 3 |
| RESULTS..... | 3 |
| •Study Population..... | 3 |
| •Demographics of Study Population..... | 3 |
| •CHAMPUS Eligible Beneficiaries Cancer Classification..... | 4 |
| •Cancer Site Distribution of CHAMPUS Eligible Clinical Trials Participants..... | 4 |
| •CHAMPUS Clinical Trials Participants..... | 5 |
| •Clinical Trials Selected for NCI Cooperative Program..... | 6 |
| RESEARCH PHASE..... | 6-7 |
| NCI COOPERATIVE PROGRAM STUDY GROUP..... | 28-29 |
| REFERENCES..... | 30 |
| DISTRIBUTION LIST..... | 31 |

APPENDIX

ICD9CM Cancer Diagnosis For Department of Defense CHAMPUS Patients Enrolled and Treated in NCI Sponsored Clinical Trials.

- Percent Frequency and Prevalence of Site Specific Cancer For In-Patient Professional Services..... A1-A18
- Percent Frequency and Prevalence of Site Specific Cancer For Out-Patient Professional Services..... A19-A36

LIST OF TABLES

| TABLE | PAGE |
|--|------|
| 1 Demographics of Study Population By Gender and Age | 8 |
| 2 Cancer Diagnosis ICD9CM 140-149 (Neoplasm Lip, Oral Cavity, Pharynx) | 8 |
| 3 Cancer Diagnosis ICD9CM 150-159 (Neoplasm Digestive Organs and Peritoneum) | 8 |
| 4 Cancer Diagnosis ICD9CM 160-165 (Neoplasm Respiratory and Intrathoracic Organs) | 9 |
| 5 Cancer Diagnosis ICD9CM 170-176 (Neoplasm Bone, Connective Tissue, Skin, Breast) | 9 |
| 6 Cancer Diagnosis ICD9CM 179-189 (Neoplasm Genitourinary Organs) | 9 |
| 7 Cancer Diagnosis ICD9CM 190-199 (Neoplasm of Other and Unspecified Sites) | 10 |
| 8 Cancer Diagnosis ICD9CM 200-208 (Neoplasm Lymphatic and Hematopoietic Tissue) | 10 |
| 9 Cancer Diagnosis ICD9CM 210-229 (Benign Neoplasm) | 10 |
| 10 Cancer Diagnosis ICD9CM 230-234 (Neoplasm Carcinoma In Situ) | 11 |
| 11 Cancer Diagnosis ICD9CM 235-238 (Neoplasm of Uncertain Behavior) | 11 |
| 12 Cancer Diagnosis ICD9CM 239 (Neoplasm of Unspecified Nature) | 12 |
| 13 CHAMPUS Eligible Beneficiaries - NCI Cancer Prevention Clinical Trials | 13 |
| 14 CHAMPUS Eligible Beneficiaries - NCI Developmental Biology Clinical Trials | 13 |
| 15 CHAMPUS Eligible Beneficiaries - NCI Brain Clinical Trials | 13 |
| 16 CHAMPUS Eligible Beneficiaries - NCI Breast Clinical Trials | 14 |
| 17 CHAMPUS Eligible Beneficiaries - NCI Gastrointestinal Clinical Trials | 15 |
| 18 CHAMPUS Eligible Beneficiaries - NCI Genitourinary System Clinical Trials | 16 |
| 19 CHAMPUS Eligible Beneficiaries - NCI Gynecological Clinical Trials | 17 |
| 20 CHAMPUS Eligible Beneficiaries - NCI Head and Neck Clinical Trials | 17 |
| 21 CHAMPUS Eligible Beneficiaries - NCI Leukemia Clinical Trials | 18 |
| 22 CHAMPUS Eligible Beneficiaries - NCI Lung Clinical Trials | 19 |
| 23 CHAMPUS Eligible Beneficiaries - NCI Lymphoma Clinical Trials | 20 |
| 24 CHAMPUS Eligible Beneficiaries - NCI Melanoma Clinical Trials | 20 |
| 25 CHAMPUS Eligible Beneficiaries - NCI Myeloma Clinical Trials | 21 |
| 26 CHAMPUS Eligible Beneficiaries - NCI Sarcoma Clinical Trials | 21 |
| 27 NCI Clinical Trials SWOG /DEERS Matched Cases By Breast Tumor | 22 |
| 28 NCI Clinical Trials SWOG /DEERS Matched Cases By Prostate Tumor | 23 |
| 29 NCI Clinical Trials SWOG /DEERS Matched Cases By Leukemia Tumor | 24 |
| 30 NCI Clinical Trials SWOG /DEERS Matched Cases By Lymphoma Tumor | 25 |
| 31 NCI Clinical Trials SWOG /DEERS Matched Cases By Colon/Rectal Tumor | 26 |
| 32 NCI Clinical Trials SWOG /DEERS Matched Cases By Lung Tumor | 27 |

LIST OF FIGURES

| FIGURE | PAGE |
|--|------|
| 1 Schema: Selection of CHAMPUS Eligible Participants in NCI Clinical Trials..... | 8 |
| 2 CHAMPUS Eligible Participants in NCI Clinical Trials..... | 13 |

Analysis Plan: Study To Measure The Cost of CHAMPUS-Eligible Participants in Southwest Oncology Group NCI Cooperative Program Cancer Clinical Trials 1988-1996

EXECUTIVE SUMMARY

Cancer is projected to be the number one cause of death, within the next decade, in the United States. A national effort is under way, to not only understand the cause and prevention of cancer, but to identify the costs associated with treatment, control and prevention of cancer (1). The National Cancer Institutes (NCI) Division of Cancer Treatment, Diagnosis, and Centers (DCTDC) has initiated efforts to expand clinical trial participation by proposing coverage agreements for NCI clinical trials participants with various third party payers. As part of a cancer demonstration project, the Department of Defense (DOD) and NCI have an agreement to evaluate the cost to treat CHAMPUS eligible beneficiaries (CEBs), diagnosed and enrolled, in NCI sponsored Southwest Oncology Group (SWOG) clinical trials from 1988-1996.

The data files from the Defense Enrollment Eligibility Reporting System (DEERS), were used to identify CEBs, enrolled in SWOG clinical trials. During 1988-1996, 69,435 cancer patients were enrolled in 423 NCI sponsored clinical trials. Of this group, 5,234 CEBs received treatment in 170 of the clinical trials. The distribution of CEBs participating in clinical trials, by specific cancer sites, was 59.1% chemoprevention trials; 10.1% breast; 7.9% genitourinary (GU); 6.6% gastrointestinal (GI); 3.5% lymphoma; 3.1% lung; 2.4% leukemia; 1.9% gynecological (GYN); 1.3% melanoma; 0.8% brain; 0.6% head and neck, and sarcoma; and 0.2% developmental biology clinical trials. Major organ site studies in which CEBs were treated included: 29 breast, 21 prostate, 30 lung, 25 colon, 19 leukemia and 46 lymphoma (lymphoma, melanoma, multiple myeloma, sarcoma) clinical trials. The study population demographics included 1178 (22.1%) females and 4056 (77.49%) males. The International Classification of Diseases ICD9CM neoplasm codes (140-239) were used to identify site specific cancer sites. CHAMPUS claims data were selected for ICD9CM neoplasm codes 140-239. Claims data were used to determine frequency and prevalence of organ specific cancer in the CHAMPUS population.

The analysis portion of this research study will determine the cost of phase 2 and 3 clinical trials that provided treatment, intervention and evaluation of adjuvant, advanced or recurrent disease. The cost of cancer treatment for CEBs enrolled in clinical trials, compared to CEBs with cancer not enrolled in clinical trials, will be determined using CHAMPUS professional services records as a detailed account of inpatient, outpatient, and institutional cancer treatment services. The evaluation of costs and benefits associated with the efficacy of cancer treatment must be understood as part of the risks and interventions associated with cancer, and the clinical management of cancer. This study contributes directly to NCI's overall goal to expand participation of cancer patients in clinical research studies. Information from this pilot study also will give NCI guidelines to negotiate coverage agreements with other health care payers for cancer clinical trials.

METHODS

Study Population

The study population for the cancer demonstration project was CHAMPUS eligible beneficiaries (CEBs) who met diagnostic protocol eligibility criteria to participate in the National Institutes of Health, National Cancer Institute (NCI) cancer treatment clinical trials for the years 1988-1996. CEBs were selected from the Army, Air Force, Navy, and Coast Guard branches of the Department of Defense (DOD) services. CEBs were identified by the Defense Enrollment Eligibility Reporting System (DEERS). DEERS is a computer-based system that establishes and reports the eligibility status of DOD beneficiaries for various services, to include care at medical treatment facilities (MTF).

Identification of NCI Clinical Trials

CEBs enrolled and treated in NCI clinical trials were identified by linking the DEERS data files with the Southwest Oncology Group (SWOG) 1988-1996 cancer trials database. The SWOG and DEERS data files were linked by name, age, date of birth (DOB), race, sponsor social security number (SSN), and dependent social security number (DSSN). The DEERS/SWOG data sets were matched by the following criteria: SSN eligible and non-eligible; DSSN eligible active duty, eligible retired, non-eligible active duty, non-eligible retired; dependents by name and DOB for eligible active duty, eligible retired, non-eligible active duty, and non-eligible retired. Patient discrepancies, duplications, and matches, within the DEERS and SWOG databases, were verified. To quality control the study population data variables, only exact CEBs and SWOG matches were used.

CHAMPUS Eligible Beneficiaries Cancer Classification

The International Classification of Diseases ICD 9 CM Neoplasm, Codes 140-239, was used to identify site specific cancer in the study population. The CHAMPUS claims data was used to identify beneficiaries with ICD9CM cancer codes 140-239 during the years 1988-1996. For simplicity in reporting, the ICD9CM cancer codes were group by major cancer organ sites: 140-149 (neoplasm lip, oral cavity, pharynx); 150-159 (neoplasm digestive organs and peritoneum); 160-165 neoplasm respiratory and intrathoracic organs); 170-176 (neoplasm bone, connective tissue, skin, breast); 179-189 (neoplasm genitourinary organs); 190-199 (neoplasm of other and unspecified sites); 200-208 (neoplasm lymphatic and hematopoietic tissue); 210-229 (benign neoplasm); 230-234 (neoplasm carcinoma in situ); 235-238 (neoplasm of uncertain behavior); and 239 (neoplasm of unspecified nature).

Percent (%) frequency of cancer diagnosis was determined as the number of specified ICD9CM cancer cases divided by the total number of all cancer cases in the time period selected. The formula used to calculate % frequency was: $\% \text{ Frequency} = \text{Total Number ICD9CM Cancer Cases} \div \text{Total Number of Cancer Cases}$. Cancer prevalence was determined as the total number of specified ICD9CM cancer cases divided by the population of professional services users at risk for cancer during a time point, as determined by fiscal year (FY). The formula used to calculate cancer prevalence was: $\text{Prevalence} = \text{Total Number of ICD9CM Cancer Cases} \div \text{Total Population of FY CHAMPUS Beneficiaries}$. The total number, or population, of CHAMPUS beneficiaries, for each year, was used as the denominator to determine cancer prevalence for inpatient and outpatient professional services. The denominators for in-patient institutional

professional services were: 300815 (FY88), 279,493 (FY89), 268,455 (FY90), 261205 (FY91), 246,607 (FY92), 218,056 (FY93), 200,160 (FY94), 195,248 (FY95), 173,265 (FY96). The denominators for out-patient (ambulatory) professional services were: 1,726,444 (FY88), 1,989,7784 (FY89), 2,303,450 (FY90), 2,319,445 (FY91), 2,182,878 (FY92), 2,110,066 (FY93), 2,0087,951 (FY94), 2,032,367 (FY95), 1,979,137 (FY96). The number of TRICARE/CHAMPUS user beneficiaries (DOD and non-DOD combined) by in-patient or out-patient category of care, for each fiscal year, was obtained from the DOD Information Systems Division, Statistics Branch (2,3).

CHAMPUS Eligible Beneficiaries Case and Cost Analysis Files

The CHAMPUS eligible beneficiaries data files, from the TRICARE/CHAMPUS Healthcare Program Information System for fiscal years 1988-1996, were used to prepare case file and cost analysis files. The original files consisted of 974 tapes by fiscal years (FY88-96) and branch of service, to include: Army, Air Force, Navy, and Coast Guard. Coast Guard data were available for FY90, FY91, FY93, and FY95. The case files were constructed as one record per person, and contained a summary of main patient-level variables for sociodemographic, socioeconomic, and clinical study variables. The cost analysis files contained all claims data information from CHAMPUS and non-CHAMPUS providers for Inpatient and Outpatient professional services, and institutional expenditures from resource utilization.

RESULTS

Study Population

The study population was derived from 14,557,571 patients identified in the 1988-1996 DEERS data base (**Figure 1**). The DEERS data base was merged with the SWOG data base, which contained 69,435 patients enrolled and treated in 423 trials during the years 1988-1996. This SWOG/DEERS selection identified 5,234 CEBs who were enrolled and treated for cancer in 279 clinical trials. The CEBs accounted for 7.5% of all patients enrolled and treated in NCI sponsored clinical trials during the years 1988-1996. From the CEBs enrolled and treated in clinical trials, a study population was selected based on the major cancer organ site clinical trials. The initial case group consisted of 4,653 (89%) patients enrolled and treated in 170 (61%) of the clinical SWOG clinical trials. These patients were enrolled in 29 breast, 21 prostate, 30 lung, 25 colon, 19 leukemia, and 46 lymphoma clinical trials.

Demographics of Study Population

CEBs enrolled and treated in NCI clinical trials were identified by gender and age (**Table 1**). The 5,234 clinical trial participants consisted of 1178 (22.1%) females and 4056 (77.49%) males. The age distribution of participants was: 4 females (0.08%) and 4 males (0.08%) in <20 years of age; 72 (1.38%) females and 25 (0.86%) males in 20-29 years of age; 143 females (2.73%) and 66 (1.26%) males in 30-39 years of age; 237 (4.53%) females and 103 (1.97%) males in 40-49 years of age; 334 females (6.38%) females and 605 (11.56%) males in 50-59 years of age; 366 females (6.99%) and 2289 (43.73%) males in 60-69 years of age, and 22 (0.44%) females and 944 (18.04%) males in ≥70 years of age. Race was not available from the DEERS or SWOG data files. Race and other demographic variables will be determined from the DOD Automated Central Tumor Registry (ACTUR) in a later phase of the study.

CHAMPUS Eligible Beneficiaries (CEBs) Cancer Classification

ICD9CM neoplasm codes were used to classify the specific cancer sites in the study population (**Appendices A, B**). The major cancer organ sites were grouped by ICD9CM codes to include: 140-149 (neoplasm lip, oral cavity, pharynx); 150-159 (neoplasm digestive organs and peritoneum); 160-165 (neoplasm respiratory and intrathoracic organs); 170-176 (neoplasm bone, connective tissue, skin, breast); 179-189 (neoplasm genitourinary organs); 190-199 (neoplasm of other and unspecified sites); 200-208 (neoplasm lymphatic and hematopoietic tissue); 210-229 (benign neoplasm); 230-234 (neoplasm carcinoma in situ); 235-238 (neoplasm of uncertain behavior); and 239 (neoplasm of unspecified nature). There were 186,734 CEBs identified, from CHAMPUS claims data, as having cancer for the years 1988-1996. These patients accounted for 1,119,156 claims, of which 342,395 were associated with Inpatient professional services, and 776,395 were associated with Outpatient (ambulatory) professional services. The percent (%) frequency and prevalence of cancer by ICD9CM neoplasm codes for CEBs is presented in **Tables 2-12**.

The percent frequency and prevalence of cancer was similar for the Inpatient and Outpatient (ambulatory) professional services. Inpatient professional services for neoplasm of bone, connective tissue, skin, and breast (170-176) were slightly higher than those observed for out-patient services. Outpatient professional services calculations for GI (150-159), and respiratory (160-165) were slightly higher than those observed for in-patient services. A linear use of ICD9CM 239 (neoplasm of unspecified nature), in both Inpatient and Outpatient professional services was observed over the nine year time period. By ICD9CM codes, the greatest frequency of cancer sites for in-patient professional services, years 1988-1996, was: 210-220 (benign neoplasm) > 170-176 (bone, skin, breast) > 190-176 (other and unspecified) > 179-189 (GU) > 160-165 (respiratory and intrathoracic) > 150-159 (GI) > 200-208 (lymphatic and hematopoietic) > 235-238 (uncertain) > 230-234 (in situ) > 140-149 (lip, oral cavity, pharynx). The greatest frequency of cancer sites for out-patient professional services, years 1988-1996, was: 210-220 (benign neoplasm) > 190-176 (other and unspecified) > 170-176 (bone, skin, breast) > 160-165 (respiratory and intrathoracic) > 179-189 (GU) > 150-159 (GI) > 200-208 (lymphatic and hematopoietic) > 235-238 (uncertain) > 230-234 (in situ) > 140-149 (lip, oral cavity, pharynx). The trends for cancer prevalence followed the trends in frequency. Prevalence was higher when calculated using Outpatient records for all ICD9CM groups for all years. Statistical modeling will be used in the analysis portion of the study to determine if statistical differences exist between Inpatient and Outpatient professional services utilization, in relationship to cancer diagnosis.

Cancer Site Distribution of CHAMPUS Eligible Clinical Trial Participants

The distribution of organ specific cancer site clinical trials within the CEBs from 1988-1996 was determined (**Figure 2**). The greatest percentage of CEBs were enrolled and treated in the chemoprevention/cancer cure (cc) trials (59.1%). Of this population, 0.04% participated in the compliance, breast self exam education trial, and 96% participated in the chemoprevention of prostate cancer with Finasteride (Proscar), phase III, inter-group study. The remaining cancer sites included: 10.1% breast; 7.9% genitourinary (GU); 6.6% gastrointestinal (GI); 3.5% lymphoma; 3.1% lung; 2.4% leukemia; 1.9% gynecological (GYN) and myeloma; 1.3% melanoma; 0.8% brain; 0.6% head and neck, sarcoma; and 0.2% developmental biology clinical trials.

CHAMPUS Clinical Trials Participants

CEBs enrolled and treated in the NCI clinical trials were identified by cancer study type, study identification number, and sponsored clinical trial phase. The total number of SWOG clinical trials participants 1988-1996 was 69,435 patients, distributed in 423 sponsored clinical trials. The DEERS database identified and matched 5,234 CEBs cancer patients, or 7.5% of the total clinical trials population, as enrolled and treated in 279 (66%) of the clinical trials. The clinical trials, categorized by administrative cancer sites, were characterized by NCI study identification code, trial phase, total N of trial, N of DEERS matched, and % enrollment of CEBs participating in each clinical trial (*Tables 13-26*). Following are summaries of Tables 13-26.

- Table 13.* Cancer prevention trials included 20,157 participants, of whom 3091 (15.30%) were enrolled in DEERS. Five percent (5%) of the participants in the compliance breast self examination education trial were CEBs, and 16.76% of the prostate chemoprevention participants were CEBs.

- Table 14.* Developmental biology trials included 118 participants, of which 8 (6.8%) were DEERS enrolled. These trials included four (4) trials of non-specified advanced cancers with various chemotherapeutics.

- Table 15.* Brain trials included 1,048 participants, of which 42 (4%) were DEERS enrolled. These trials included both solid and CNS tumors.

- Table 16.* Breast trials included 13,308 participants, of which 531 (4%) were DEERS enrolled.

- Table 17.* Gastrointestinal (GI) trials included 7,366 participants, of which 346 (4.7%) were DEERS enrolled. These trials included gastric, colon, colorectal, esophageal, pancreas, and hepatic cancer sites.

- Table 18.* Genitourinary (GU) trials included 6,282 participants, of which 415 (6.6%) were DEERS enrolled. These trials included prostate, bladder, penis, testis, and renal cancer sites.

- Table 19.* Gynecological (GYN) trials included 2,031 participants, of which 99 (4.9%) were DEERS enrolled. These trials included ovarian, cervical, and peritoneal cancer sites.

- Table 20.* Head and neck trials included 858 participants, of which 31 (3.6%) were DEERS enrolled. The head and neck trials included nasopharyngeal cancer sites.

- Table 21.* Leukemia trials included 3400 participants, of which 127 (3.7%) were DEERS enrolled. These trials included ANL, ALL, AL, CML, CLL, AML, and B-CLL cancer sites.

- Table 22.* Lung trials included 3,269 participants, of which 165 (5.1%) were DEERS enrolled. These trials included small cell and non-small cell cancer sites.

- Table 23.* Lymphoma trials included 3,969 participants, of which 183 (4.6%) were DEERS enrolled. These trials included non-Hodgkin's and Hodgkin's lymphoma, and AIDS.

- Table 24.* Melanoma trials included 1,689 participants, of which 66 (3.9%) were DEERS enrolled.

•*Table 25.* Multiple myeloma trials included 1,984 participants, of which 97 (4.9%) were DEERS enrolled.

•*Table 26.* Sarcoma trials included 333 participants, of which 819 (4%) were DEERS enrolled.

Clinical Trials Selected for NCI Cooperative Program

This study focused on the selection of clinical trials for the major cancer organ sites. Of the original 279 clinical trials, 170 were selected for the pilot study. The NCI clinical trials, for the SWOG/DEERS matched cases, were identified by cancer organ site study ID, phase, trial, and number of participants in the adjuvant, advanced/recurrent disease stage, or other category of the trial (Tables 27-32). There were 4,653 CEBs identified, as SWOG/DEERS matched cases, that received treatment in the 170 trials. These clinical trials included: 29 breast trials; 21 prostate trials; 19 leukemia trials; 46 lymphoma (lymphoma, melanoma, multiple myeloma, sarcoma) trials; 25 colon/rectal trials; and 30 lung trials. The clinical trials included participation by SWOG, Eastern Cooperative Oncology Groups (ECOG), North Central Cancer Treatment Group (NCCTG), Veterans Administration Prostate Intervention vs Observation Trials (VA PIVOT). Trials included the Cancer and Leukemia Group B (CALGVB) study, Quality of Life (QOL) study, and Prostate Cancer Prevention Trial (PCPT) study.

•*Table 27.* The 29 breast tumor trials included phase-3, phase-2, and cancer control studies. The number of patients in the various phase trials included: 400 adjuvant studies (399 phase-3 and 1 cancer control study); 37 advanced cancer studies (30 phase-3, and 7 phase-2); and 203 other studies (74 phase-3, 6 phase-2 and 123 in cancer control).

•*Table 28.* The 21 prostate tumor clinical trials included phase-3, phase-2, and cancer control studies. The number of patients in the various phase trials included: 63 adjuvant (55 phase-3 and 8 phase-2); 2969 advanced cancer (2968 cancer control and 1 phase-2); and 239 other studies (111 phase-3, 27 phase-2, and 101 cancer control).

•*Table 29.* The 19 leukemia clinical trials included phase-3, phase-2,3, phase-2, and phase-1 studies. There were 89 patients in the various leukemia trials: 72 phase-3, 15 phase-2, 1 phase-2,3, and 3 phase-1 studies.

•*Table 30.* The 46 lymphoma clinical trials included phase-3, phase-2, phase-1, and pilot studies. Three hundred (300) patients were in the various lymphoma studies: 215 phase-3, 73 phase-2, 1 phase-1, and 11 pilot studies.

•*Table 31.* The 25 colon/rectal tumor clinical trials included phase-3, phase-2, phase-1, pilot, and cancer control studies. The number of patients in the phase trials included: 194 adjuvant (192 phase-3, 1 phase-2, 1 pilot), 37 advanced cancer (20 phase-3, 16 phase-2, 3 phase-2,3), and 41 other cancer studies (4 phase-3, 26 pilot, 11 cancer control)

•*Table 32.* The 30 lung tumor clinical trials included phase-3 and phase-2 studies. The number of patients in the phase trials included: 16 adjuvant (3 phase-3, 13 phase-2), 41 advanced (22 phase-3, 19 phase-2), and 108 other studies (85 phase-3, 23 phase-2).

Phase 2 Research

Phase 2 of this pilot study will complete the cost analysis of the cancer clinical trials cooperative program. Patients identified in the phase 2 and 3 trials of adjuvant therapy or advanced/recurrent disease will be matched, according to clinical disease identifiers, with a comparison group of cancer patients in the CHAMPUS program, who were not enrolled in clinical trials. CHAMPUS claims data for professional inpatient and outpatient (ambulatory) services will be combined with institutional resource utilization data to compare the costs of trial and non-trial treatment for the major cancer organ sites.




Figure 1. Schema: Selection of analysis study group from CHAMPUS eligible beneficiaries (CEBs) identified in Defense Enrollment Eligibility Reporting System (DEERS) as enrolled and treated in Southwest Oncology Group (SWOG) cancer clinical trials sponsored by the National Cancer Institute.

Table 1: Demographics of Study Population By Gender and Age

| Age | Females | | Males | | Total | |
|-------|---------|-------|-------|-------|-------|-------|
| | N | % | N | % | N | % |
| <20 | 4 | 0.08 | 4 | 0.08 | 8 | 0.15 |
| 20-29 | 72 | 1.38 | 45 | 0.86 | 117 | 2.24 |
| 30-39 | 143 | 2.73 | 66 | 1.26 | 209 | 3.99 |
| 40-49 | 237 | 4.53 | 103 | 1.97 | 340 | 6.50 |
| 50-59 | 334 | 6.38 | 605 | 11.56 | 939 | 17.94 |
| 60-69 | 366 | 6.99 | 2289 | 43.73 | 2655 | 50.73 |
| ≥70 | 22 | 0.42 | 944 | 18.04 | 966 | 18.46 |
| TOTAL | 1178 | 22.51 | 4056 | 77.49 | 5234 | 100 |

Table 2: Cancer Diagnosis ICD9CM 140-149 (Neoplasm Lip, Oral Cavity, Pharynx)

| Fiscal Year | In Patient Services | | Out Patient Services | |
|-------------|---------------------|------------|----------------------|------------|
| | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 1.93 | 0.07 | 1.74 | 0.20 |
| 1989 | 1.95 | 0.07 | 1.58 | 0.20 |
| 1990 | 2.02 | 0.07 | 1.76 | 0.23 |
| 1991 | 1.90 | 0.08 | 1.45 | 0.23 |
| 1992 | 1.90 | 0.08 | 1.50 | 0.24 |
| 1993 | 1.84 | 0.09 | 1.56 | 0.31 |
| 1994 | 1.84 | 0.08 | 1.42 | 0.29 |
| 1995 | 1.89 | 0.08 | 1.51 | 0.29 |
| 1996 | 1.76 | 0.08 | 1.46 | 0.30 |

Table 3: Cancer Diagnosis ICD9CM 150-159 (Neoplasm Digestive Organs and Peritoneum)

| Fiscal Year | In Patient Services | | Out Patient Services | |
|-------------|---------------------|------------|----------------------|------------|
| | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 7.95 | 0.28 | 9.02 | 1.06 |
| 1989 | 7.97 | 0.28 | 9.42 | 1.17 |
| 1990 | 8.09 | 0.28 | 9.87 | 1.30 |
| 1991 | 8.02 | 0.33 | 9.83 | 1.56 |
| 1992 | 8.01 | 0.35 | 9.58 | 1.52 |
| 1993 | 8.07 | 0.37 | 9.44 | 1.80 |
| 1994 | 8.38 | 0.40 | 9.69 | 1.92 |
| 1995 | 8.48 | 0.37 | 10.28 | 1.95 |
| 1996 | 8.47 | 0.38 | 10.09 | 2.06 |

Table 4: Cancer Diagnosis ICD9CM 160-165 (Neoplasm Respiratory and Intrathoracic Organs)

| In Patient Services | | | Out Patient Services | |
|---------------------|-------------|------------|----------------------|------------|
| Fiscal Year | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 8.47 | 0.29 | 11.04 | 1.29 |
| 1989 | 8.56 | 0.30 | 11.72 | 1.46 |
| 1990 | 8.29 | 0.28 | 10.95 | 1.44 |
| 1991 | 8.20 | 0.34 | 10.79 | 1.71 |
| 1992 | 8.39 | 0.36 | 11.06 | 1.75 |
| 1993 | 8.22 | 0.38 | 10.49 | 2.08 |
| 1994 | 8.16 | 0.39 | 10.56 | 2.14 |
| 1995 | 8.07 | 0.36 | 10.44 | 1.98 |
| 1996 | 8.07 | 0.37 | 10.25 | 2.10 |

Table 5: Cancer Diagnosis ICD9CM 170-176 (Neoplasm Bone, Connective Tissue, Skin, Breast)

| In Patient Services | | | Out Patient Services | |
|---------------------|-------------|------------|----------------------|------------|
| Fiscal Year | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 15.72 | 0.55 | 12.02 | 1.41 |
| 1989 | 16.29 | 0.57 | 11.60 | 1.45 |
| 1990 | 16.28 | 0.56 | 11.58 | 1.53 |
| 1991 | 16.25 | 0.67 | 11.43 | 1.81 |
| 1992 | 16.90 | 0.73 | 11.13 | 1.77 |
| 1993 | 16.65 | 0.77 | 10.46 | 2.08 |
| 1994 | 17.28 | 0.83 | 10.56 | 2.14 |
| 1995 | 18.07 | 0.80 | 10.60 | 2.02 |
| 1996 | 18.64 | 0.89 | 10.37 | 2.12 |

Table 6: Cancer Diagnosis ICD9CM 179-189 (Neoplasm Genitourinary Organs)

| In Patient Services | | | Out Patient Services | |
|---------------------|-------------|------------|----------------------|------------|
| Fiscal Year | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 7.58 | 0.26 | 9.16 | 1.07 |
| 1989 | 8.16 | 0.28 | 9.85 | 1.23 |
| 1990 | 8.38 | 0.29 | 9.85 | 1.30 |
| 1991 | 8.58 | 0.36 | 9.77 | 1.55 |
| 1992 | 9.47 | 0.41 | 10.76 | 1.71 |
| 1993 | 9.97 | 0.46 | 10.97 | 2.18 |
| 1994 | 10.34 | 0.50 | 10.93 | 2.22 |
| 1995 | 11.03 | 0.49 | 11.47 | 2.18 |
| 1996 | 11.07 | 0.50 | 11.37 | 2.33 |

Table 7: Cancer Diagnosis ICD9CM 190-199 (Neoplasm of Other and Unspecified Sites)

| In Patient Services | | | Out Patient Services | |
|---------------------|-------------|------------|----------------------|------------|
| Fiscal Year | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 14.53 | 0.51 | 13.19 | 1.54 |
| 1989 | 13.86 | 0.48 | 13.43 | 1.68 |
| 1990 | 13.18 | 0.45 | 12.77 | 1.68 |
| 1991 | 12.45 | 0.52 | 12.66 | 2.00 |
| 1992 | 12.03 | 0.52 | 12.54 | 1.99 |
| 1993 | 11.48 | 0.53 | 11.87 | 2.36 |
| 1994 | 11.17 | 0.54 | 11.45 | 2.32 |
| 1995 | 11.20 | 0.49 | 11.59 | 2.20 |
| 1996 | 10.93 | 0.50 | 11.83 | 2.42 |

Table 8: Cancer Diagnosis ICD9CM 200-208 (Neoplasm Lymphatic and Hematopoietic Tissue)

| In Patient Services | | | Out Patient Services | |
|---------------------|-------------|------------|----------------------|------------|
| Fiscal Year | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 5.95 | 0.21 | 5.42 | 0.64 |
| 1989 | 5.94 | 0.21 | 5.51 | 0.69 |
| 1990 | 5.97 | 0.20 | 5.69 | 0.75 |
| 1991 | 6.58 | 0.27 | 6.10 | 0.97 |
| 1992 | 5.81 | 0.25 | 5.77 | 0.91 |
| 1993 | 8.04 | 0.37 | 6.92 | 1.37 |
| 1994 | 6.66 | 0.32 | 6.83 | 1.39 |
| 1995 | 6.55 | 0.29 | 6.64 | 1.26 |
| 1996 | 6.71 | 0.30 | 6.57 | 1.34 |

Table 9: Cancer Diagnosis ICD9CM 210-229 (Benign Neoplasm)

| In Patient Services | | | Out Patient Services | |
|---------------------|-------------|------------|----------------------|------------|
| Fiscal Year | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 19.15 | 0.67 | 22.00 | 2.57 |
| 1989 | 19.53 | 0.68 | 20.79 | 2.57 |
| 1990 | 20.08 | 0.69 | 21.51 | 2.83 |
| 1991 | 19.69 | 0.82 | 21.15 | 3.35 |
| 1992 | 19.62 | 0.86 | 21.66 | 3.43 |
| 1993 | 19.32 | 0.89 | 22.39 | 4.45 |
| 1994 | 19.37 | 0.94 | 22.65 | 4.60 |
| 1995 | 18.90 | 0.83 | 22.97 | 4.37 |
| 1996 | 19.15 | 0.87 | 23.93 | 4.89 |

Table 10: Cancer Diagnosis ICD9CM 230-234 (Neoplasm Carcinoma In Situ)

| In Patient Services | | | Out Patient Services | |
|---------------------|-------------|------------|----------------------|------------|
| Fiscal Year | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 2.93 | 0.10 | 3.15 | 0.37 |
| 1989 | 3.45 | 0.12 | 3.50 | 0.44 |
| 1990 | 3.42 | 0.12 | 3.33 | 0.44 |
| 1991 | 3.78 | 0.16 | 3.56 | 0.56 |
| 1992 | 3.60 | 0.16 | 3.33 | 0.53 |
| 1993 | 3.35 | 0.15 | 3.35 | 0.67 |
| 1994 | 3.48 | 0.17 | 3.47 | 0.71 |
| 1995 | 3.22 | 0.14 | 3.04 | 0.58 |
| 1996 | 3.10 | 0.14 | 2.75 | 0.56 |

Table 11: Cancer Diagnosis ICD9CM 235-238 (Neoplasm of Uncertain Behavior)

| In Patient Services | | | Out Patient Services | |
|---------------------|-------------|------------|----------------------|------------|
| Fiscal Year | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 2.94 | 0.10 | 2.56 | 0.30 |
| 1989 | 3.02 | 0.11 | 2.80 | 0.35 |
| 1990 | 3.32 | 0.11 | 3.05 | 0.40 |
| 1991 | 3.85 | 0.16 | 3.34 | 0.53 |
| 1992 | 4.25 | 0.18 | 3.76 | 0.60 |
| 1993 | 4.38 | 0.20 | 4.13 | 0.82 |
| 1994 | 4.78 | 0.23 | 3.99 | 0.81 |
| 1995 | 4.82 | 0.21 | 3.70 | 0.70 |
| 1996 | 5.04 | 0.23 | 4.47 | 0.91 |

Table 12: Cancer Diagnosis ICD9CM 239 (Neoplasm of Unspecified Nature)

| In Patient Services | | | Out Patient Services | |
|---------------------|-------------|------------|----------------------|------------|
| Fiscal Year | % Frequency | Prevalence | % Frequency | Prevalence |
| 1988 | 12.80 | 0.45 | 10.64 | 1.24 |
| 1989 | 11.31 | 0.39 | 9.42 | 1.17 |
| 1990 | 10.92 | 0.38 | 9.65 | 1.27 |
| 1991 | 10.70 | 0.44 | 9.94 | 1.57 |
| 1992 | 9.73 | 0.42 | 8.91 | 1.41 |
| 1993 | 8.68 | 0.40 | 8.40 | 1.67 |
| 1994 | 8.56 | 0.41 | 8.44 | 1.71 |
| 1995 | 7.77 | 0.34 | 7.76 | 1.48 |
| 1996 | 6.71 | 0.30 | 6.90 | 1.41 |




Figure 2. Distribution of CHAMPUS eligible beneficiaries (CEBs) (N = 5,234) in NCI cancer clinical trials by cancer site.

Table 13: CHAMPUS Eligible Beneficiaries - NCI Cancer Prevention Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|---------------------------|-------|------------|------------------|---------------|
| S8807 | Compliance, BSE Education | cc | 2451 | 123 | 5.02 |
| S9217 | Prostate Chemoprevention | cc | 17706 | 2968 | 16.76 |
| TOTAL | | | 20157 | 3091 | 15.30 |

Table 14: CHAMPUS Eligible Beneficiaries - NCI Developmental Biology Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|-------------------------------------|-------|------------|------------------|---------------|
| S8902 | Multiple Advanced ADR+CBRA+/-GM-CSF | I | 21 | 1 | 4.76 |
| S8940 | Multiple Advanced IL-1/VP-16/CBRA | I | 64 | 5 | 7.81 |
| S9026 | IL-3, VP-16, CBDCA | I | 32 | 1 | 3.13 |
| S9112 | Multiple Advanced Chemo+GM-CS+IL-2 | I | 1 | 1 | 100.00 |
| TOTAL | | | 118 | 8 | 6.80 |

Table 15: CHAMPUS Eligible Beneficiaries - NCI Brain Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|---------------------------------|-------|------------|------------------|---------------|
| S8737 | Glioma, AZQ vs BCNU | III | 246 | 7 | 2.85 |
| S8829 | CNS, Amonafide | II | 29 | 1 | 3.45 |
| S8834 | CNS Tumors, Fazarabine | II | 27 | 1 | 3.70 |
| S9005 | Meningioma, RU-486 vs Placebo | III | 184 | 3 | 1.63 |
| S9016 | Brain, RT+CDDP/BCNU | II | 74 | 6 | 8.11 |
| S9021 | Brain Met, Post-OP RT vs Obs | III | 54 | 1 | 1.85 |
| S9110 | Brain, Adv, STG III-IV, PH II | II | 48 | 4 | 8.33 |
| S9149 | REC AA/GBM, HU+ARC+CDDP | II | 57 | 2 | 3.51 |
| S9310 | CNS Lymphoms, Comb Modlity | II | 31 | 1 | 3.23 |
| S9340 | Astro, RT+PCV+BUDR, RTOG | III | 50 | 3 | 6.00 |
| S9402 | Oligodendro, Chemo +RT, RTOG | III | 22 | 1 | 4.55 |
| S9436 | REC Glioma, Taxol PHI-II, NABTC | I-II | 57 | 2 | 3.51 |
| S9462 | Solid Tumors, BCNU/TEM, NABTC | I | 45 | 2 | 4.44 |
| S9503 | GBM/GS, BCNU+(H)RT+(P), NCCTG | III | 124 | 8 | 6.45 |
| TOTAL | | | 1048 | 42 | 4.00 |

Table 16: CHAMPUS Eligible Beneficiaries - NCI Breast Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|---|-------|------------|------------------|---------------|
| S7827 | Stage II, Adjuvant | III | 193 | 13 | 6.74 |
| S8312 | Adjuvant ER+, 2 nd Endocrine | III | 141 | 5 | 3.55 |
| S8313 | Stage II, ER-, Comb Chemo | III | 297 | 15 | 5.05 |
| S8366 | TI-3 NO-1. Cell Kinetics | III | 370 | 4 | 1.08 |
| S8568 | Stage III or IV, Comb Mod | II | 34 | 1 | 2.94 |
| S8621 | Advanced ER/PGR-, Post Phase | III | 63 | 3 | 4.76 |
| S8692 | Advanced ER/PGR-, Pre Phase | III | 138 | 1 | 0.72 |
| S8697 | Intergr, Advanced ER- | III | 115 | 3 | 2.61 |
| S8741 | Advanced RTNF | II | 22 | 2 | 9.09 |
| S8748 | Advanced Alternating Chemo | II | 27 | 2 | 7.41 |
| S8811 | Advanced 5-FU+CF | II | 58 | 1 | 1.72 |
| S8814 | N1 Post CAF/TAM | III | 1558 | 54 | 3.47 |
| S8851 | Adjuvant N1, REC+, Pre Phase | III | 507 | 29 | 5.72 |
| S8897 | Adjuvant N0, Chemo /TAM | III | 4406 | 180 | 4.09 |
| S8931 | Adjuvant N1, REC- | III | 213 | 9 | 4.23 |
| S9061 | Adjuvant Chemo + ABMI vs CAP | III | 135 | 8 | 5.93 |
| S9114 | Adjuvant HD Chemo +ABMS | III | 121 | 15 | 12.40 |
| S9115 | Adjuvant STAMPV V-ABMS | III | 41 | 4 | 9.76 |
| S9215 | Adjuvant N1, RC-, QOL | cc | 24 | 1 | 4.17 |
| S9248 | Adjuvant PACLITAXEL | II | 135 | 3 | 2.22 |
| S9313 | Adjuvant N0-N1 Hi-dose AC | III | 3176 | 101 | 3.18 |
| S9332 | Adjuvant | III | 176 | 5 | 2.84 |
| S9347 | Adjuvant N0, TAM+/-OVX | III | 115 | 2 | 1.74 |
| S9410 | Adjuvant N1, ADR+, -TAXOL | III | 804 | 38 | 4.73 |
| S9412 | Adjuvant Chemo ABMT | III | 90 | 8 | 8.89 |
| S9514 | Adjuvant Elderly N1, TAM/4HPR | III | 82 | 4 | 4.88 |
| S9520 | MET, DOX, TAXOL | II | 92 | 5 | 5.43 |
| S9623 | Adjuvant A+T+C/C=Chemo+AHPCS | III | 164 | 13 | 7.93 |
| S9630 | MA s OBS for Endometrial Pathology | III | 8 | 1 | 12.50 |
| S9632 | Enhancing Well Being Breast Ca | Pilot | 3 | 1 | 33.33 |
| TOTAL | | | 13308 | 531 | 4.00 |

Table 17: CHAMPUS Eligible Beneficiaries - NCI Gastrointestinal Clinical Trials

| Study ID | Study Name | Phase | Trial | DEERS | % |
|----------|--|--------|-------|---------|----------|
| | | | N | Matched | Enrolled |
| S7804 | Gastric, Adjuvant FAM vs Control | III | 50 | 2 | 4.00 |
| S8572 | Colon, Adjuvant 5-FU + RT | pilot | 52 | 1 | 1.92 |
| S8591 | Colon, Adjuvant LEV vs LEV/5-FU | III | 37 | 1 | 2.70 |
| S8598 | Esophageal, 5FU/CDDP/RT vs RT | III | 55 | 1 | 1.82 |
| S8611 | Colorectal, Advanced TMTM vs 5-FU | II-III | 70 | 1 | 1.43 |
| S8626 | Pancreas Advanced, Gamma IFN | II | 32 | 1 | 3.13 |
| 28630 | Colorectal Advanced Gamma IFN | II | 42 | 2 | 4.76 |
| S8721 | Esophageal Advanced, TMTX | II | 24 | 1 | 4.17 |
| S8730 | Esophageal, Amonafide | II | 16 | 1 | 6.25 |
| S8743 | Colorectal Advanced RTNF | II | 25 | 1 | 4.00 |
| S8896 | Rectal Adjuvant 5-FU+RT +/- MECCNU | III | 165 | 6 | 3.64 |
| S8899 | Colon Adjuvant Chemo vs Obs | III | 1530 | 91 | 5.95 |
| S8905 | Colorectal Advanced 5-FU Modulation | II-III | 620 | 21 | 3.39 |
| S8906 | Hepatoma Advanced Merbarone | II | 22 | 1 | 4.55 |
| S8910 | Gastric, Advanced 5-FU + CDDP | II | 46 | 2 | 4.35 |
| S8917 | Colorectal Advanced 5-FU/CF/Roflerona | II | 54 | 8 | 14.81 |
| S8933 | Pancreas Advanced Piroxantrone | II | 42 | 1 | 2.38 |
| S8936 | Gastric Advanced Piroxantrone | II | 27 | 3 | 11.11 |
| S8939 | Colorectal Advanced Merbarone | II | 8 | 1 | 12.50 |
| S8990 | Colorectal Hepatoma Mets Resection | III | 40 | 1 | 2.50 |
| S9008 | Gastric Adjuvant, Chemoradiation | III | 543 | 21 | 3.87 |
| S9013 | Esophageal Neoadjuvant CHEM/SRG vs SRG | III | 95 | 9 | 9.47 |
| S9040 | Rectal Adjuvant Chemo + RT | III | 443 | 20 | 4.51 |
| S9041 | Colorectal Chemoprevention | pilot | 202 | 26 | 12.87 |
| S9045 | Colorectal QOL | cc | 287 | 11 | 3.83 |
| S9051 | Colorectal Advanced, HEPCHEMO+5-FU/CF | II | 33 | 1 | 3.03 |
| S9060 | Esophageal 5-FU/CDDP/RT | II | 33 | 1 | 3.03 |
| S9100 | Pancreas Advanced 5-FU/CF/PALA | II | 30 | 3 | 10.00 |
| S9107 | Colorectal Advanced 5-FU/CF/PALA | II | 28 | 2 | 7.14 |
| S9135 | Pancreas Advanced 5-FU/CF/PALA | II | 45 | 1 | 2.22 |
| S9150 | Gastric TOPOTECAN | II | 20 | 1 | 5.00 |
| S9151 | Hepatoma TOPOTECAN | II | 38 | 2 | 5.26 |
| S9157 | Hepatoma Trans-Retinoic Acid | II | 30 | 1 | 3.33 |
| S9241 | Colorectal Advanced TOPOTECAN | II | 50 | 1 | 2.00 |
| S9250 | Colon, Peri 5-FU Adjuvant 5-FU/LEV | III | 108 | 13 | 12.04 |
| S9303 | Colon Adjuvant RT/5-FU/LEV | III | 54 | 3 | 5.56 |
| S9304 | Colon Adjuvant 5-FU/RT/LV/LEV | III | 1089 | 31 | 2.85 |
| S9306 | Rectal Adjuvant 5-FU/RT/LV/LEV | II | 19 | 1 | 5.26 |
| S9339 | Esophageal TOPOTECAN | II | 47 | 1 | 2.13 |
| S9401 | Colorectal Adjuvant 5-FU/LEV/LV | III | 29 | 2 | 6.90 |
| S9411 | Colon LAP vs Open Colectomy | III | 74 | 3 | 4.05 |
| S9413 | Pancreas Advanced ELFI | II | 55 | 1 | 1.82 |
| S9415 | Colon Adjuvant 5-FU/LV/LEV | III | 696 | 25 | 3.59 |
| S9420 | Colon Advanced 5-FU | III | 361 | 19 | 5.26 |
| TOTAL | | | 7366 | 346 | 4.70 |

Table 18: CHAMPUS Eligible Beneficiaries - NCI Genitourinary System Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|---|-------|------------|------------------|---------------|
| JPR3 | Pros, Blockade vs Blockade/RT | III | 9 | 1 | 11.11 |
| S8507 | Bladder, BCG vs BCG+Maintenance | III | 298 | 5 | 1.68 |
| S8520 | Penis, Stage III-IV, CDDP, MTX & Bleo | II | 42 | 2 | 4.76 |
| S8708 | Prostrate, Stage D, CHIP | II | 46 | 1 | 2.17 |
| S8710 | Bladder, Advanced, Cystmy vs MVAC | III | 306 | 11 | 3.56 |
| S8711 | Testis Reproduction | cc | 207 | 11 | 5.31 |
| S8719 | Prostate, DIDDMNIN-B, IFF/MESNA | II | 78 | 2 | 2.56 |
| S8733 | Bladder, RT+/-5-F | pilot | 81 | 4 | 4.94 |
| S8788 | Testis, Advanced, High vs Standard CDDP | III | 42 | 1 | 2.38 |
| S8789 | Germ CL, Advanced, VP16+(CDDPVSCBDCA) | III | 106 | 6 | 5.66 |
| S8792 | Renal, Wellfron vs Observation | III | 166 | 11 | 6.63 |
| S8793 | Prostate, D1, Hormonal vs Observation | III | 73 | 6 | 8.22 |
| S8794 | Prostate, Path C, RT vs Observation | III | 431 | 55 | 12.76 |
| S8795 | Bladder, Superficial, BCG vs MMC | III | 469 | 16 | 3.41 |
| S8802 | Renal, Echinomycin | II | 49 | 1 | 2.04 |
| S8824 | Renal RIL-2 | II | 47 | 1 | 2.13 |
| S8894 | Prostate, D2, Orch+FLUT/Placebo | III | 1387 | 86 | 6.20 |
| S8925 | Adrenal, CDDP+VP16, Mitotane | II | 47 | 3 | 6.38 |
| S8929 | Renal Cell, Merbarone | II | 41 | 2 | 4.88 |
| S8949 | Renal Mer, INTRON-A +/-Nephrectomy | III | 231 | 15 | 6.49 |
| S8955 | Prostate, HR, 5-FU+ROFERON-A | II | 23 | 1 | 4.35 |
| S8956 | Bladder, CDDP+5-FU-I | II | 38 | 1 | 2.63 |
| S8994 | Prostate, Stage C, QOL | cc | 219 | 47 | 21.46 |
| S8997 | Testes, CDDP & VP-16+/-BLEO/IFF | III | 94 | 2 | 2.13 |
| S9012 | Advanced Renal, Los Dose ALPHA-IFN | II | 59 | 2 | 3.39 |
| S9024 | Prostate, Clin C, RT+5-FU | II | 31 | 8 | 25.81 |
| S9039 | Prostate, Stage D2, QOL | cc | 739 | 54 | 7.31 |
| S9109 | Prostate C, Zoladex/Flutamide | II | 62 | 9 | 14.52 |
| S9122 | Renal, A-IFN W/5-FU | II | 40 | 1 | 2.50 |
| S9124 | GC, REL/REF EDATREXATE | II | 25 | 2 | 8.00 |
| S9130 | Bladder, Smoking Cessation | cc | 25 | 2 | 8.00 |
| S9140 | Bladder, CIS, BROPIRIMINE+BCG | II | 49 | 1 | 2.04 |
| S9142 | Bladder, Gallium Nitrate | II | 46 | 4 | 8.70 |
| S9230 | Renal, IL-4 | II | 58 | 2 | 3.45 |
| S9235 | Prostate, CASODEX | II | 53 | 1 | 1.89 |
| S9312 | Bladder, CDDP+5FU+XRT | II | 54 | 3 | 5.56 |
| S9338 | Renal, 5-FU+INTRONA+IL-2 | II | 38 | 1 | 2.63 |
| S9343 | Prostate, SUMARIN | II | 62 | 4 | 6.45 |
| S9346 | Prostate, Intermittent Androgen Deprivation | III | 145 | 3 | 2.07 |
| S9407 | Prostate, Hormone, EMCYT & VP-16 | II | 55 | 4 | 7.27 |
| S9426 | Prostate, FLUTAMIDE Withdrawal | II | 70 | 2 | 2.86 |
| S9450 | Prostatectomy vs Observation | III | 14 | 5 | 35.71 |
| S9452 | Prostate, SURAMIN | III | 10 | 1 | 10.00 |
| S9457 | Bladder, TAXOL & CBDCA | II | 53 | 1 | 1.89 |
| S9460 | Chemoprevention of 4-HPR in TCC | cc | 16 | 1 | 6.25 |
| S9510 | Prostate, TOPOTECAN | II | 23 | 7 | 30.43 |
| S9615 | Prostate, Neoadjuvant Therapy | III | 22 | 6 | 27.27 |
| TOTAL | | | 6282 | 415 | 6.60 |

Table 19: CHAMPUS Eligible Beneficiaries - NCI Gynecological Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|---------------------------------------|-------|------------|------------------|---------------|
| S8412 | Ovarian Stage III-IV | III | 166 | 3 | 1.81 |
| S8501 | Ovarian OPT Stage III, IP vs CDDP | III | 571 | 33 | 5.78 |
| S8695 | Cervical Stage 11B—IVA, Chem/RT | III | 37 | 2 | 5.41 |
| S8717 | Ovarian Advanced Stage III-IV | II | 38 | 1 | 2.63 |
| S8745 | Cervical Folic Acid | cc | 135 | 10 | 7.41 |
| S8790 | Ovarian Stage III CR, IFN vs Obs | III | 61 | 1 | 1.64 |
| S8797 | Cervical Stage IA2-IIA, Chem/RT | III | 268 | 13 | 4.85 |
| S8835 | Ovarian <1cm Resistant IP | II | 83 | 1 | 1.20 |
| S8914 | Ovarian Advanced, Chemo+GMM-CSF | III | 109 | 3 | 2.75 |
| S9106 | Ovarian Advanced, Chemo+ABMT | II | 62 | 11 | 17.74 |
| S9132 | Cervical Stage III-IV, IFN+C/TRA | II | 62 | 1 | 1.59 |
| S9227 | Ovarian OPT, Stage III | III | 70 | 1 | 1.43 |
| S9238 | Ovarian, Plat Resistant, Stage III | III | 40 | 2 | 5.00 |
| S9249 | Ovarian, SUBOPT, Chemo PACL | III | 57 | 4 | 7.02 |
| S9324 | Ovarian, REL, Navelbione | II | 92 | 7 | 7.61 |
| S9326 | Ovarian CLINCR, AALTRET | II | 112 | 2 | 1.79 |
| S9618 | Peritoneal Advanced, ABDCA/PACLITAXEL | II | 18 | 1 | 5.56 |
| S9619 | Ovarian, OPTSTIII IP/IV CDDP/PACL | II | 49 | 3 | 6.12 |
| TOTAL | | | 2031 | 99 | 4.90 |

Table 20: CHAMPUS Eligible Beneficiaries - NCI Head and Neck Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|--|-------|------------|------------------|---------------|
| S8590 | HN Adjuvant CDDP/5-FU+XRT vs XRT | III | 72 | 2 | 2.78 |
| S8810 | HN Local Advanced CDDP+5-FU | II | 110 | 1 | 0.91 |
| S8852 | Hn Local Advanced ACC FR RT+CDDP | II | 48 | 1 | 2.08 |
| S8892 | Nasopharyngeal, CDDP+RT vs RT | III | 193 | 8 | 4.15 |
| S8895 | HN Cricopharyngeal Myotomy | III | 21 | 3 | 14.29 |
| S8957 | HN Resection, RT+CDDP/5-FU+CDDP | II | 72 | 4 | 5.56 |
| S9046 | HN Recurrent, 10-EDAM | II | 52 | 4 | 7.69 |
| S9059 | HN RT vs RT+CDDP vs RT+CDDP+5-FU | III | 122 | 2 | 1.64 |
| S9062 | HN Recurrent 5-FU+CDDP+AIFN | II | 52 | 1 | 1.92 |
| S9201 | HN Laryngeal Preservation | III | 53 | 3 | 5.66 |
| S9446 | HN State I-III, 13-CRA Chemoprevention | III | 36 | 1 | 2.78 |
| S9519 | HN REC/MET SCC, TOMIDEX | II | 27 | 1 | 3.70 |
| TOTAL | | | 858 | 31 | 3.60 |

Table 21: CHAMPUS Eligible Beneficiaries - NCI Leukemia Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|--------------------------------------|-------|------------|------------------|---------------|
| S8326 | ANL, CGL Relapse Induction | III | 373 | 9 | 2.41 |
| S8417 | ALL Post Remission Therapy | III | 288 | 99 | 3.13 |
| S8600 | ANL, ARA-C+DNR | III | 728 | 20 | 2.75 |
| S8612 | AL HighRisk, CML ASS/BLAST, BMT | III | 120 | 3 | 2.50 |
| S8691 | HCL, Untreated DCF vs A-IFN | III | 301 | 6 | 1.99 |
| S8735 | CML Untreated IFN | I-II | 20 | 1 | 5.00 |
| S8833 | CLL, REL/REF, CLB+FLAMP | I | 21 | 1 | 4.76 |
| S9030 | ALL, REL/REFR, HIDAC+DHAD | II | 33 | 4 | 12.12 |
| S9031 | AML, DNM, ARA-C+GCSF/Placebo | III | 234 | 9 | 3.85 |
| S9034 | ANL, Post Remission Therapy | III | 293 | 14 | 4.78 |
| S9108 | B-CLL, FLAMP vs CHLOR vs FLAMP+CHLOR | III | 158 | 9 | 5.70 |
| S9120 | MDS,GGCSF, T-RA | I | 7 | 1 | 14.29 |
| S9126 | AML, ARA-C/DNR+/-Cyclosporin | III | 213 | 12 | 5.63 |
| S9129 | APL, TRA vs RA-C/DNR | III | 92 | 3 | 3.26 |
| S9300 | CML, AATRA?IFN and ATRA/HU | II | 93 | 4 | 4.30 |
| S9333 | AML, DHAD/VP-16 vs ARA-C/DNR | III | 233 | 14 | 6.01 |
| S9400 | ALL,Chemo+/-PIXY321, BMT | II | 75 | 2 | 2.67 |
| S9500 | AML, Intensive ARA-C+DNR | II | 104 | 5 | 4.81 |
| S9617 | AML, PSC833 PTS>55 | I | 14 | 1 | 7.14 |
| TOTAL | | | 3400 | 127 | 3.70 |

Table 22: CHAMPUS Eligible Beneficiaries - NCI Lung Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|---------------------------------------|-------|------------|------------------|---------------|
| S8609 | SCL, Ext VM-26 | II | 45 | 2 | 4.44 |
| S8625 | NSCL,EXT CDDP+CONS | II | 81 | 1 | 1.23 |
| S8738 | NSCL, Adv, CDDP | III | 356 | 6 | 1.69 |
| S8805 | NSCL, Neoadj CDDP/VP-16+RT | II | 156 | 10 | 6.41 |
| S8812 | SCL, LTD, IND+/-GM-CSF, +/-IFN | III | 304 | 13 | 4.28 |
| S8836 | NSCL, Local Advanced, RT/CDDP,CONS | II | 65 | 2 | 3.08 |
| S8850 | NSCL Advanced, Novobiocin+CDDP | II | 36 | 1 | 2.78 |
| S8857 | SCL, EXT, CDDP/VP-16/Cont CAV | II | 67 | 7 | 10.45 |
| S8991 | SCL, LTD, RT/CHEMPO | III | 50 | 3 | 6.00 |
| S8992 | NSCL, Local Advanced, RT vs RT/Chemo | III | 28 | 1 | 3.57 |
| S9019 | NSCL, Stage IIIB, CDDP/VP-16+RT | III | 145 | 12 | 8.28 |
| S9038 | NSCL, Advanced, Oral VP-16/Cytosan | II | 66 | 3 | 4.55 |
| S9127 | NSCL, Advanced, CDDP/CBDCA/VP-16 | II | 83 | 4 | 4.82 |
| S9148 | SCL/NSCL, Advanced, CDDP/ARA-C/HU | II | 58 | 3 | 5.17 |
| S9158 | Squamous, Trans-Ret A/A-IFN | II | 18 | 1 | 5.56 |
| S9207 | NSCL, Advanced, 10-EDAM, CBDCA | II | 24 | 3 | 12.50 |
| S9216 | SCL, Ext, CODE/RT vs CAV/EP | III | 143 | 13 | 9.09 |
| S9221 | NSCL, Stage I, 13-CRA Chemoprevention | III | 226 | 22 | 9.73 |
| S9229 | SCL, LTD, CDDP/VP, VCR, PCI | II | 58 | 1 | 1.72 |
| S9242 | SCL, Ext, Taxotere | II | 47 | 1 | 2.13 |
| S9252 | NSCL, State II-III A, Adjuvant | III | 38 | 3 | 7.89 |
| S9307 | SCL, ET, Po VP-16/Cytosan/PCI | II | 65 | 6 | 9.23 |
| S9308 | NSCL, Advanced, CDDP vs CDDP+VINLB | III | 432 | 15 | 3.47 |
| S9336 | NSCL, Stage IIIA, Chemo/RT+/-Surgery | III | 49 | 7 | 14.29 |
| S9416 | NSCL, PANCOAST, Chemo/RT/Surgery | II | 61 | 1 | 1.64 |
| S9424 | NSCL, Advanced, HD Tamoxifen+CDDP | II | 82 | 3 | 3.66 |
| S9429 | NSCL, Stage III, Poor Risk | II | 63 | 3 | 4.76 |
| S9504 | NSCL, CDDP/VP-16/RT+Taxotere | II | 41 | 2 | 4.88 |
| S9509 | NSCL, CDDP/VIN vs CBDCA/PAC | III | 348 | 15 | 4.31 |
| X1195 | NSCLC, PACLITAXEL/CBDCA | II | 34 | 1 | 2.94 |
| TOTAL | | | 3269 | 165 | 5.10 |

Table 23: CHAMPUS Eligible Beneficiaries -NCI Lymphoma Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|-----------------------------------|-------|------------|------------------|---------------|
| S8309 | NHL, Autologous BMT | II | 17 | 2 | 11.76 |
| S8406 | Lymphoma, Malignant ESORUBICIN | II | 24 | 2 | 8.33 |
| S8516 | NHL, Four Treatment Comparison | III | 963 | 22 | 2.28 |
| S8736 | NHL, CHOP vs CHOP/RT | III | 442 | 31 | 7.01 |
| S8796 | HD, Combo Chemo | III | 158 | 5 | 3.16 |
| S8809 | NHL, Promace-MOPP | III | 571 | 28 | 4.90 |
| S8816 | Lymphoma, MF, 13-CIS RA+Roferon-A | II | 25 | 3 | 12.00 |
| S8942 | NHL, ABMT, Chemo or TBI Prep | II | 104 | 5 | 4.81 |
| S8952 | HD, Combo Chemo | III | 305 | 17 | 5.57 |
| S8954 | Lymphoblastic NHL, L-17M | II | 37 | 1 | 2.70 |
| S9011 | HD, ABMT, Chemo o TBI Prep | II | 81 | 6 | 7.41 |
| S9125 | NHL, CVAD. VERAPAMIL/QUININE | II | 100 | 6 | 6.00 |
| S9133 | HD, I-IIA, SNRT vs AV+SNRT | III | 263 | 16 | 6.08 |
| S9208 | Early Stage HD, QOL | cc | 178 | 10 | 5.62 |
| S9219 | NHL or HD, Interleukin-4 | II | 29 | 1 | 3.45 |
| S9240 | NHLK< CVAD | II | 112 | 4 | 3.57 |
| S9246 | NHL or HD, Relapses TAXOL | II | 69 | 2 | 2.90 |
| S9320 | AIDS. Lymphoma, PROMACE-CYTABOM | II | 35 | 2 | 5.71 |
| S9349 | NHL, CHOP vs PROMACE-CYTABOM | II | 210 | 4 | 1.90 |
| S9438 | TBI, PBSCT, IL-2 vs Observation | III | 154 | 13 | 8.44 |
| S9501 | NHL, FLUDARABINE/MITOXANTRONE | II | 92 | 3 | 3.26 |
| TOTAL | | | 3969 | 183 | 4.60 |

Table 24: CHAMPUS Eligible Beneficiaries - NCI Melanoma Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|--------------------------|-------|------------|------------------|---------------|
| S8393 | Stage I, Surgery, INTGR | III | 36 | 5 | 13.89 |
| S8569 | Interleukin | II | 10 | 1 | 10.00 |
| S8642 | IFN-GAMMA vs Observation | III | 284 | 7 | 2.46 |
| S8723 | AMONAFIDE | II | 23 | 1 | 4.35 |
| S8921 | 3 Phase Trials | II | 96 | 1 | 1.04 |
| S9035 | Immunotherapy | III | 689 | 32 | 4.64 |
| S9111 | T4 or N+, A-IFN 2 | III | 272 | 8 | 2.94 |
| S9116 | PIROXANTRONE | II | 52 | 1 | 1.92 |
| S9223 | A-IFN+TRA | II | 57 | 4 | 7.02 |
| S9228 | IL-4 | II | 236 | 1 | 2.78 |
| S9348 | BCNU/DTIC/CDDP/TAM | II | 84 | 3 | 3.57 |
| S9350 | IFN/DTIC/CDDP/TAM | II | 26 | 1 | 3.85 |
| S9622 | CI-980 | II | 24 | 1 | 4.17 |
| TOTAL | | | 1689 | 66 | 3.90 |

Table 25: CHAMPUS Eligible Beneficiaries - NCI Multiple Myeloma Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|-----------------------|-------|------------|------------------|---------------|
| S8624 | Combined Therapy | III | 467 | 11 | 2.36 |
| S8726 | REF | II | 17 | 1 | 5.88 |
| S8744 | REF | II | 9 | 1 | 11.11 |
| S8900 | REF | II | 127 | 2 | 1.57 |
| S8944 | REF | I-II | 19 | 1 | 5.26 |
| S8993 | REF Stem Cell Support | II | 72 | 6 | 8.33 |
| S9003 | Fludarabine | pilot | 222 | 10 | 4.50 |
| S9028 | Combined Therapy | III | 23 | 12 | 5.15 |
| S9210 | VAD-P/Q | III | 259 | 15 | 5.79 |
| S9237 | REF TOTOTECAN | II | 46 | 2 | 4.35 |
| S9321 | Standard vs High Dose | III | 500 | 35 | 7.00 |
| S9628 | DEX+Interferon | pilot | 13 | 1 | 7.69 |
| TOTAL | | | 1984 | 97 | 4.90 |

Table 26: CHAMPUS Eligible Beneficiaries - NCI Sarcoma Clinical Trials

| Study ID | Study Name | Phase | Trial N | DEERS Matched | % Enrolled |
|----------|------------------------|-------|------------|------------------|---------------|
| S8616 | ISS 4 | III | 434 | 10 | 2.30 |
| S8693 | Osteosarcoma ISS 3 | III | 6 | 1 | 16.67 |
| S8922 | ADR+DTIC+IFF+GM-CSF | I | 17 | 1 | 5.88 |
| S8930 | PIROXANTRONE | II | 25 | 2 | 9.00 |
| S8943 | MERBARONE | II | 37 | 1 | 2.70 |
| S9119 | MAID | II | 57 | 3 | 5.26 |
| S9128 | ADR+DTIC+IFFGMCSF | I | 1 | 1 | 14.29 |
| S9134 | TAXOL+GCSF | II | 51 | 2 | 3.92 |
| S9139 | ADR+CDDP+IFF | II | 65 | 3 | 4.62 |
| S9143 | CDDP+ARA-C+HYDROX | II | 43 | 3 | 6.98 |
| S9147 | DESMOID< TAM | II | 14 | 1 | 7.14 |
| S9341 | IFF+MESMA+G-CSF | II | 41 | 3 | 7.32 |
| S9518 | Soft Tissue, TOPOTECAN | II | 22 | 2 | 9.09 |
| TOTAL | | | 333 | 33 | 4.00 |

Table 27: NCI Clinical Trials SWOG/DEERS Matched Cases By Breast Tumor

| Breast Study ID | Phase | Trial | N | N | N |
|--------------------|-------|-------|----------|----------|-------|
| | | | Adjuvant | Advanced | Other |
| S7827 | 3 | | 13 | | |
| S8312 | 3 | | | 5 | |
| S8313 | 3 | ECOG | | | 15 |
| S8366 | 3 | | | | 4 |
| S8568 | 2 | | | | 1 |
| S8621 | 3 | | | 3 | |
| S8692 | 3 | | | 1 | |
| S8697 | 3 | ECOG | | 3 | |
| S8741 | 2 | | | 2 | |
| S8748 | 2 | | | 2 | |
| S8807* | cc | | | | 123 |
| S8811 | 2 | | | 1 | |
| S8814 | 3 | | | | 54 |
| S8851 | 3 | ECOG | 29 | | |
| S8897 | 3 | | 180 | | |
| S8931 | 3 | ECOG | 9 | | |
| S9061 | 3 | ECOG | 8 | | |
| S9114 | 3 | CALGB | 15 | | |
| S9115 | 3 | | | 4 | |
| S9215 | cc | QOL | 1 | | |
| S9248 | 2 | | | 3 | |
| S9313 | 3 | | 101 | | |
| S9332 | 3 | ECOG | | 5 | |
| S9347 | 3 | ECOG | 2 | | |
| S9410 | 3 | CALGB | 38 | | |
| S9412 | 3 | ECOG | | 8 | |
| S9514 | 3 | | 4 | | |
| S9520 | 2 | | | | 5 |
| S9623 | 3 | QOL | | | 1 |
| N=29 | | | 400 | 37 | 203 |

*chemoprevention trials

Table 28: NCI Clinical Trials SWOG/DEERS Matched Cases By Prostate Tumor

| Prostate Study ID | Phase | Trial | N | N | N |
|----------------------|-------|----------|----------|----------|-------|
| | | | Adjuvant | Advanced | Other |
| JPR3 | 3 | | | | 1 |
| S8708 | 2 | | | | 1 |
| S8719 | 2 | | | | 2 |
| S8793 | 3 | | | | 6 |
| S8794 | 3 | | 55 | | |
| S8894 | 3 | | | | 86 |
| S8955 | 2 | | | | 1 |
| S8994 | cc | QOL | | | 47 |
| S9024 | 2 | | | | 8 |
| S9039 | cc | QOL | | | 54 |
| S9109 | 2 | | | | 9 |
| S9217* | cc | PCPT | | 2968 | |
| S9235 | 2 | | | 1 | |
| S9343 | 2 | | 4 | | |
| S9346 | 3 | | | | 3 |
| S9407 | 2 | | 4 | | |
| S9426 | 2 | | | | 2 |
| S9450 | 3 | VA PIVOT | | | 5 |
| S9452 | 3 | | | | 1 |
| S9510 | 2 | | | | 7 |
| S9615 | 3 | | | | 6 |
| N=21 | | | 63 | 2969 | 239 |

*chemoprevention trials

Table 29: NCI Clinical Trials SWOG/DEERS Matched Cases By Leukemia Tumor

| Leukemia Study ID | Phase | Trial | N | | |
|----------------------|-------|-------|----------|----------|-------|
| | | | Adjuvant | Advanced | Other |
| S8326 | 3 | CALGB | | | 9 |
| S8417 | 3 | | | | 9 |
| S8600 | 3 | | | | 20 |
| S8612 | 3 | | | | 3 |
| S8691 | 3 | | | | 6 |
| S8735 | 2,3 | | | | 1 |
| S8833 | 1 | | | | 1 |
| S9030 | 2 | | | | 4 |
| S9031 | 3 | | | | 9 |
| S9034 | 3 | | | | 14 |
| S9108 | 3 | | | | 9 |
| S9120 | 1 | | | | 1 |
| S9126 | 3 | | | | 12 |
| S9129 | 3 | | | | 3 |
| S9300 | 2 | | | | 4 |
| S9333 | 3 | | | | 14 |
| S9400 | 2 | | | | 2 |
| S9500 | 2 | | | | 5 |
| S9617 | 1 | | | | 1 |
| N=19 | | | | | 89 |

Table 30: NCI Clinical Trials SWOG/DEERS Matched Cases By Lymphoma Tumor

| Lymphoma Study ID | Phase | Trial | N | N | N |
|----------------------|-------|-------|----------|----------|-------|
| | | | Adjuvant | Advanced | Other |
| S8309 | 2 | | | | 2 |
| S8406 | 2 | | | | 2 |
| S8516 | 3 | | | | 22 |
| S8616 | 3 | | | | 10 |
| S8624 | 3 | | | | 11 |
| S8693 | 3 | | | | 1 |
| S8726 | 2 | | | | 1 |
| S8736 | 3 | | | | 31 |
| S8744 | 2 | | | | 1 |
| S8796 | 3 | | | | 5 |
| S8809 | 3 | | | | 28 |
| S8816 | 2 | | | | 3 |
| S8900 | 2 | | | | 2 |
| S8922 | 1 | | | | 1 |
| S8930 | 2 | | | | 2 |
| S8942 | 2 | | | | 5 |
| S8943 | 2 | | | | 1 |
| S8944 | 2 | | | | 1 |
| S8952 | 3 | CALGB | | | 17 |
| S8954 | 2 | | | | 1 |
| S8993 | 2 | | | | 6 |
| S9003 | pilot | | | | 10 |
| S9011 | 2 | | | | 6 |
| S9028 | 3 | | | | 12 |
| S9119 | 2 | | | | 3 |
| S9125 | 2 | | | | 6 |
| S9128 | 1 | | | | 1 |
| S9133 | 3 | | | | 16 |
| S9134 | 2 | | | | 2 |
| S9139 | 2 | | | | 3 |
| S9143 | 2 | | | | 3 |
| S9147 | 2 | | | | 1 |
| S9208 | cc | QOL | | | 10 |
| S9210 | 3 | | | | 15 |
| S9219 | 2 | | | | 1 |
| S9237 | 2 | | | | 2 |
| S9240 | 2 | | | | 4 |
| S9246 | 2 | | | | 2 |
| S9320 | 2 | | | | 2 |
| S9321 | 3 | | | | 35 |
| S9341 | 2 | | | | 2 |
| S9349 | 2 | | | | 4 |
| S9438 | 3 | | | | 13 |
| S9501 | 2 | | | | 3 |
| S9518 | 2 | | | | 2 |
| S9628 | pilot | | | | 1 |
| N=46 | | | | | 216 |

Table 31: NCI Clinical Trials SWOG/DEERS Matched Cases By Colon/Rectal Tumor

| Colon / Rectal Study ID | Phase | Trial | N | N | N |
|----------------------------|-------|-------|----------|----------|-------|
| | | | Adjuvant | Advanced | Other |
| S8572 | pilot | | 1 | | |
| S8591 | 3 | | 1 | | |
| S8611 | 2,3 | | | | |
| S8630 | 2 | | | 2 | |
| S8743 | 2 | | | 1 | |
| S8896 | 3 | | 6 | | |
| S8899 | 3 | | 91 | | |
| S8905 | 2,3 | | | 2 | |
| S8917 | 2 | | | 8 | |
| S8939 | 2 | | | 1 | |
| S8990 | 3 | | | | 1 |
| S9040 | 3 | CALGB | 20 | | |
| S9041* | pilot | | | | 26 |
| S9045 | cc | QOL | | | 11 |
| S9051 | 2 | | | 1 | |
| S9107 | 2 | | | 2 | |
| S9241 | 2 | | | 1 | |
| S9250 | 3 | | 13 | | |
| S9303 | 3 | | 3 | | |
| S9304 | 3 | | 31 | | |
| S9306 | 2 | | 1 | | |
| S9401 | 3 | | 2 | | |
| S9411 | 3 | NCCTG | | | 3 |
| S9415 | 3 | | 25 | | |
| S9420 | 3 | | | 19 | |
| N=25 | | | 194 | 37 | 41 |

*chemoprevention trials

Table 32: NCI Clinical Trials SWOG/DEERS Matched Cases By Lung Tumor

| Lung Study ID | Phase | Trial | N | N | N |
|------------------|-------|-------|----------|----------|-------|
| | | | Adjuvant | Advanced | Other |
| S8609 | 2 | | | | 2 |
| S8625 | 2 | | | | 1 |
| S8738 | 3 | | | 6 | |
| S8805 | 2 | | 10 | | |
| S8812 | 3 | | | | 13 |
| S8836 | 2 | | | 2 | |
| S8850 | 2 | | | 1 | |
| S8857 | 2 | | | | 7 |
| S8991 | 3 | | | | 3 |
| S8992 | 3 | | | 1 | |
| S9019 | 3 | | | | 12 |
| S9038 | 2 | | | 3 | |
| S9127 | 2 | | | 4 | |
| S9148 | 2 | | | 3 | |
| S9158 | 2 | | | | 1 |
| S9207 | 2 | | | 3 | |
| S9216 | 3 | | | | 13 |
| S9221* | 3 | | | | 22 |
| S9229 | 2 | | | | 1 |
| S9242 | 2 | | | | 1 |
| S9252 | 3 | | 3 | | |
| S9307 | 2 | | | | 6 |
| S9308 | 3 | | | 15 | |
| S9336 | 3 | | | | 7 |
| S9416 | 2 | | | | 1 |
| S9424 | 2 | | | 3 | |
| S9429 | 2 | | | | 3 |
| S9504 | 2 | | 2 | | |
| S9509 | 3 | | | | 15 |
| X1195 | 2 | | 1 | | |
| N=30 | | | 16 | 41 | 108 |

*chemoprevention trials

NCI Cooperative Program Study Group

Co - Principle Investigators

Scott A Optenberg, DrPH
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Sandra L. Schneider, DrPH
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Arnold Potosky, PhD
Division of Cancer Prevention and Control
National Cancer Institute
Bethesda, MD

Mary McCabe, RN
Office of Clinical Research Promotions
National Cancer Institute
Bethesda, MD

Systems and Technical Transfer Programmers

Steve Willhoite
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Don Saathoff
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Robert Serafin
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Steve Condit
Southwest Oncology Group
Statistical Center
Fred Hutchinson Research Center
Seattle Washington

Collaborators

Charles A. Coltman, Jr., MD
Southwest Oncology Group
Cancer Therapy and Research Center (CTRC)
San Antonio Texas

John Crowley, PhD
Southwest Oncology Group
Statistical Center
Fred Hutchinson Research Center
Seattle Washington

Rick Barnett, PhD
OCHAMPUS
Department of Defense
Statistics Branch
TRICARE Support Office (TSO)
Office of Civilian and Health and Medical Program of the Uniformed Services
Aurora, Colorado

Administration and Operations

Tony Guillen
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Marge Godfrey
Southwest Oncology Group
Cancer Therapy and Research Center (CTRC)
San Antonio Texas

REFERENCES

1. Kiberstis, P and Marx, J (eds). Frontiers in Cancer Research. Science 278:1035-1077, 1997.
2. Department of Defense. CHAMPUS Chartbook of Statistics: OCHAMPUS Guide 5400.2-CB. Civilian Health and Medical Program of the Uniformed Services. Information Systems Division Statistics Branch,. Office of Civilian Health and Medical Program of the Uniformed Services, Aurora, Co. December 1995
3. Department of Defense. CHAMPUS Chartbook of Statistics: TSO/OCHAMPUS Guide 5400.2-CB. Civilian Health and Medical Program of the Uniformed Services. Information Systems Division Statistics Branch,. Office of Civilian Health and Medical Program of the Uniformed Services, Aurora, Co. January 1997.

DISTRIBUTION LIST

HQDA, ATTN: DASG-ZA, Suite 672, 5109 Leesburg Pike, Falls Church, VA 22041-3258 (1)
HQDA, ATTN: DASG-ZB, Suite 672, 5109 Leesburg Pike, Falls Church, VA 22041-3258 (1)
HQDA, ATTN: DASG-HSZ, 5111 Leesburg Pike, Falls Church, VA 22041-3258 (1)
HQDA, ATTN: DASG-RMZ (COL Blum), Room 638, 5111 Leesburg Pike, Falls Church, VA 22041-3258 (3)
HQDA, ATTN: DASG-HS&AP, Room 611, Skyline 5, 5111 Leesburg, Pike, Falls Church, VA 22041-3258 (1)
Defense Technical Information Center, ATTN: Pat Mawby, (Acquisition), Suite 0944, 8725 John J. Kingman Rd, Fort Belvoir, VA 22060-6218 (2)
Commandant, Academy of Health Sciences, ATTN: MCCS-H, Suite 310, 2250 Stanley Rd, Fort Sam Houston, TX 78234-6100 (1)
HQDA, Armed Forces Medical Library, ATTN: DASG-AAFJML, Room 670, 5109 Leesburg Pike, Falls Church, VA 22041-3258 (1)
HQ MEDCOM, ATTN: MCCG, Suite 223, Bldg 2792, Worth Rd, Fort Sam Houston, TX 78234-6009 (1)
HQ MEDCOM, ATTN: MCCL-M (COL Ferguson), Bldg 2792, Worth Rd, Fort Sam Houston, TX 78234-6009 (3)
HQ MEDCOM, ATTN: MCRM (COL Clouse), Rm 203, Suite 9, Bldg 2792, Worth Rd, Fort Sam Houston, TX 78234-6009 (8)
Academy of Health Sciences, Stimson Library, ATTN: MCCS-HSL, Bldg 2840, Fort Sam Houston, TX 78234-6100 (1)
Brooke Army Medical Center, Medical Library, ATTN: MCHE-CSL, Bldg 3600, 3851 Roger Brooke Dr, Fort Sam Houston, TX 78234-6200 (1)
Defense Logistics Studies Information Exchange, U.S. Army Logistic Management College, ATTN: DLSIE-ATSZ-DL (Director), Bldg 12500, 2401 Quarters Rd, Fort Lee, VA 23801-1705 (1)
Robert Wittes, MD, Office of Clinical Research Promotions, National Cancer Institute, 31 Center Drive, MSC 2440, Bldg 31, Room 3A44, Bethesda, MD, 20892-2440 (2)
Mary McCabe, RN, Office of Clinical Research Promotions, National Cancer Institute, 31 Center Drive, MSC 2440, Bldg 31, Room 3A44, Bethesda, MD, 20892-2440 (5)
Faina Shtern, PhD, Office of Clinical Research Promotions, National Cancer Institute, 31 Center Drive, MSC 2440, Bldg 31, Room 3A44, Bethesda, MD, 20892-2440 (1)
Arnold Potosky, PhD, Division of Cancer Prevention and Control, National Cancer Institute, Executive Plaza North, Room 3313, Bethesda, MD 20892-7344 (3)
Martin Brown, PhD, Division of Cancer Prevention and Control, National Cancer Institute, Executive Plaza North, Room 3313, Bethesda, MD 20892-7344 (1)
Kim McGuigan, PhD, RAND Corporation, Research Director 1700 Main St, Santa Monica, Calif 90407-2138 (1)
Charles A. Coltman, Jr., MD, Southwest Oncology Group, Cancer Therapy and Research Center (CTRC), 8122 Data Point Dr., Suite 600, San Antonio Texas, 78229-3264 (3)
Robert Opsut, PhD, Program Review and Evaluations, OASD Health Affairs, Department of Defense, 5111 Leesburg Pike, Suite 810, Falls Church, VA 22041 (1)
Capt Deborah Kamin, NC, USN, Director Health Services Financing Policy, Pentagon, Room 1B657, Washington, DC 20301-1200 (1)

APPENDIX

ICD9CM Cancer Diagnosis For Department of Defense CHAMPUS Patients Enrolled and Treated in NCI Sponsored Clinical Trials

Percent Frequency and Prevalence of Site Specific Cancer For In-Patient Professional Services (FY88-96)

Percent Frequency and Prevalence of Site Specific Cancer For Out-Patient Professional Services (FY88-96)

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1988
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 300815

A1

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 19 | 0.05% | 0.01% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 148 | 0.42% | 0.05% |
| 3 | MAL NEOPL MAJOR SG | 142 | 54 | 0.15% | 0.02% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 15 | 0.04% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 50 | 0.14% | 0.02% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 85 | 0.24% | 0.03% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 63 | 0.18% | 0.02% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 53 | 0.15% | 0.02% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 39 | 0.11% | 0.01% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 87 | 0.25% | 0.03% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 233 | 0.66% | 0.08% |
| 12 | MAL NEOPL STOMACH | 151 | 259 | 0.74% | 0.09% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 40 | 0.11% | 0.01% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 929 | 2.64% | 0.31% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 991 | 2.82% | 0.33% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 261 | 0.74% | 0.09% |
| 17 | MAL NEOPL GB/BD | 156 | 56 | 0.16% | 0.02% |
| 18 | MAL NEOPL PANCREAS | 157 | 286 | 0.81% | 0.10% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 44 | 0.13% | 0.01% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 77 | 0.22% | 0.03% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 52 | 0.15% | 0.02% |
| 22 | MAL NEOPL LARYNX | 161 | 253 | 0.72% | 0.08% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 3450 | 9.80% | 1.15% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 32 | 0.09% | 0.01% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 76 | 0.22% | 0.03% |
| 26 | MAL NEOPL RESP NEC | 165 | 21 | 0.06% | 0.01% |
| 27 | MAL NEOPL BONE/CART | 170 | 307 | 0.87% | 0.10% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 280 | 0.80% | 0.09% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 253 | 0.72% | 0.08% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 336 | 0.95% | 0.11% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 3033 | 8.62% | 1.01% |
| 32 | MAL NEOPL MALE BREAST | 175 | 22 | 0.06% | 0.01% |
| 33 | MAL NEOPL UTERUS NOS | 179 | 176 | 0.50% | 0.06% |
| 34 | MAL NEOPL CERVIX UTERI | 180 | 511 | 1.45% | 0.17% |
| 35 | MALIGNANT NEOPL PLACENTA | 181 | 6 | 0.02% | 0.00% |
| 36 | MAL NEOPL UTERUS BODY | 182 | 352 | 1.00% | 0.12% |
| 37 | MAL NEOPL UTERINE ADNEXA | 183 | 602 | 1.71% | 0.20% |
| 38 | MAL NEOPL FE GENIT NEC | 184 | 68 | 0.19% | 0.02% |
| 39 | MAL NEOPL PROSTATE | 185 | 576 | 1.64% | 0.19% |
| 40 | MAL NEOPL TESTIS | 186 | 44 | 0.13% | 0.01% |
| 41 | MAL NEOPL MALE GENIT NEC | 187 | 16 | 0.05% | 0.01% |
| 42 | MAL NEOPL BLADDER | 188 | 469 | 1.33% | 0.16% |
| 43 | MAL GU NEOPL NEC/NOS | 189 | 405 | 1.15% | 0.13% |
| 44 | MALIGNANT NEOPLASM EYE | 190 | 63 | 0.18% | 0.02% |
| 45 | MALIGNANT NEOPLASM BRAIN | 191 | 952 | 2.71% | 0.32% |
| 46 | MAL NEOPL NERVE NEC/NOS | 192 | 102 | 0.29% | 0.03% |
| 47 | MALIGNANT NEOPL THYROID | 193 | 151 | 0.43% | 0.05% |
| 48 | MAL NEOPL ENDOCRINE NEC | 194 | 156 | 0.44% | 0.05% |
| 49 | MAL NEOPL ILL-DEF SITES | 195 | 491 | 1.40% | 0.16% |
| 50 | SECONDARY MAL NEOPL LN | 196 | 130 | 0.37% | 0.04% |
| 51 | 2ND MAL NEOPLASM GI/RESP | 197 | 496 | 1.41% | 0.16% |
| 52 | 2ND MAL NEOPL OTH SITES | 198 | 711 | 2.02% | 0.24% |
| 53 | MALIGNANT NEOPLASM NOS | 199 | 1391 | 3.95% | 0.46% |
| 54 | LYMPHOSARC/RETICULOSARC | 200 | 141 | 0.40% | 0.05% |
| 55 | HODGKIN'S DISEASE | 201 | 196 | 0.56% | 0.07% |
| 56 | OTH MAL NEOPL LYMPH/HIST | 202 | 544 | 1.55% | 0.18% |
| 57 | MULTIPLE MYELOMA ET AL | 203 | 160 | 0.45% | 0.05% |
| 58 | LYMPHOID LEUKEMIA | 204 | 275 | 0.78% | 0.09% |
| 59 | MYELOID LEUKEMIA | 205 | 203 | 0.58% | 0.07% |
| 60 | MONOCYTIC LEUKEMIA | 206 | 23 | 0.07% | 0.01% |
| 61 | OTHER SPECIFIED LEUKEMIA | 207 | 18 | 0.05% | 0.01% |
| 62 | LEUKEMIA-UNSPECIF CELL | 208 | 365 | 1.04% | 0.12% |
| 63 | BEN NEOPL MOUTH/PHARYNX | 210 | 137 | 0.39% | 0.05% |
| 64 | OTH BENIGN NEOPLASM GI | 211 | 825 | 2.34% | 0.27% |
| 65 | BEN INTRATHOR NEOPLASM | 212 | 182 | 0.52% | 0.06% |
| 66 | BEN NEOPLASM BONE/CART | 213 | 1297 | 3.69% | 0.43% |
| 67 | LIPOMA | 214 | 176 | 0.50% | 0.06% |
| 68 | OTH BEN NEOPL SOFT TISS | 215 | 229 | 0.65% | 0.08% |
| 69 | BENIGN NEOPLASM OF SKIN | 216 | 339 | 0.96% | 0.11% |
| 70 | BENIGN NEOPLASM BREAST | 217 | 174 | 0.49% | 0.06% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1988
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 300815

A2

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | UTERINE LEIOMYOMA | 218 | 2846 | 8.09% | 0.95% |
| 72 | OTH BENIGN NEOPL UTERUS | 219 | 138 | 0.39% | 0.05% |
| 73 | BENIGN NEOPLASM OVARY | 220 | 247 | 0.70% | 0.08% |
| 74 | BEN NEOPL OTH FEM GENIT | 221 | 71 | 0.20% | 0.02% |
| 75 | BENIGN NEOPL MALE GENIT | 222 | 49 | 0.14% | 0.02% |
| 76 | BENIGN NEOPLASM URINARY | 223 | 80 | 0.23% | 0.03% |
| 77 | BENIGN NEOPLASM OF EYE | 224 | 16 | 0.05% | 0.01% |
| 78 | BENIGN NEOPL NERV SYST | 225 | 338 | 0.96% | 0.11% |
| 79 | BENIGN NEOPLASM THYROID | 226 | 130 | 0.37% | 0.04% |
| 80 | BEN NEOPL OTH ENDOCRINE | 227 | 108 | 0.31% | 0.04% |
| 81 | HEMANGIOMA/LYMPHANGIOMA | 228 | 158 | 0.45% | 0.05% |
| 82 | BENIGN NEOPLASM NEC/NOS | 229 | 202 | 0.57% | 0.07% |
| 83 | CA IN SITU DIGESTIVE ORG | 230 | 195 | 0.55% | 0.06% |
| 84 | CA IN SITU RESPIRATORY | 231 | 217 | 0.62% | 0.07% |
| 85 | CARCINOMA IN SITU SKIN | 232 | 29 | 0.08% | 0.01% |
| 86 | CA IN SITU BREAST/GU | 233 | 582 | 1.65% | 0.19% |
| 87 | CA IN SITU NEC/NOS | 234 | 86 | 0.24% | 0.03% |
| 88 | UNC BEHAV NEOPL GI/RESP | 235 | 196 | 0.56% | 0.07% |
| 89 | UNC BEHAV NEOPL GU | 236 | 185 | 0.53% | 0.06% |
| 90 | UNC NEOPL ENDOCR/NERV | 237 | 194 | 0.55% | 0.06% |
| 91 | UNC BEHAV NEOPL NEC/NOS | 238 | 326 | 0.93% | 0.11% |
| 92 | UNSPECIFIED NEOPLASM | 239 | 3745 | 10.64% | 1.24% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1989
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 279493

A3

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 18 | 0.05% | 0.01% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 145 | 0.42% | 0.05% |
| 3 | MAL NEOPL MAJOR SG | 142 | 43 | 0.12% | 0.02% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 12 | 0.03% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 31 | 0.09% | 0.01% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 74 | 0.21% | 0.03% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 67 | 0.19% | 0.02% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 54 | 0.15% | 0.02% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 32 | 0.09% | 0.01% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 75 | 0.22% | 0.03% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 253 | 0.73% | 0.09% |
| 12 | MAL NEOPL STOMACH | 151 | 263 | 0.75% | 0.09% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 46 | 0.13% | 0.02% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1040 | 2.98% | 0.37% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 923 | 2.65% | 0.33% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 280 | 0.80% | 0.10% |
| 17 | MAL NEOPL GB/BD | 156 | 61 | 0.17% | 0.02% |
| 18 | MAL NEOPL PANCREAS | 157 | 319 | 0.91% | 0.11% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 48 | 0.14% | 0.02% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 51 | 0.15% | 0.02% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 51 | 0.15% | 0.02% |
| 22 | MAL NEOPL LARYNX | 161 | 297 | 0.85% | 0.11% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 3611 | 10.35% | 1.29% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 39 | 0.11% | 0.01% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 67 | 0.19% | 0.02% |
| 26 | MAL NEOPL RESP NEC | 165 | 21 | 0.06% | 0.01% |
| 27 | MAL NEOPL BONE/CART | 170 | 298 | 0.85% | 0.11% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 254 | 0.73% | 0.09% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 249 | 0.71% | 0.09% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 298 | 0.85% | 0.11% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 2931 | 8.40% | 1.05% |
| 32 | MAL NEOPL MALE BREAST | 175 | 17 | 0.05% | 0.01% |
| 33 | MAL NEOPL UTERUS NOS | 179 | 145 | 0.42% | 0.05% |
| 34 | MAL NEOPL CERVIX UTERI | 180 | 553 | 1.59% | 0.20% |
| 35 | MALIGNANT NEOPL PLACENTA | 181 | 5 | 0.01% | 0.00% |
| 36 | MAL NEOPL UTERUS BODY | 182 | 333 | 0.95% | 0.12% |
| 37 | MAL NEOPL UTERINE ADNEXA | 183 | 620 | 1.78% | 0.22% |
| 38 | MAL NEOPL FE GENIT NEC | 184 | 79 | 0.23% | 0.03% |
| 39 | MAL NEOPL PROSTATE | 185 | 618 | 1.77% | 0.22% |
| 40 | MAL NEOPL TESTIS | 186 | 62 | 0.18% | 0.02% |
| 41 | MAL NEOPL MALE GENIT NEC | 187 | 21 | 0.06% | 0.01% |
| 42 | MAL NEOPL BLADDER | 188 | 538 | 1.54% | 0.19% |
| 43 | MAL GU NEOPL NEC/NOS | 189 | 462 | 1.32% | 0.17% |
| 44 | MALIGNANT NEOPLASM EYE | 190 | 56 | 0.16% | 0.02% |
| 45 | MALIGNANT NEOPLASM BRAIN | 191 | 894 | 2.56% | 0.32% |
| 46 | MAL NEOPL NERVE NEC/NOS | 192 | 91 | 0.26% | 0.03% |
| 47 | MALIGNANT NEOPL THYROID | 193 | 135 | 0.39% | 0.05% |
| 48 | MAL NEOPL ENDOCRINE NEC | 194 | 139 | 0.40% | 0.05% |
| 49 | MAL NEOPL ILL-DEF SITES | 195 | 453 | 1.30% | 0.16% |
| 50 | SECONDARY MAL NEOPL LN | 196 | 160 | 0.46% | 0.06% |
| 51 | 2ND MAL NEOPLASM GI/RESP | 197 | 575 | 1.65% | 0.21% |
| 52 | 2ND MAL NEOPL OTH SITES | 198 | 847 | 2.43% | 0.30% |
| 53 | MALIGNANT NEOPLASM NOS | 199 | 1334 | 3.83% | 0.48% |
| 54 | LYMPHOSARC/RETICULOSARC | 200 | 120 | 0.34% | 0.04% |
| 55 | HODGKIN'S DISEASE | 201 | 196 | 0.56% | 0.07% |
| 56 | OTH MAL NEOPL LYMPH/HIST | 202 | 567 | 1.63% | 0.20% |
| 57 | MULTIPLE MYELOMA ET AL | 203 | 159 | 0.46% | 0.06% |
| 58 | LYMPHOID LEUKEMIA | 204 | 273 | 0.78% | 0.10% |
| 59 | MYELOID LEUKEMIA | 205 | 227 | 0.65% | 0.08% |
| 60 | MONOCYTIC LEUKEMIA | 206 | 23 | 0.07% | 0.01% |
| 61 | OTHER SPECIFIED LEUKEMIA | 207 | 36 | 0.10% | 0.01% |
| 62 | LEUKEMIA-UNSPECIF CELL | 208 | 322 | 0.92% | 0.12% |
| 63 | BEN NEOPL MOUTH/PHARYNX | 210 | 134 | 0.38% | 0.05% |
| 64 | OTH BENIGN NEOPLASM GI | 211 | 786 | 2.25% | 0.28% |
| 65 | BEN INTRATHOR NEOPLASM | 212 | 184 | 0.53% | 0.07% |
| 66 | BEN NEOPLASM BONE/CART | 213 | 718 | 2.06% | 0.26% |
| 67 | LIPOMA | 214 | 231 | 0.66% | 0.08% |
| 68 | OTH BEN NEOPL SOFT TISS | 215 | 250 | 0.72% | 0.09% |
| 69 | BENIGN NEOPLASM OF SKIN | 216 | 273 | 0.78% | 0.10% |
| 70 | BENIGN NEOPLASM BREAST | 217 | 188 | 0.54% | 0.07% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1989
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 279493

A4

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | UTERINE LEIOMYOMA | 218 | 2845 | 8.16% | 1.02% |
| 72 | OTH BENIGN NEOPL UTERUS | 219 | 142 | 0.41% | 0.05% |
| 73 | BENIGN NEOPLASM OVARY | 220 | 216 | 0.62% | 0.08% |
| 74 | BEN NEOPL OTH FEM GENIT | 221 | 74 | 0.21% | 0.03% |
| 75 | BENIGN NEOPL MALE GENIT | 222 | 57 | 0.16% | 0.02% |
| 76 | BENIGN NEOPLASM URINARY | 223 | 90 | 0.26% | 0.03% |
| 77 | BENIGN NEOPLASM OF EYE | 224 | 18 | 0.05% | 0.01% |
| 78 | BENIGN NEOPL NERV SYST | 225 | 334 | 0.96% | 0.12% |
| 79 | BENIGN NEOPLASM THYROID | 226 | 175 | 0.50% | 0.06% |
| 80 | BEN NEOPL OTH ENDOCRINE | 227 | 146 | 0.42% | 0.05% |
| 81 | HEMANGIOMA/LYMPHANGIOMA | 228 | 176 | 0.50% | 0.06% |
| 82 | BENIGN NEOPLASM NEC/NOS | 229 | 215 | 0.62% | 0.08% |
| 83 | CA IN SITU DIGESTIVE ORG | 230 | 219 | 0.63% | 0.08% |
| 84 | CA IN SITU RESPIRATORY | 231 | 215 | 0.62% | 0.08% |
| 85 | CARCINOMA IN SITU SKIN | 232 | 44 | 0.13% | 0.02% |
| 86 | CA IN SITU BREAST/GU | 233 | 631 | 1.81% | 0.23% |
| 87 | CA IN SITU NEC/NOS | 234 | 112 | 0.32% | 0.04% |
| 88 | UNC BEHAV NEOPL GI/RESP | 235 | 226 | 0.65% | 0.08% |
| 89 | UNC BEHAV NEOPL GU | 236 | 186 | 0.53% | 0.07% |
| 90 | UNC NEOPL ENDOCR/NERV | 237 | 218 | 0.63% | 0.08% |
| 91 | UNC BEHAV NEOPL NEC/NOS | 238 | 346 | 0.99% | 0.12% |
| 92 | UNSPECIFIED NEOPLASM | 239 | 3414 | 9.79% | 1.22% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1990
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 268455

A5

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 15 | 0.04% | 0.01% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 146 | 0.41% | 0.05% |
| 3 | MAL NEOPL MAJOR SG | 142 | 59 | 0.17% | 0.02% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 11 | 0.03% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 52 | 0.15% | 0.02% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 102 | 0.29% | 0.04% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 55 | 0.16% | 0.02% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 50 | 0.14% | 0.02% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 55 | 0.16% | 0.02% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 76 | 0.21% | 0.03% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 287 | 0.81% | 0.11% |
| 12 | MAL NEOPL STOMACH | 151 | 294 | 0.83% | 0.11% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 68 | 0.19% | 0.03% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1093 | 3.09% | 0.41% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 935 | 2.64% | 0.35% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 236 | 0.67% | 0.09% |
| 17 | MAL NEOPL GB/BD | 156 | 57 | 0.16% | 0.02% |
| 18 | MAL NEOPL PANCREAS | 157 | 379 | 1.07% | 0.14% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 65 | 0.18% | 0.02% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 75 | 0.21% | 0.03% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 42 | 0.12% | 0.02% |
| 22 | MAL NEOPL LARYNX | 161 | 261 | 0.74% | 0.10% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 3467 | 9.80% | 1.29% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 34 | 0.10% | 0.01% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 54 | 0.15% | 0.02% |
| 26 | MAL NEOPL RESP NEC | 165 | 13 | 0.04% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 321 | 0.91% | 0.12% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 257 | 0.73% | 0.10% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 232 | 0.66% | 0.09% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 272 | 0.77% | 0.10% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 2999 | 8.48% | 1.12% |
| 32 | MAL NEOPL MALE BREAST | 175 | 15 | 0.04% | 0.01% |
| 33 | MAL NEOPL UTERUS NOS | 179 | 110 | 0.31% | 0.04% |
| 34 | MAL NEOPL CERVIX UTERI | 180 | 469 | 1.33% | 0.17% |
| 35 | MALIGNANT NEOPL PLACENTA | 181 | 5 | 0.01% | 0.00% |
| 36 | MAL NEOPL UTERUS BODY | 182 | 284 | 0.80% | 0.11% |
| 37 | MAL NEOPL UTERINE ADNEXA | 183 | 746 | 2.11% | 0.28% |
| 38 | MAL NEOPL FE GENIT NEC | 184 | 82 | 0.23% | 0.03% |
| 39 | MAL NEOPL PROSTATE | 185 | 652 | 1.84% | 0.24% |
| 40 | MAL NEOPL TESTIS | 186 | 58 | 0.16% | 0.02% |
| 41 | MAL NEOPL MALE GENIT NEC | 187 | 25 | 0.07% | 0.01% |
| 42 | MAL NEOPL BLADDER | 188 | 561 | 1.59% | 0.21% |
| 43 | MAL GU NEOPL NEC/NOS | 189 | 490 | 1.39% | 0.18% |
| 44 | MALIGNANT NEOPLASM EYE | 190 | 62 | 0.18% | 0.02% |
| 45 | MALIGNANT NEOPLASM BRAIN | 191 | 872 | 2.47% | 0.32% |
| 46 | MAL NEOPL NERVE NEC/NOS | 192 | 115 | 0.33% | 0.04% |
| 47 | MALIGNANT NEOPL THYROID | 193 | 170 | 0.48% | 0.06% |
| 48 | MAL NEOPL ENDOCRINE NEC | 194 | 153 | 0.43% | 0.06% |
| 49 | MAL NEOPL ILL-DEF SITES | 195 | 403 | 1.14% | 0.15% |
| 50 | SECONDARY MAL NEOPL LN | 196 | 147 | 0.42% | 0.05% |
| 51 | 2ND MAL NEOPLASM GI/RESP | 197 | 602 | 1.70% | 0.22% |
| 52 | 2ND MAL NEOPL OTH SITES | 198 | 936 | 2.65% | 0.35% |
| 53 | MALIGNANT NEOPLASM NOS | 199 | 1056 | 2.99% | 0.39% |
| 54 | LYMPHOSARC/RETICULOSARC | 200 | 157 | 0.44% | 0.06% |
| 55 | HODGKIN'S DISEASE | 201 | 180 | 0.51% | 0.07% |
| 56 | OTH MAL NEOPL LYMPH/HIST | 202 | 570 | 1.61% | 0.21% |
| 57 | MULTIPLE MYELOMA ET AL | 203 | 152 | 0.43% | 0.06% |
| 58 | LYMPHOID LEUKEMIA | 204 | 292 | 0.83% | 0.11% |
| 59 | MYELOID LEUKEMIA | 205 | 238 | 0.67% | 0.09% |
| 60 | MONOCYTIC LEUKEMIA | 206 | 30 | 0.08% | 0.01% |
| 61 | OTHER SPECIFIED LEUKEMIA | 207 | 24 | 0.07% | 0.01% |
| 62 | LEUKEMIA-UNSPECIF CELL | 208 | 369 | 1.04% | 0.14% |
| 63 | BEN NEOPL MOUTH/PHARYNX | 210 | 145 | 0.41% | 0.05% |
| 64 | OTH BENIGN NEOPLASM GI | 211 | 896 | 2.53% | 0.33% |
| 65 | BEN INTRATHOR NEOPLASM | 212 | 218 | 0.62% | 0.08% |
| 66 | BEN NEOPLASM BONE/CART | 213 | 420 | 1.19% | 0.16% |
| 67 | LIPOMA | 214 | 246 | 0.70% | 0.09% |
| 68 | OTH BEN NEOPL SOFT TISS | 215 | 221 | 0.62% | 0.08% |
| 69 | BENIGN NEOPLASM OF SKIN | 216 | 367 | 1.04% | 0.14% |
| 70 | BENIGN NEOPLASM BREAST | 217 | 156 | 0.44% | 0.06% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1990
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 268455

A6

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | UTERINE LEIOMYOMA | 218 | 3098 | 8.76% | 1.15% |
| 72 | OTH BENIGN NEOPL UTERUS | 219 | 211 | 0.60% | 0.08% |
| 73 | BENIGN NEOPLASM OVARY | 220 | 336 | 0.95% | 0.13% |
| 74 | BEN NEOPL OTH FEM GENIT | 221 | 121 | 0.34% | 0.05% |
| 75 | BENIGN NEOPL MALE GENIT | 222 | 67 | 0.19% | 0.02% |
| 76 | BENIGN NEOPLASM URINARY | 223 | 72 | 0.20% | 0.03% |
| 77 | BENIGN NEOPLASM OF EYE | 224 | 17 | 0.05% | 0.01% |
| 78 | BENIGN NEOPL NERV SYST | 225 | 336 | 0.95% | 0.13% |
| 79 | BENIGN NEOPLASM THYROID | 226 | 176 | 0.50% | 0.07% |
| 80 | BEN NEOPL OTH ENDOCRINE | 227 | 120 | 0.34% | 0.04% |
| 81 | HEMANGIOMA/LYMPHANGIOMA | 228 | 150 | 0.42% | 0.06% |
| 82 | BENIGN NEOPLASM NEC/NOS | 229 | 232 | 0.66% | 0.09% |
| 83 | CA IN SITU DIGESTIVE ORG | 230 | 227 | 0.64% | 0.08% |
| 84 | CA IN SITU RESPIRATORY | 231 | 214 | 0.61% | 0.08% |
| 85 | CARCINOMA IN SITU SKIN | 232 | 28 | 0.08% | 0.01% |
| 86 | CA IN SITU BREAST/GU | 233 | 605 | 1.71% | 0.23% |
| 87 | CA IN SITU NEC/NOS | 234 | 104 | 0.29% | 0.04% |
| 88 | UNC BEHAV NEOPL GI/RESP | 235 | 263 | 0.74% | 0.10% |
| 89 | UNC BEHAV NEOPL GU | 236 | 234 | 0.66% | 0.09% |
| 90 | UNC NEOPL ENDOCR/NERV | 237 | 225 | 0.64% | 0.08% |
| 91 | UNC BEHAV NEOPL NEC/NOS | 238 | 358 | 1.01% | 0.13% |
| 92 | UNSPECIFIED NEOPLASM | 239 | 3413 | 9.65% | 1.27% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1991
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 261205

A7

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 17 | 0.04% | 0.01% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 147 | 0.36% | 0.06% |
| 3 | MAL NEOPL MAJOR SG | 142 | 54 | 0.13% | 0.02% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 17 | 0.04% | 0.01% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 43 | 0.10% | 0.02% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 85 | 0.21% | 0.03% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 68 | 0.16% | 0.03% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 50 | 0.12% | 0.02% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 44 | 0.11% | 0.02% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 73 | 0.18% | 0.03% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 321 | 0.78% | 0.12% |
| 12 | MAL NEOPL STOMACH | 151 | 300 | 0.73% | 0.11% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 55 | 0.13% | 0.02% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1392 | 3.37% | 0.53% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 1096 | 2.65% | 0.42% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 281 | 0.68% | 0.11% |
| 17 | MAL NEOPL GB/BD | 156 | 81 | 0.20% | 0.03% |
| 18 | MAL NEOPL PANCREAS | 157 | 413 | 1.00% | 0.16% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 66 | 0.16% | 0.03% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 58 | 0.14% | 0.02% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 39 | 0.09% | 0.01% |
| 22 | MAL NEOPL LARYNX | 161 | 332 | 0.80% | 0.13% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 3989 | 9.65% | 1.53% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 40 | 0.10% | 0.02% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 50 | 0.12% | 0.02% |
| 26 | MAL NEOPL RESP NEC | 165 | 12 | 0.03% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 344 | 0.83% | 0.13% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 268 | 0.65% | 0.10% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 260 | 0.63% | 0.10% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 369 | 0.89% | 0.14% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 3471 | 8.40% | 1.33% |
| 32 | MAL NEOPL MALE BREAST | 175 | 15 | 0.04% | 0.01% |
| 33 | MAL NEOPL UTERUS NOS | 179 | 127 | 0.31% | 0.05% |
| 34 | MAL NEOPL CERVIX UTERI | 180 | 519 | 1.26% | 0.20% |
| 35 | MALIGNANT NEOPL PLACENTA | 181 | 4 | 0.01% | 0.00% |
| 36 | MAL NEOPL UTERUS BODY | 182 | 320 | 0.77% | 0.12% |
| 37 | MAL NEOPL UTERINE ADNEXA | 183 | 735 | 1.78% | 0.28% |
| 38 | MAL NEOPL FE GENIT NEC | 184 | 86 | 0.21% | 0.03% |
| 39 | MAL NEOPL PROSTATE | 185 | 945 | 2.29% | 0.36% |
| 40 | MAL NEOPL TESTIS | 186 | 51 | 0.12% | 0.02% |
| 41 | MAL NEOPL MALE GENIT NEC | 187 | 18 | 0.04% | 0.01% |
| 42 | MAL NEOPL BLADDER | 188 | 703 | 1.70% | 0.27% |
| 43 | MAL GU NEOPL NEC/NOS | 189 | 530 | 1.28% | 0.20% |
| 44 | MALIGNANT NEOPLASM EYE | 190 | 68 | 0.16% | 0.03% |
| 45 | MALIGNANT NEOPLASM BRAIN | 191 | 1045 | 2.53% | 0.40% |
| 46 | MAL NEOPL NERVE NEC/NOS | 192 | 129 | 0.31% | 0.05% |
| 47 | MALIGNANT NEOPL THYROID | 193 | 197 | 0.48% | 0.08% |
| 48 | MAL NEOPL ENDOCRINE NEC | 194 | 166 | 0.40% | 0.06% |
| 49 | MAL NEOPL ILL-DEF SITES | 195 | 484 | 1.17% | 0.19% |
| 50 | SECONDARY MAL NEOPL LN | 196 | 202 | 0.49% | 0.08% |
| 51 | 2ND MAL NEOPLASM GI/RESP | 197 | 783 | 1.89% | 0.30% |
| 52 | 2ND MAL NEOPL OTH SITES | 198 | 1180 | 2.85% | 0.45% |
| 53 | MALIGNANT NEOPLASM NOS | 199 | 979 | 2.37% | 0.37% |
| 54 | LYMPHOSARC/RETICULOSARC | 200 | 174 | 0.42% | 0.07% |
| 55 | HODGKIN'S DISEASE | 201 | 277 | 0.67% | 0.11% |
| 56 | OTH MAL NEOPL LYMPH/HIST | 202 | 713 | 1.72% | 0.27% |
| 57 | MULTIPLE MYELOMA ET AL | 203 | 197 | 0.48% | 0.08% |
| 58 | LYMPHOID LEUKEMIA | 204 | 391 | 0.95% | 0.15% |
| 59 | MYELOID LEUKEMIA | 205 | 287 | 0.69% | 0.11% |
| 60 | MONOCYTIC LEUKEMIA | 206 | 34 | 0.08% | 0.01% |
| 61 | OTHER SPECIFIED LEUKEMIA | 207 | 23 | 0.06% | 0.01% |
| 62 | LEUKEMIA-UNSPECIF CELL | 208 | 425 | 1.03% | 0.16% |
| 63 | BEN NEOPL MOUTH/PHARYNX | 210 | 154 | 0.37% | 0.06% |
| 64 | OTH BENIGN NEOPLASM GI | 211 | 1143 | 2.76% | 0.44% |
| 65 | BEN INTRATHOR NEOPLASM | 212 | 281 | 0.68% | 0.11% |
| 66 | BEN NEOPLASM BONE/CART | 213 | 291 | 0.70% | 0.11% |
| 67 | LIPOMA | 214 | 221 | 0.53% | 0.08% |
| 68 | OTH BEN NEOPL SOFT TISS | 215 | 207 | 0.50% | 0.08% |
| 69 | BENIGN NEOPLASM OF SKIN | 216 | 424 | 1.03% | 0.16% |
| 70 | BENIGN NEOPLASM BREAST | 217 | 217 | 0.52% | 0.08% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1991
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 261205

A8

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | UTERINE LEIOMYOMA | 218 | 3719 | 9.00% | 1.42% |
| 72 | OTH BENIGN NEOPL UTERUS | 219 | 172 | 0.42% | 0.07% |
| 73 | BENIGN NEOPLASM OVARY | 220 | 389 | 0.94% | 0.15% |
| 74 | BEN NEOPL OTH FEM GENIT | 221 | 107 | 0.26% | 0.04% |
| 75 | BENIGN NEOPL MALE GENIT | 222 | 81 | 0.20% | 0.03% |
| 76 | BENIGN NEOPLASM URINARY | 223 | 74 | 0.18% | 0.03% |
| 77 | BENIGN NEOPLASM OF EYE | 224 | 26 | 0.06% | 0.01% |
| 78 | BENIGN NEOPL NERV SYST | 225 | 397 | 0.96% | 0.15% |
| 79 | BENIGN NEOPLASM THYROID | 226 | 182 | 0.44% | 0.07% |
| 80 | BEN NEOPL OTH ENDOCRINE | 227 | 193 | 0.47% | 0.07% |
| 81 | HEMANGIOMA/LYMPHANGIOMA | 228 | 207 | 0.50% | 0.08% |
| 82 | BENIGN NEOPLASM NEC/NOS | 229 | 259 | 0.63% | 0.10% |
| 83 | CA IN SITU DIGESTIVE ORG | 230 | 261 | 0.63% | 0.10% |
| 84 | CA IN SITU RESPIRATORY | 231 | 215 | 0.52% | 0.08% |
| 85 | CARCINOMA IN SITU SKIN | 232 | 56 | 0.14% | 0.02% |
| 86 | CA IN SITU BREAST/GU | 233 | 819 | 1.98% | 0.31% |
| 87 | CA IN SITU NEC/NOS | 234 | 119 | 0.29% | 0.05% |
| 88 | UNC BEHAV NEOPL GI/RESP | 235 | 349 | 0.84% | 0.13% |
| 89 | UNC BEHAV NEOPL GU | 236 | 302 | 0.73% | 0.12% |
| 90 | UNC NEOPL ENDOCR/NERV | 237 | 278 | 0.67% | 0.11% |
| 91 | UNC BEHAV NEOPL NEC/NOS | 238 | 450 | 1.09% | 0.17% |
| 92 | UNSPECIFIED NEOPLASM | 239 | 4108 | 9.94% | 1.57% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1992
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 246607

A9

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 21 | 0.05% | 0.01% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 159 | 0.41% | 0.06% |
| 3 | MAL NEOPL MAJOR SG | 142 | 50 | 0.13% | 0.02% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 10 | 0.03% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 49 | 0.13% | 0.02% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 75 | 0.19% | 0.03% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 71 | 0.18% | 0.03% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 45 | 0.12% | 0.02% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 41 | 0.10% | 0.02% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 64 | 0.16% | 0.03% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 282 | 0.72% | 0.11% |
| 12 | MAL NEOPL STOMACH | 151 | 276 | 0.71% | 0.11% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 55 | 0.14% | 0.02% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1291 | 3.30% | 0.52% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 967 | 2.47% | 0.39% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 283 | 0.72% | 0.11% |
| 17 | MAL NEOPL GB/BD | 156 | 81 | 0.21% | 0.03% |
| 18 | MAL NEOPL PANCREAS | 157 | 398 | 1.02% | 0.16% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 66 | 0.17% | 0.03% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 46 | 0.12% | 0.02% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 47 | 0.12% | 0.02% |
| 22 | MAL NEOPL LARYNX | 161 | 268 | 0.69% | 0.11% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 3890 | 9.95% | 1.58% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 47 | 0.12% | 0.02% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 57 | 0.15% | 0.02% |
| 26 | MAL NEOPL RESP NEC | 165 | 15 | 0.04% | 0.01% |
| 27 | MAL NEOPL BONE/CART | 170 | 311 | 0.80% | 0.13% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 252 | 0.64% | 0.10% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 249 | 0.64% | 0.10% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 335 | 0.86% | 0.14% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 3186 | 8.15% | 1.29% |
| 32 | MAL NEOPL MALE BREAST | 175 | 16 | 0.04% | 0.01% |
| 33 | KAPOSI'S SARCOMA | 176 | 4 | 0.01% | 0.00% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 100 | 0.26% | 0.04% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 480 | 1.23% | 0.19% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 6 | 0.02% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 305 | 0.78% | 0.12% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 776 | 1.98% | 0.31% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 71 | 0.18% | 0.03% |
| 40 | MAL NEOPL PROSTATE | 185 | 1305 | 3.34% | 0.53% |
| 41 | MAL NEOPL TESTIS | 186 | 58 | 0.15% | 0.02% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 16 | 0.04% | 0.01% |
| 43 | MAL NEOPL BLADDER | 188 | 609 | 1.56% | 0.25% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 482 | 1.23% | 0.20% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 73 | 0.19% | 0.03% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 967 | 2.47% | 0.39% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 107 | 0.27% | 0.04% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 189 | 0.48% | 0.08% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 129 | 0.33% | 0.05% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 460 | 1.18% | 0.19% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 212 | 0.54% | 0.09% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 802 | 2.05% | 0.33% |
| 53 | 2ND MAL NEOPL OTH SITES | 198 | 1088 | 2.78% | 0.44% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 877 | 2.24% | 0.36% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 165 | 0.42% | 0.07% |
| 56 | HODGKIN'S DISEASE | 201 | 188 | 0.48% | 0.08% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 605 | 1.55% | 0.25% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 196 | 0.50% | 0.08% |
| 59 | LYMPHOID LEUKEMIA | 204 | 380 | 0.97% | 0.15% |
| 60 | MYELOID LEUKEMIA | 205 | 280 | 0.72% | 0.11% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 31 | 0.08% | 0.01% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 15 | 0.04% | 0.01% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 396 | 1.01% | 0.16% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 169 | 0.43% | 0.07% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 1141 | 2.92% | 0.46% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 284 | 0.73% | 0.12% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 247 | 0.63% | 0.10% |
| 68 | LIPOMA | 214 | 237 | 0.61% | 0.10% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 211 | 0.54% | 0.09% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 408 | 1.04% | 0.17% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1992
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 246607

A10

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 173 | 0.44% | 0.07% |
| 72 | UTERINE LEIOMYOMA | 218 | 3639 | 9.31% | 1.48% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 157 | 0.40% | 0.06% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 389 | 1.00% | 0.16% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 127 | 0.32% | 0.05% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 81 | 0.21% | 0.03% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 78 | 0.20% | 0.03% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 14 | 0.04% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 385 | 0.98% | 0.16% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 172 | 0.44% | 0.07% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 141 | 0.36% | 0.06% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 187 | 0.48% | 0.08% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 228 | 0.58% | 0.09% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 233 | 0.60% | 0.09% |
| 85 | CA IN SITU RESPIRATORY | 231 | 186 | 0.48% | 0.08% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 47 | 0.12% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 763 | 1.95% | 0.31% |
| 88 | CA IN SITU NEC/NOS | 234 | 71 | 0.18% | 0.03% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 364 | 0.93% | 0.15% |
| 90 | UNC BEHAV NEOPL GU | 236 | 281 | 0.72% | 0.11% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 293 | 0.75% | 0.12% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 531 | 1.36% | 0.22% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 3482 | 8.91% | 1.41% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1993
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 218056

A11

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 17 | 0.04% | 0.01% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 138 | 0.32% | 0.06% |
| 3 | MAL NEOPL MAJOR SG | 142 | 45 | 0.10% | 0.02% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 14 | 0.03% | 0.01% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 56 | 0.13% | 0.03% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 129 | 0.30% | 0.06% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 70 | 0.16% | 0.03% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 59 | 0.14% | 0.03% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 61 | 0.14% | 0.03% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 85 | 0.20% | 0.04% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 357 | 0.82% | 0.16% |
| 12 | MAL NEOPL STOMACH | 151 | 300 | 0.69% | 0.14% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 51 | 0.12% | 0.02% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1472 | 3.40% | 0.68% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 997 | 2.30% | 0.46% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 328 | 0.76% | 0.15% |
| 17 | MAL NEOPL GB/BD | 156 | 80 | 0.18% | 0.04% |
| 18 | MAL NEOPL PANCREAS | 157 | 389 | 0.90% | 0.18% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 58 | 0.13% | 0.03% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 57 | 0.13% | 0.03% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 49 | 0.11% | 0.02% |
| 22 | MAL NEOPL LARYNX | 161 | 264 | 0.61% | 0.12% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 4125 | 9.52% | 1.89% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 42 | 0.10% | 0.02% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 53 | 0.12% | 0.02% |
| 26 | MAL NEOPL RESP NEC | 165 | 13 | 0.03% | 0.01% |
| 27 | MAL NEOPL BONE/CART | 170 | 329 | 0.76% | 0.15% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 260 | 0.60% | 0.12% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 298 | 0.69% | 0.14% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 298 | 0.69% | 0.14% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 3326 | 7.68% | 1.53% |
| 32 | MAL NEOPL MALE BREAST | 175 | 12 | 0.03% | 0.01% |
| 33 | KAPOSI'S SARCOMA | 176 | 9 | 0.02% | 0.00% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 96 | 0.22% | 0.04% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 461 | 1.06% | 0.21% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 6 | 0.01% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 346 | 0.80% | 0.16% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 897 | 2.07% | 0.41% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 69 | 0.16% | 0.03% |
| 40 | MAL NEOPL PROSTATE | 185 | 1676 | 3.87% | 0.77% |
| 41 | MAL NEOPL TESTIS | 186 | 58 | 0.13% | 0.03% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 16 | 0.04% | 0.01% |
| 43 | MAL NEOPL BLADDER | 188 | 634 | 1.46% | 0.29% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 496 | 1.14% | 0.23% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 57 | 0.13% | 0.03% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 1030 | 2.38% | 0.47% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 118 | 0.27% | 0.05% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 201 | 0.46% | 0.09% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 148 | 0.34% | 0.07% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 419 | 0.97% | 0.19% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 226 | 0.52% | 0.10% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 809 | 1.87% | 0.37% |
| 53 | 2ND MAL NEOPL OTH SITES | 198 | 1299 | 3.00% | 0.60% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 836 | 1.93% | 0.38% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 212 | 0.49% | 0.10% |
| 56 | HODGKIN'S DISEASE | 201 | 247 | 0.57% | 0.11% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 780 | 1.80% | 0.36% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 286 | 0.66% | 0.13% |
| 59 | LYMPHOID LEUKEMIA | 204 | 527 | 1.22% | 0.24% |
| 60 | MYELOID LEUKEMIA | 205 | 406 | 0.94% | 0.19% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 37 | 0.09% | 0.02% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 23 | 0.05% | 0.01% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 480 | 1.11% | 0.22% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 187 | 0.43% | 0.09% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 1406 | 3.25% | 0.64% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 326 | 0.75% | 0.15% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 276 | 0.64% | 0.13% |
| 68 | LIPOMA | 214 | 233 | 0.54% | 0.11% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 208 | 0.48% | 0.10% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 406 | 0.94% | 0.19% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1993
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 218056

A12

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 174 | 0.40% | 0.08% |
| 72 | UTERINE LEIOMYOMA | 218 | 4163 | 9.61% | 1.91% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 234 | 0.54% | 0.11% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 399 | 0.92% | 0.18% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 142 | 0.33% | 0.07% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 86 | 0.20% | 0.04% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 108 | 0.25% | 0.05% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 20 | 0.05% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 465 | 1.07% | 0.21% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 197 | 0.45% | 0.09% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 198 | 0.46% | 0.09% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 227 | 0.52% | 0.10% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 244 | 0.56% | 0.11% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 238 | 0.55% | 0.11% |
| 85 | CA IN SITU RESPIRATORY | 231 | 247 | 0.57% | 0.11% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 46 | 0.11% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 840 | 1.94% | 0.39% |
| 88 | CA IN SITU NEC/NOS | 234 | 82 | 0.19% | 0.04% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 424 | 0.98% | 0.19% |
| 90 | UNC BEHAV NEOPL GU | 236 | 310 | 0.72% | 0.14% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 364 | 0.84% | 0.17% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 691 | 1.59% | 0.32% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 3649 | 8.42% | 1.67% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1994
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 200160

A13

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 10 | 0.02% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 151 | 0.37% | 0.08% |
| 3 | MAL NEOPL MAJOR SG | 142 | 37 | 0.09% | 0.02% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 10 | 0.02% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 55 | 0.14% | 0.03% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 106 | 0.26% | 0.05% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 65 | 0.16% | 0.03% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 42 | 0.10% | 0.02% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 40 | 0.10% | 0.02% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 61 | 0.15% | 0.03% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 327 | 0.80% | 0.16% |
| 12 | MAL NEOPL STOMACH | 151 | 323 | 0.79% | 0.16% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 50 | 0.12% | 0.02% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1412 | 3.47% | 0.71% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 972 | 2.39% | 0.49% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 275 | 0.68% | 0.14% |
| 17 | MAL NEOPL GB/BD | 156 | 69 | 0.17% | 0.03% |
| 18 | MAL NEOPL PANCREAS | 157 | 410 | 1.01% | 0.20% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 57 | 0.14% | 0.03% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 45 | 0.11% | 0.02% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 43 | 0.11% | 0.02% |
| 22 | MAL NEOPL LARYNX | 161 | 254 | 0.62% | 0.13% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 3888 | 9.57% | 1.94% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 47 | 0.12% | 0.02% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 47 | 0.12% | 0.02% |
| 26 | MAL NEOPL RESP NEC | 165 | 12 | 0.03% | 0.01% |
| 27 | MAL NEOPL BONE/CART | 170 | 283 | 0.70% | 0.14% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 272 | 0.67% | 0.14% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 242 | 0.60% | 0.12% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 331 | 0.81% | 0.17% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 3137 | 7.72% | 1.57% |
| 32 | MAL NEOPL MALE BREAST | 175 | 19 | 0.05% | 0.01% |
| 33 | KAPOSI'S SARCOMA | 176 | 8 | 0.02% | 0.00% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 83 | 0.20% | 0.04% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 450 | 1.11% | 0.22% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 3 | 0.01% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 335 | 0.82% | 0.17% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 815 | 2.01% | 0.41% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 69 | 0.17% | 0.03% |
| 40 | MAL NEOPL PROSTATE | 185 | 1572 | 3.87% | 0.79% |
| 41 | MAL NEOPL TESTIS | 186 | 45 | 0.11% | 0.02% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 20 | 0.05% | 0.01% |
| 43 | MAL NEOPL BLADDER | 188 | 544 | 1.34% | 0.27% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 507 | 1.25% | 0.25% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 59 | 0.15% | 0.03% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 971 | 2.39% | 0.49% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 117 | 0.29% | 0.06% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 196 | 0.48% | 0.10% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 144 | 0.35% | 0.07% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 340 | 0.84% | 0.17% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 208 | 0.51% | 0.10% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 844 | 2.08% | 0.42% |
| 53 | 2ND MAL NEOPL OTH SITES | 198 | 1126 | 2.77% | 0.56% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 648 | 1.59% | 0.32% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 230 | 0.57% | 0.11% |
| 56 | HODGKIN'S DISEASE | 201 | 219 | 0.54% | 0.11% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 763 | 1.88% | 0.38% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 243 | 0.60% | 0.12% |
| 59 | LYMPHOID LEUKEMIA | 204 | 494 | 1.22% | 0.25% |
| 60 | MYELOID LEUKEMIA | 205 | 375 | 0.92% | 0.19% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 35 | 0.09% | 0.02% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 8 | 0.02% | 0.00% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 409 | 1.01% | 0.20% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 203 | 0.50% | 0.10% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 1408 | 3.46% | 0.70% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 351 | 0.86% | 0.18% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 236 | 0.58% | 0.12% |
| 68 | LIPOMA | 214 | 213 | 0.52% | 0.11% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 190 | 0.47% | 0.09% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 390 | 0.96% | 0.19% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1994
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 200160

A14

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 172 | 0.42% | 0.09% |
| 72 | UTERINE LEIOMYOMA | 218 | 3775 | 9.29% | 1.89% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 231 | 0.57% | 0.12% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 350 | 0.86% | 0.17% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 127 | 0.31% | 0.06% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 82 | 0.20% | 0.04% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 123 | 0.30% | 0.06% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 17 | 0.04% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 532 | 1.31% | 0.27% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 159 | 0.39% | 0.08% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 190 | 0.47% | 0.09% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 195 | 0.48% | 0.10% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 261 | 0.64% | 0.13% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 247 | 0.61% | 0.12% |
| 85 | CA IN SITU RESPIRATORY | 231 | 222 | 0.55% | 0.11% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 44 | 0.11% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 840 | 2.07% | 0.42% |
| 88 | CA IN SITU NEC/NOS | 234 | 59 | 0.15% | 0.03% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 384 | 0.94% | 0.19% |
| 90 | UNC BEHAV NEOPL GU | 236 | 296 | 0.73% | 0.15% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 345 | 0.85% | 0.17% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 598 | 1.47% | 0.30% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 3432 | 8.44% | 1.71% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1995
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 195248

A15

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 12 | 0.03% | 0.01% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 140 | 0.38% | 0.07% |
| 3 | MAL NEOPL MAJOR SG | 142 | 39 | 0.11% | 0.02% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 11 | 0.03% | 0.01% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 57 | 0.15% | 0.03% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 78 | 0.21% | 0.04% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 79 | 0.21% | 0.04% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 39 | 0.11% | 0.02% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 49 | 0.13% | 0.03% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 56 | 0.15% | 0.03% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 291 | 0.78% | 0.15% |
| 12 | MAL NEOPL STOMACH | 151 | 319 | 0.86% | 0.16% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 57 | 0.15% | 0.03% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1402 | 3.78% | 0.72% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 928 | 2.50% | 0.48% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 277 | 0.75% | 0.14% |
| 17 | MAL NEOPL GB/BD | 156 | 79 | 0.21% | 0.04% |
| 18 | MAL NEOPL PANCREAS | 157 | 358 | 0.96% | 0.18% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 58 | 0.16% | 0.03% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 47 | 0.13% | 0.02% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 42 | 0.11% | 0.02% |
| 22 | MAL NEOPL LARYNX | 161 | 238 | 0.64% | 0.12% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 3483 | 9.38% | 1.78% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 50 | 0.13% | 0.03% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 57 | 0.15% | 0.03% |
| 26 | MAL NEOPL RESP NEC | 165 | 5 | 0.01% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 267 | 0.72% | 0.14% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 237 | 0.64% | 0.12% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 207 | 0.56% | 0.11% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 231 | 0.62% | 0.12% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 2970 | 8.00% | 1.52% |
| 32 | MAL NEOPL MALE BREAST | 175 | 21 | 0.06% | 0.01% |
| 33 | KAPOSI'S SARCOMA | 176 | 3 | 0.01% | 0.00% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 98 | 0.26% | 0.05% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 421 | 1.13% | 0.22% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 2 | 0.01% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 319 | 0.86% | 0.16% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 689 | 1.86% | 0.35% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 49 | 0.13% | 0.03% |
| 40 | MAL NEOPL PROSTATE | 185 | 1574 | 4.24% | 0.81% |
| 41 | MAL NEOPL TESTIS | 186 | 51 | 0.14% | 0.03% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 14 | 0.04% | 0.01% |
| 43 | MAL NEOPL BLADDER | 188 | 554 | 1.49% | 0.28% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 488 | 1.31% | 0.25% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 48 | 0.13% | 0.02% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 892 | 2.40% | 0.46% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 103 | 0.28% | 0.05% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 216 | 0.58% | 0.11% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 112 | 0.30% | 0.06% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 295 | 0.79% | 0.15% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 173 | 0.47% | 0.09% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 846 | 2.28% | 0.43% |
| 53 | 2ND MAL NEOPL OTH SITES | 198 | 1022 | 2.75% | 0.52% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 597 | 1.61% | 0.31% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 181 | 0.49% | 0.09% |
| 56 | HODGKIN'S DISEASE | 201 | 185 | 0.50% | 0.09% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 682 | 1.84% | 0.35% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 227 | 0.61% | 0.12% |
| 59 | LYMPHOID LEUKEMIA | 204 | 405 | 1.09% | 0.21% |
| 60 | MYELOID LEUKEMIA | 205 | 346 | 0.93% | 0.18% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 23 | 0.06% | 0.01% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 12 | 0.03% | 0.01% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 406 | 1.09% | 0.21% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 150 | 0.40% | 0.08% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 1360 | 3.66% | 0.70% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 284 | 0.76% | 0.15% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 200 | 0.54% | 0.10% |
| 68 | LIPOMA | 214 | 194 | 0.52% | 0.10% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 151 | 0.41% | 0.08% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 298 | 0.80% | 0.15% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1995
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 195248

A16

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 149 | 0.40% | 0.08% |
| 72 | UTERINE LEIOMYOMA | 218 | 3580 | 9.64% | 1.83% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 239 | 0.64% | 0.12% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 366 | 0.99% | 0.19% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 130 | 0.35% | 0.07% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 70 | 0.19% | 0.04% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 99 | 0.27% | 0.05% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 23 | 0.06% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 430 | 1.16% | 0.22% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 186 | 0.50% | 0.10% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 192 | 0.52% | 0.10% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 168 | 0.45% | 0.09% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 261 | 0.70% | 0.13% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 207 | 0.56% | 0.11% |
| 85 | CA IN SITU RESPIRATORY | 231 | 176 | 0.47% | 0.09% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 30 | 0.08% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 670 | 1.80% | 0.34% |
| 88 | CA IN SITU NEC/NOS | 234 | 44 | 0.12% | 0.02% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 371 | 1.00% | 0.19% |
| 90 | UNC BEHAV NEOPL GU | 236 | 266 | 0.72% | 0.14% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 291 | 0.78% | 0.15% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 446 | 1.20% | 0.23% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 2881 | 7.76% | 1.48% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1996
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 173265

A17

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 15 | 0.04% | 0.01% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 140 | 0.40% | 0.08% |
| 3 | MAL NEOPL MAJOR SG | 142 | 32 | 0.09% | 0.02% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 8 | 0.02% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 45 | 0.13% | 0.03% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 66 | 0.19% | 0.04% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 71 | 0.20% | 0.04% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 50 | 0.14% | 0.03% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 39 | 0.11% | 0.02% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 50 | 0.14% | 0.03% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 313 | 0.88% | 0.18% |
| 12 | MAL NEOPL STOMACH | 151 | 313 | 0.88% | 0.18% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 51 | 0.14% | 0.03% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1286 | 3.63% | 0.74% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 820 | 2.31% | 0.47% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 242 | 0.68% | 0.14% |
| 17 | MAL NEOPL GB/BD | 156 | 90 | 0.25% | 0.05% |
| 18 | MAL NEOPL PANCREAS | 157 | 350 | 0.99% | 0.20% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 70 | 0.20% | 0.04% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 41 | 0.12% | 0.02% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 44 | 0.12% | 0.03% |
| 22 | MAL NEOPL LARYNX | 161 | 183 | 0.52% | 0.11% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 3302 | 9.32% | 1.91% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 35 | 0.10% | 0.02% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 61 | 0.17% | 0.04% |
| 26 | MAL NEOPL RESP NEC | 165 | 6 | 0.02% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 236 | 0.67% | 0.14% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 249 | 0.70% | 0.14% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 200 | 0.56% | 0.12% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 239 | 0.67% | 0.14% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 2722 | 7.68% | 1.57% |
| 32 | MAL NEOPL MALE BREAST | 175 | 14 | 0.04% | 0.01% |
| 33 | KAPOSI'S SARCOMA | 176 | 13 | 0.04% | 0.01% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 103 | 0.29% | 0.06% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 438 | 1.24% | 0.25% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 6 | 0.02% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 337 | 0.95% | 0.19% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 696 | 1.96% | 0.40% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 56 | 0.16% | 0.03% |
| 40 | MAL NEOPL PROSTATE | 185 | 1424 | 4.02% | 0.82% |
| 41 | MAL NEOPL TESTIS | 186 | 39 | 0.11% | 0.02% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 17 | 0.05% | 0.01% |
| 43 | MAL NEOPL BLADDER | 188 | 453 | 1.28% | 0.26% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 460 | 1.30% | 0.27% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 40 | 0.11% | 0.02% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 869 | 2.45% | 0.50% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 88 | 0.25% | 0.05% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 205 | 0.58% | 0.12% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 125 | 0.35% | 0.07% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 302 | 0.85% | 0.17% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 202 | 0.57% | 0.12% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 810 | 2.29% | 0.47% |
| 53 | 2ND MAL NEOPL OTH SITES | 198 | 995 | 2.81% | 0.57% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 554 | 1.56% | 0.32% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 179 | 0.51% | 0.10% |
| 56 | HODGKIN'S DISEASE | 201 | 139 | 0.39% | 0.08% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 726 | 2.05% | 0.42% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 222 | 0.63% | 0.13% |
| 59 | LYMPHOID LEUKEMIA | 204 | 385 | 1.09% | 0.22% |
| 60 | MYELOID LEUKEMIA | 205 | 321 | 0.91% | 0.19% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 22 | 0.06% | 0.01% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 8 | 0.02% | 0.00% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 327 | 0.92% | 0.19% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 111 | 0.31% | 0.06% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 1313 | 3.71% | 0.76% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 290 | 0.82% | 0.17% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 173 | 0.49% | 0.10% |
| 68 | LIPOMA | 214 | 136 | 0.38% | 0.08% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 165 | 0.47% | 0.10% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 272 | 0.77% | 0.16% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1996
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 173265

A18

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 155 | 0.44% | 0.09% |
| 72 | UTERINE LEIOMYOMA | 218 | 3797 | 10.72% | 2.19% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 213 | 0.60% | 0.12% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 394 | 1.11% | 0.23% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 156 | 0.44% | 0.09% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 52 | 0.15% | 0.03% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 93 | 0.26% | 0.05% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 16 | 0.05% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 458 | 1.29% | 0.26% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 154 | 0.43% | 0.09% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 207 | 0.58% | 0.12% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 141 | 0.40% | 0.08% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 183 | 0.52% | 0.11% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 194 | 0.55% | 0.11% |
| 85 | CA IN SITU RESPIRATORY | 231 | 126 | 0.36% | 0.07% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 26 | 0.07% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 584 | 1.65% | 0.34% |
| 88 | CA IN SITU NEC/NOS | 234 | 46 | 0.13% | 0.03% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 448 | 1.26% | 0.26% |
| 90 | UNC BEHAV NEOPL GU | 236 | 314 | 0.89% | 0.18% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 344 | 0.97% | 0.20% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 479 | 1.35% | 0.28% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 2443 | 6.90% | 1.41% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1988
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1726444

A19

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 56 | 0.09% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 270 | 0.45% | 0.02% |
| 3 | MAL NEOPL MAJOR SG | 142 | 80 | 0.13% | 0.00% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 24 | 0.04% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 75 | 0.12% | 0.00% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 172 | 0.29% | 0.01% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 147 | 0.24% | 0.01% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 116 | 0.19% | 0.01% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 67 | 0.11% | 0.00% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 156 | 0.26% | 0.01% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 306 | 0.51% | 0.02% |
| 12 | MAL NEOPL STOMACH | 151 | 347 | 0.58% | 0.02% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 41 | 0.07% | 0.00% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1406 | 2.34% | 0.08% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 1630 | 2.71% | 0.09% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 412 | 0.69% | 0.02% |
| 17 | MAL NEOPL GB/BD | 156 | 81 | 0.13% | 0.00% |
| 18 | MAL NEOPL PANCREAS | 157 | 361 | 0.60% | 0.02% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 52 | 0.09% | 0.00% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 146 | 0.24% | 0.01% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 104 | 0.17% | 0.01% |
| 22 | MAL NEOPL LARYNX | 161 | 482 | 0.80% | 0.03% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 4342 | 7.22% | 0.25% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 49 | 0.08% | 0.00% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 85 | 0.14% | 0.00% |
| 26 | MAL NEOPL RESP NEC | 165 | 29 | 0.05% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 654 | 1.09% | 0.04% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 555 | 0.92% | 0.03% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 558 | 0.93% | 0.03% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 1888 | 3.14% | 0.11% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 5771 | 9.60% | 0.33% |
| 32 | MAL NEOPL MALE BREAST | 175 | 57 | 0.09% | 0.00% |
| 33 | MAL NEOPL UTERUS NOS | 179 | 227 | 0.38% | 0.01% |
| 34 | MAL NEOPL CERVIX UTERI | 180 | 762 | 1.27% | 0.04% |
| 35 | MALIGNANT NEOPL PLACENTA | 181 | 9 | 0.01% | 0.00% |
| 36 | MAL NEOPL UTERUS BODY | 182 | 352 | 0.59% | 0.02% |
| 37 | MAL NEOPL UTERINE ADNEXA | 183 | 713 | 1.19% | 0.04% |
| 38 | MAL NEOPL FE GENIT NEC | 184 | 135 | 0.22% | 0.01% |
| 39 | MAL NEOPL PROSTATE | 185 | 878 | 1.46% | 0.05% |
| 40 | MAL NEOPL TESTIS | 186 | 71 | 0.12% | 0.00% |
| 41 | MAL NEOPL MALE GENIT NEC | 187 | 33 | 0.05% | 0.00% |
| 42 | MAL NEOPL BLADDER | 188 | 826 | 1.37% | 0.05% |
| 43 | MAL GU NEOPL NEC/NOS | 189 | 552 | 0.92% | 0.03% |
| 44 | MALIGNANT NEOPLASM EYE | 190 | 176 | 0.29% | 0.01% |
| 45 | MALIGNANT NEOPLASM BRAIN | 191 | 1286 | 2.14% | 0.07% |
| 46 | MAL NEOPL NERVE NEC/NOS | 192 | 141 | 0.23% | 0.01% |
| 47 | MALIGNANT NEOPL THYROID | 193 | 241 | 0.40% | 0.01% |
| 48 | MAL NEOPL ENDOCRINE NEC | 194 | 229 | 0.38% | 0.01% |
| 49 | MAL NEOPL ILL-DEF SITES | 195 | 1030 | 1.71% | 0.06% |
| 50 | SECONDARY MAL NEOPL LN | 196 | 224 | 0.37% | 0.01% |
| 51 | 2ND MAL NEOPLASM GI/RESP | 197 | 612 | 1.02% | 0.04% |
| 52 | 2ND MAL NEOPL OTH SITES | 198 | 993 | 1.65% | 0.06% |
| 53 | MALIGNANT NEOPLASM NOS | 199 | 3808 | 6.33% | 0.22% |
| 54 | LYMPHOSARC/RETICULOSARC | 200 | 252 | 0.42% | 0.01% |
| 55 | HODGKIN'S DISEASE | 201 | 404 | 0.67% | 0.02% |
| 56 | OTH MAL NEOPL LYMPH/HIST | 202 | 1073 | 1.78% | 0.06% |
| 57 | MULTIPLE MYELOMA ET AL | 203 | 288 | 0.48% | 0.02% |
| 58 | LYMPHOID LEUKEMIA | 204 | 516 | 0.86% | 0.03% |
| 59 | MYELOID LEUKEMIA | 205 | 319 | 0.53% | 0.02% |
| 60 | MONOCYTIC LEUKEMIA | 206 | 43 | 0.07% | 0.00% |
| 61 | OTHER SPECIFIED LEUKEMIA | 207 | 43 | 0.07% | 0.00% |
| 62 | LEUKEMIA-UNSPECIF CELL | 208 | 638 | 1.06% | 0.04% |
| 63 | BEN NEOPL MOUTH/PHARYNX | 210 | 215 | 0.36% | 0.01% |
| 64 | OTH BENIGN NEOPLASM GI | 211 | 2006 | 3.34% | 0.12% |
| 65 | BEN INTRATHOR NEOPLASM | 212 | 211 | 0.35% | 0.01% |
| 66 | BEN NEOPLASM BONE/CART | 213 | 661 | 1.10% | 0.04% |
| 67 | LIPOMA | 214 | 561 | 0.93% | 0.03% |
| 68 | OTH BEN NEOPL SOFT TISS | 215 | 369 | 0.61% | 0.02% |
| 69 | BENIGN NEOPLASM OF SKIN | 216 | 2509 | 4.17% | 0.15% |
| 70 | BENIGN NEOPLASM BREAST | 217 | 631 | 1.05% | 0.04% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1988
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1726444

A20

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | UTERINE LEIOMYOMA | 218 | 2213 | 3.68% | 0.13% |
| 72 | OTH BENIGN NEOPL UTERUS | 219 | 167 | 0.28% | 0.01% |
| 73 | BENIGN NEOPLASM OVARY | 220 | 148 | 0.25% | 0.01% |
| 74 | BEN NEOPL OTH FEM GENIT | 221 | 94 | 0.16% | 0.01% |
| 75 | BENIGN NEOPL MALE GENIT | 222 | 55 | 0.09% | 0.00% |
| 76 | BENIGN NEOPLASM URINARY | 223 | 116 | 0.19% | 0.01% |
| 77 | BENIGN NEOPLASM OF EYE | 224 | 83 | 0.14% | 0.00% |
| 78 | BENIGN NEOPL NERV SYST | 225 | 373 | 0.62% | 0.02% |
| 79 | BENIGN NEOPLASM THYROID | 226 | 97 | 0.16% | 0.01% |
| 80 | BEN NEOPL OTH ENDOCRINE | 227 | 118 | 0.20% | 0.01% |
| 81 | HEMANGIOMA/LYMPHANGIOMA | 228 | 320 | 0.53% | 0.02% |
| 82 | BENIGN NEOPLASM NEC/NOS | 229 | 566 | 0.94% | 0.03% |
| 83 | CA IN SITU DIGESTIVE ORG | 230 | 263 | 0.44% | 0.02% |
| 84 | CA IN SITU RESPIRATORY | 231 | 281 | 0.47% | 0.02% |
| 85 | CARCINOMA IN SITU SKIN | 232 | 169 | 0.28% | 0.01% |
| 86 | CA IN SITU BREAST/GU | 233 | 862 | 1.43% | 0.05% |
| 87 | CA IN SITU NEC/NOS | 234 | 189 | 0.31% | 0.01% |
| 88 | UNC BEHAV NEOPL GI/RESP | 235 | 333 | 0.55% | 0.02% |
| 89 | UNC BEHAV NEOPL GU | 236 | 228 | 0.38% | 0.01% |
| 90 | UNC NEOPL ENDOCR/NERV | 237 | 286 | 0.48% | 0.02% |
| 91 | UNC BEHAV NEOPL NEC/NOS | 238 | 919 | 1.53% | 0.05% |
| 92 | UNSPECIFIED NEOPLASM | 239 | 7695 | 12.80% | 0.45% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1989
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1989784

A21

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 61 | 0.09% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 294 | 0.42% | 0.01% |
| 3 | MAL NEOPL MAJOR SG | 142 | 67 | 0.10% | 0.00% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 15 | 0.02% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 90 | 0.13% | 0.00% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 223 | 0.32% | 0.01% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 152 | 0.22% | 0.01% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 155 | 0.22% | 0.01% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 76 | 0.11% | 0.00% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 220 | 0.32% | 0.01% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 366 | 0.53% | 0.02% |
| 12 | MAL NEOPL STOMACH | 151 | 366 | 0.53% | 0.02% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 61 | 0.09% | 0.00% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 1784 | 2.58% | 0.09% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 1820 | 2.63% | 0.09% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 461 | 0.67% | 0.02% |
| 17 | MAL NEOPL GB/BD | 156 | 70 | 0.10% | 0.00% |
| 18 | MAL NEOPL PANCREAS | 157 | 387 | 0.56% | 0.02% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 56 | 0.08% | 0.00% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 151 | 0.22% | 0.01% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 99 | 0.14% | 0.00% |
| 22 | MAL NEOPL LARYNX | 161 | 599 | 0.86% | 0.03% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 5063 | 7.31% | 0.25% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 44 | 0.06% | 0.00% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 90 | 0.13% | 0.00% |
| 26 | MAL NEOPL RESP NEC | 165 | 33 | 0.05% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 741 | 1.07% | 0.04% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 583 | 0.84% | 0.03% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 723 | 1.04% | 0.04% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 2155 | 3.11% | 0.11% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 7030 | 10.15% | 0.35% |
| 32 | MAL NEOPL MALE BREAST | 175 | 49 | 0.07% | 0.00% |
| 33 | MAL NEOPL UTERUS NOS | 179 | 246 | 0.36% | 0.01% |
| 34 | MAL NEOPL CERVIX UTERI | 180 | 826 | 1.19% | 0.04% |
| 35 | MALIGNANT NEOPL PLACENTA | 181 | 12 | 0.02% | 0.00% |
| 36 | MAL NEOPL UTERUS BODY | 182 | 419 | 0.60% | 0.02% |
| 37 | MAL NEOPL UTERINE ADNEXA | 183 | 891 | 1.29% | 0.04% |
| 38 | MAL NEOPL FE GENIT NEC | 184 | 174 | 0.25% | 0.01% |
| 39 | MAL NEOPL PROSTATE | 185 | 1170 | 1.69% | 0.06% |
| 40 | MAL NEOPL TESTIS | 186 | 93 | 0.13% | 0.00% |
| 41 | MAL NEOPL MALE GENIT NEC | 187 | 37 | 0.05% | 0.00% |
| 42 | MAL NEOPL BLADDER | 188 | 1103 | 1.59% | 0.06% |
| 43 | MAL GU NEOPL NEC/NOS | 189 | 680 | 0.98% | 0.03% |
| 44 | MALIGNANT NEOPLASM EYE | 190 | 196 | 0.28% | 0.01% |
| 45 | MALIGNANT NEOPLASM BRAIN | 191 | 1377 | 1.99% | 0.07% |
| 46 | MAL NEOPL NERVE NEC/NOS | 192 | 165 | 0.24% | 0.01% |
| 47 | MALIGNANT NEOPL THYROID | 193 | 279 | 0.40% | 0.01% |
| 48 | MAL NEOPL ENDOCRINE NEC | 194 | 246 | 0.36% | 0.01% |
| 49 | MAL NEOPL ILL-DEF SITES | 195 | 1063 | 1.53% | 0.05% |
| 50 | SECONDARY MAL NEOPL LN | 196 | 252 | 0.36% | 0.01% |
| 51 | 2ND MAL NEOPLASM GI/RESP | 197 | 764 | 1.10% | 0.04% |
| 52 | 2ND MAL NEOPL OTH SITES | 198 | 1239 | 1.79% | 0.06% |
| 53 | MALIGNANT NEOPLASM NOS | 199 | 4021 | 5.80% | 0.20% |
| 54 | LYMPHOSARC/RETICULOSARC | 200 | 331 | 0.48% | 0.02% |
| 55 | HODGKIN'S DISEASE | 201 | 466 | 0.67% | 0.02% |
| 56 | OTH MAL NEOPL LYMPH/HIST | 202 | 1225 | 1.77% | 0.06% |
| 57 | MULTIPLE MYELOMA ET AL | 203 | 356 | 0.51% | 0.02% |
| 58 | LYMPHOID LEUKEMIA | 204 | 624 | 0.90% | 0.03% |
| 59 | MYELOID LEUKEMIA | 205 | 331 | 0.48% | 0.02% |
| 60 | MONOCYTIC LEUKEMIA | 206 | 36 | 0.05% | 0.00% |
| 61 | OTHER SPECIFIED LEUKEMIA | 207 | 56 | 0.08% | 0.00% |
| 62 | LEUKEMIA-UNSPECIF CELL | 208 | 691 | 1.00% | 0.03% |
| 63 | BEN NEOPL MOUTH/PHARYNX | 210 | 259 | 0.37% | 0.01% |
| 64 | OTH BENIGN NEOPLASM GI | 211 | 2480 | 3.58% | 0.12% |
| 65 | BEN INTRATHOR NEOPLASM | 212 | 266 | 0.38% | 0.01% |
| 66 | BEN NEOPLASM BONE/CART | 213 | 647 | 0.93% | 0.03% |
| 67 | LIPOMA | 214 | 690 | 1.00% | 0.03% |
| 68 | OTH BEN NEOPL SOFT TISS | 215 | 548 | 0.79% | 0.03% |
| 69 | BENIGN NEOPLASM OF SKIN | 216 | 2913 | 4.21% | 0.15% |
| 70 | BENIGN NEOPLASM BREAST | 217 | 713 | 1.03% | 0.04% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1989
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1989784

A22

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | UTERINE LEIOMYOMA | 218 | 2480 | 3.58% | 0.12% |
| 72 | OTH BENIGN NEOPL UTERUS | 219 | 160 | 0.23% | 0.01% |
| 73 | BENIGN NEOPLASM OVARY | 220 | 156 | 0.23% | 0.01% |
| 74 | BEN NEOPL OTH FEM GENIT | 221 | 99 | 0.14% | 0.00% |
| 75 | BENIGN NEOPL MALE GENIT | 222 | 75 | 0.11% | 0.00% |
| 76 | BENIGN NEOPLASM URINARY | 223 | 141 | 0.20% | 0.01% |
| 77 | BENIGN NEOPLASM OF EYE | 224 | 91 | 0.13% | 0.00% |
| 78 | BENIGN NEOPL NERV SYST | 225 | 473 | 0.68% | 0.02% |
| 79 | BENIGN NEOPLASM THYROID | 226 | 125 | 0.18% | 0.01% |
| 80 | BEN NEOPL OTH ENDOCRINE | 227 | 185 | 0.27% | 0.01% |
| 81 | HEMANGIOMA/LYMPHANGIOMA | 228 | 411 | 0.59% | 0.02% |
| 82 | BENIGN NEOPLASM NEC/NOS | 229 | 614 | 0.89% | 0.03% |
| 83 | CA IN SITU DIGESTIVE ORG | 230 | 332 | 0.48% | 0.02% |
| 84 | CA IN SITU RESPIRATORY | 231 | 344 | 0.50% | 0.02% |
| 85 | CARCINOMA IN SITU SKIN | 232 | 262 | 0.38% | 0.01% |
| 86 | CA IN SITU BREAST/GU | 233 | 1140 | 1.65% | 0.06% |
| 87 | CA IN SITU NEC/NOS | 234 | 288 | 0.42% | 0.01% |
| 88 | UNC BEHAV NEOPL GI/RESP | 235 | 392 | 0.57% | 0.02% |
| 89 | UNC BEHAV NEOPL GU | 236 | 260 | 0.38% | 0.01% |
| 90 | UNC NEOPL ENDOCR/NERV | 237 | 375 | 0.54% | 0.02% |
| 91 | UNC BEHAV NEOPL NEC/NOS | 238 | 1064 | 1.54% | 0.05% |
| 92 | UNSPECIFIED NEOPLASM | 239 | 7834 | 11.31% | 0.39% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1990
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2303450

A23

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 65 | 0.08% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 353 | 0.45% | 0.02% |
| 3 | MAL NEOPL MAJOR SG | 142 | 96 | 0.12% | 0.00% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 38 | 0.05% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 97 | 0.12% | 0.00% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 249 | 0.32% | 0.01% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 179 | 0.23% | 0.01% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 153 | 0.19% | 0.01% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 117 | 0.15% | 0.01% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 245 | 0.31% | 0.01% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 446 | 0.57% | 0.02% |
| 12 | MAL NEOPL STOMACH | 151 | 433 | 0.55% | 0.02% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 86 | 0.11% | 0.00% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 2192 | 2.78% | 0.10% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 1924 | 2.44% | 0.08% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 477 | 0.61% | 0.02% |
| 17 | MAL NEOPL GB/BD | 156 | 96 | 0.12% | 0.00% |
| 18 | MAL NEOPL PANCREAS | 157 | 456 | 0.58% | 0.02% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 87 | 0.11% | 0.00% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 174 | 0.22% | 0.01% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 88 | 0.11% | 0.00% |
| 22 | MAL NEOPL LARYNX | 161 | 675 | 0.86% | 0.03% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 5615 | 7.13% | 0.24% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 52 | 0.07% | 0.00% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 76 | 0.10% | 0.00% |
| 26 | MAL NEOPL RESP NEC | 165 | 21 | 0.03% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 789 | 1.00% | 0.03% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 641 | 0.81% | 0.03% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 792 | 1.01% | 0.03% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 2461 | 3.13% | 0.11% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 8092 | 10.28% | 0.35% |
| 32 | MAL NEOPL MALE BREAST | 175 | 49 | 0.06% | 0.00% |
| 33 | MAL NEOPL UTERUS NOS | 179 | 226 | 0.29% | 0.01% |
| 34 | MAL NEOPL CERVIX UTERI | 180 | 895 | 1.14% | 0.04% |
| 35 | MALIGNANT NEOPL PLACENTA | 181 | 14 | 0.02% | 0.00% |
| 36 | MAL NEOPL UTERUS BODY | 182 | 454 | 0.58% | 0.02% |
| 37 | MAL NEOPL UTERINE ADNEXA | 183 | 1093 | 1.39% | 0.05% |
| 38 | MAL NEOPL FE GENIT NEC | 184 | 172 | 0.22% | 0.01% |
| 39 | MAL NEOPL PROSTATE | 185 | 1461 | 1.86% | 0.06% |
| 40 | MAL NEOPL TESTIS | 186 | 119 | 0.15% | 0.01% |
| 41 | MAL NEOPL MALE GENIT NEC | 187 | 47 | 0.06% | 0.00% |
| 42 | MAL NEOPL BLADDER | 188 | 1286 | 1.63% | 0.06% |
| 43 | MAL GU NEOPL NEC/NOS | 189 | 830 | 1.05% | 0.04% |
| 44 | MALIGNANT NEOPLASM EYE | 190 | 234 | 0.30% | 0.01% |
| 45 | MALIGNANT NEOPLASM BRAIN | 191 | 1523 | 1.93% | 0.07% |
| 46 | MAL NEOPL NERVE NEC/NOS | 192 | 171 | 0.22% | 0.01% |
| 47 | MALIGNANT NEOPL THYROID | 193 | 319 | 0.41% | 0.01% |
| 48 | MAL NEOPL ENDOCRINE NEC | 194 | 272 | 0.35% | 0.01% |
| 49 | MAL NEOPL ILL-DEF SITES | 195 | 1118 | 1.42% | 0.05% |
| 50 | SECONDARY MAL NEOPL LN | 196 | 307 | 0.39% | 0.01% |
| 51 | 2ND MAL NEOPLASM GI/RESP | 197 | 843 | 1.07% | 0.04% |
| 52 | 2ND MAL NEOPL OTH SITES | 198 | 1517 | 1.93% | 0.07% |
| 53 | MALIGNANT NEOPLASM NOS | 199 | 4077 | 5.18% | 0.18% |
| 54 | LYMPHOSARC/RETICULOSARC | 200 | 403 | 0.51% | 0.02% |
| 55 | HODGKIN'S DISEASE | 201 | 541 | 0.69% | 0.02% |
| 56 | OTH MAL NEOPL LYMPH/HIST | 202 | 1391 | 1.77% | 0.06% |
| 57 | MULTIPLE MYELOMA ET AL | 203 | 366 | 0.46% | 0.02% |
| 58 | LYMPHOID LEUKEMIA | 204 | 744 | 0.94% | 0.03% |
| 59 | MYELOID LEUKEMIA | 205 | 393 | 0.50% | 0.02% |
| 60 | MONOCYTIC LEUKEMIA | 206 | 39 | 0.05% | 0.00% |
| 61 | OTHER SPECIFIED LEUKEMIA | 207 | 46 | 0.06% | 0.00% |
| 62 | LEUKEMIA-UNSPECIF CELL | 208 | 777 | 0.99% | 0.03% |
| 63 | BEN NEOPL MOUTH/PHARYNX | 210 | 296 | 0.38% | 0.01% |
| 64 | OTH BENIGN NEOPLASM GI | 211 | 2876 | 3.65% | 0.12% |
| 65 | BEN INTRATHOR NEOPLASM | 212 | 344 | 0.44% | 0.01% |
| 66 | BEN NEOPLASM BONE/CART | 213 | 564 | 0.72% | 0.02% |
| 67 | LIPOMA | 214 | 825 | 1.05% | 0.04% |
| 68 | OTH BEN NEOPL SOFT TISS | 215 | 569 | 0.72% | 0.02% |
| 69 | BENIGN NEOPLASM OF SKIN | 216 | 3627 | 4.61% | 0.16% |
| 70 | BENIGN NEOPLASM BREAST | 217 | 714 | 0.91% | 0.03% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1990
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2303450

A24

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | UTERINE LEIOMYOMA | 218 | 3140 | 3.99% | 0.14% |
| 72 | OTH BENIGN NEOPL UTERUS | 219 | 255 | 0.32% | 0.01% |
| 73 | BENIGN NEOPLASM OVARY | 220 | 195 | 0.25% | 0.01% |
| 74 | BEN NEOPL OTH FEM GENIT | 221 | 84 | 0.11% | 0.00% |
| 75 | BENIGN NEOPL MALE GENIT | 222 | 108 | 0.14% | 0.00% |
| 76 | BENIGN NEOPLASM URINARY | 223 | 158 | 0.20% | 0.01% |
| 77 | BENIGN NEOPLASM OF EYE | 224 | 107 | 0.14% | 0.00% |
| 78 | BENIGN NEOPL NERV SYST | 225 | 489 | 0.62% | 0.02% |
| 79 | BENIGN NEOPLASM THYROID | 226 | 162 | 0.21% | 0.01% |
| 80 | BEN NEOPL OTH ENDOCRINE | 227 | 191 | 0.24% | 0.01% |
| 81 | HEMANGIOMA/LYMPHANGIOMA | 228 | 466 | 0.59% | 0.02% |
| 82 | BENIGN NEOPLASM NEC/NOS | 229 | 641 | 0.81% | 0.03% |
| 83 | CA IN SITU DIGESTIVE ORG | 230 | 358 | 0.45% | 0.02% |
| 84 | CA IN SITU RESPIRATORY | 231 | 377 | 0.48% | 0.02% |
| 85 | CARCINOMA IN SITU SKIN | 232 | 376 | 0.48% | 0.02% |
| 86 | CA IN SITU BREAST/GU | 233 | 1287 | 1.63% | 0.06% |
| 87 | CA IN SITU NEC/NOS | 234 | 292 | 0.37% | 0.01% |
| 88 | UNC BEHAV NEOPL GI/RESP | 235 | 515 | 0.65% | 0.02% |
| 89 | UNC BEHAV NEOPL GU | 236 | 351 | 0.45% | 0.02% |
| 90 | UNC NEOPL ENDOCR/NERV | 237 | 424 | 0.54% | 0.02% |
| 91 | UNC BEHAV NEOPL NEC/NOS | 238 | 1324 | 1.68% | 0.06% |
| 92 | UNSPECIFIED NEOPLASM | 239 | 8642 | 10.97% | 0.38% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1991
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2319445

A25

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 74 | 0.08% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 394 | 0.41% | 0.02% |
| 3 | MAL NEOPL MAJOR SG | 142 | 113 | 0.12% | 0.00% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 48 | 0.05% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 108 | 0.11% | 0.00% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 308 | 0.32% | 0.01% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 218 | 0.23% | 0.01% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 178 | 0.19% | 0.01% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 142 | 0.15% | 0.01% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 244 | 0.25% | 0.01% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 548 | 0.57% | 0.02% |
| 12 | MAL NEOPL STOMACH | 151 | 495 | 0.52% | 0.02% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 103 | 0.11% | 0.00% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 2771 | 2.89% | 0.12% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 2306 | 2.40% | 0.10% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 527 | 0.55% | 0.02% |
| 17 | MAL NEOPL GB/BD | 156 | 121 | 0.13% | 0.01% |
| 18 | MAL NEOPL PANCREAS | 157 | 572 | 0.60% | 0.02% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 96 | 0.10% | 0.00% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 163 | 0.17% | 0.01% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 123 | 0.13% | 0.01% |
| 22 | MAL NEOPL LARYNX | 161 | 826 | 0.86% | 0.04% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 6713 | 6.99% | 0.29% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 57 | 0.06% | 0.00% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 125 | 0.13% | 0.01% |
| 26 | MAL NEOPL RESP NEC | 165 | 33 | 0.03% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 881 | 0.92% | 0.04% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 707 | 0.74% | 0.03% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 956 | 1.00% | 0.04% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 3109 | 3.24% | 0.13% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 9892 | 10.30% | 0.43% |
| 32 | MAL NEOPL MALE BREAST | 175 | 57 | 0.06% | 0.00% |
| 33 | MAL NEOPL UTERUS NOS | 179 | 243 | 0.25% | 0.01% |
| 34 | MAL NEOPL CERVIX UTERI | 180 | 989 | 1.03% | 0.04% |
| 35 | MALIGNANT NEOPL PLACENTA | 181 | 12 | 0.01% | 0.00% |
| 36 | MAL NEOPL UTERUS BODY | 182 | 587 | 0.61% | 0.03% |
| 37 | MAL NEOPL UTERINE ADNEXA | 183 | 1240 | 1.29% | 0.05% |
| 38 | MAL NEOPL FE GENIT NEC | 184 | 215 | 0.22% | 0.01% |
| 39 | MAL NEOPL PROSTATE | 185 | 2047 | 2.13% | 0.09% |
| 40 | MAL NEOPL TESTIS | 186 | 117 | 0.12% | 0.01% |
| 41 | MAL NEOPL MALE GENIT NEC | 187 | 81 | 0.08% | 0.00% |
| 42 | MAL NEOPL BLADDER | 188 | 1699 | 1.77% | 0.07% |
| 43 | MAL GU NEOPL NEC/NOS | 189 | 1011 | 1.05% | 0.04% |
| 44 | MALIGNANT NEOPLASM EYE | 190 | 254 | 0.26% | 0.01% |
| 45 | MALIGNANT NEOPLASM BRAIN | 191 | 1817 | 1.89% | 0.08% |
| 46 | MAL NEOPL NERVE NEC/NOS | 192 | 174 | 0.18% | 0.01% |
| 47 | MALIGNANT NEOPL THYROID | 193 | 415 | 0.43% | 0.02% |
| 48 | MAL NEOPL ENDOCRINE NEC | 194 | 349 | 0.36% | 0.02% |
| 49 | MAL NEOPL ILL-DEF SITES | 195 | 1277 | 1.33% | 0.06% |
| 50 | SECONDARY MAL NEOPL LN | 196 | 441 | 0.46% | 0.02% |
| 51 | 2ND MAL NEOPLASM GI/RESP | 197 | 1215 | 1.27% | 0.05% |
| 52 | 2ND MAL NEOPL OTH SITES | 198 | 2140 | 2.23% | 0.09% |
| 53 | MALIGNANT NEOPLASM NOS | 199 | 3879 | 4.04% | 0.17% |
| 54 | LYMPHOSARC/RETICULOSARC | 200 | 562 | 0.59% | 0.02% |
| 55 | HODGKIN'S DISEASE | 201 | 807 | 0.84% | 0.03% |
| 56 | OTH MAL NEOPL LYMPH/HIST | 202 | 2198 | 2.29% | 0.09% |
| 57 | MULTIPLE MYELOMA ET AL | 203 | 394 | 0.41% | 0.02% |
| 58 | LYMPHOID LEUKEMIA | 204 | 870 | 0.91% | 0.04% |
| 59 | MYELOID LEUKEMIA | 205 | 506 | 0.53% | 0.02% |
| 60 | MONOCYTIC LEUKEMIA | 206 | 53 | 0.06% | 0.00% |
| 61 | OTHER SPECIFIED LEUKEMIA | 207 | 41 | 0.04% | 0.00% |
| 62 | LEUKEMIA-UNSPECIF CELL | 208 | 884 | 0.92% | 0.04% |
| 63 | BEN NEOPL MOUTH/PHARYNX | 210 | 328 | 0.34% | 0.01% |
| 64 | OTH BENIGN NEOPLASM GI | 211 | 3538 | 3.68% | 0.15% |
| 65 | BEN INTRATHOR NEOPLASM | 212 | 468 | 0.49% | 0.02% |
| 66 | BEN NEOPLASM BONE/CART | 213 | 492 | 0.51% | 0.02% |
| 67 | LIPOMA | 214 | 984 | 1.02% | 0.04% |
| 68 | OTH BEN NEOPL SOFT TISS | 215 | 573 | 0.60% | 0.02% |
| 69 | BENIGN NEOPLASM OF SKIN | 216 | 4420 | 4.60% | 0.19% |
| 70 | BENIGN NEOPLASM BREAST | 217 | 855 | 0.89% | 0.04% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1991
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2319445

A26

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | UTERINE LEIOMYOMA | 218 | 3769 | 3.92% | 0.16% |
| 72 | OTH BENIGN NEOPL UTERUS | 219 | 275 | 0.29% | 0.01% |
| 73 | BENIGN NEOPLASM OVARY | 220 | 222 | 0.23% | 0.01% |
| 74 | BEN NEOPL OTH FEM GENIT | 221 | 152 | 0.16% | 0.01% |
| 75 | BENIGN NEOPL MALE GENIT | 222 | 138 | 0.14% | 0.01% |
| 76 | BENIGN NEOPLASM URINARY | 223 | 168 | 0.17% | 0.01% |
| 77 | BENIGN NEOPLASM OF EYE | 224 | 158 | 0.16% | 0.01% |
| 78 | BENIGN NEOPL NERV SYST | 225 | 660 | 0.69% | 0.03% |
| 79 | BENIGN NEOPLASM THYROID | 226 | 159 | 0.17% | 0.01% |
| 80 | BEN NEOPL OTH ENDOCRINE | 227 | 268 | 0.28% | 0.01% |
| 81 | HEMANGIOMA/LYMPHANGIOMA | 228 | 584 | 0.61% | 0.03% |
| 82 | BENIGN NEOPLASM NEC/NOS | 229 | 695 | 0.72% | 0.03% |
| 83 | CA IN SITU DIGESTIVE ORG | 230 | 495 | 0.52% | 0.02% |
| 84 | CA IN SITU RESPIRATORY | 231 | 527 | 0.55% | 0.02% |
| 85 | CARCINOMA IN SITU SKIN | 232 | 592 | 0.62% | 0.03% |
| 86 | CA IN SITU BREAST/GU | 233 | 1633 | 1.70% | 0.07% |
| 87 | CA IN SITU NEC/NOS | 234 | 385 | 0.40% | 0.02% |
| 88 | UNC BEHAV NEOPL GI/RESP | 235 | 602 | 0.63% | 0.03% |
| 89 | UNC BEHAV NEOPL GU | 236 | 509 | 0.53% | 0.02% |
| 90 | UNC NEOPL ENDOCR/NERV | 237 | 569 | 0.59% | 0.02% |
| 91 | UNC BEHAV NEOPL NEC/NOS | 238 | 2020 | 2.10% | 0.09% |
| 92 | UNSPECIFIED NEOPLASM | 239 | 10275 | 10.70% | 0.44% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1992
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2182878

A27

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 54 | 0.06% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 392 | 0.41% | 0.02% |
| 3 | MAL NEOPL MAJOR SG | 142 | 105 | 0.11% | 0.00% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 34 | 0.04% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 125 | 0.13% | 0.01% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 285 | 0.30% | 0.01% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 240 | 0.25% | 0.01% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 178 | 0.19% | 0.01% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 134 | 0.14% | 0.01% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 249 | 0.26% | 0.01% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 500 | 0.53% | 0.02% |
| 12 | MAL NEOPL STOMACH | 151 | 480 | 0.51% | 0.02% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 96 | 0.10% | 0.00% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 2799 | 2.95% | 0.13% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 2228 | 2.35% | 0.10% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 572 | 0.60% | 0.03% |
| 17 | MAL NEOPL GB/BD | 156 | 108 | 0.11% | 0.00% |
| 18 | MAL NEOPL PANCREAS | 157 | 579 | 0.61% | 0.03% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 79 | 0.08% | 0.00% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 143 | 0.15% | 0.01% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 122 | 0.13% | 0.01% |
| 22 | MAL NEOPL LARYNX | 161 | 819 | 0.86% | 0.04% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 6793 | 7.17% | 0.31% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 76 | 0.08% | 0.00% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 108 | 0.11% | 0.00% |
| 26 | MAL NEOPL RESP NEC | 165 | 31 | 0.03% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 853 | 0.90% | 0.04% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 725 | 0.77% | 0.03% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 955 | 1.01% | 0.04% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 3026 | 3.19% | 0.14% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 10385 | 10.96% | 0.48% |
| 32 | MAL NEOPL MALE BREAST | 175 | 55 | 0.06% | 0.00% |
| 33 | KAPOSI'S SARCOMA | 176 | 12 | 0.01% | 0.00% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 223 | 0.24% | 0.01% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 1013 | 1.07% | 0.05% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 9 | 0.01% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 594 | 0.63% | 0.03% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 1273 | 1.34% | 0.06% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 191 | 0.20% | 0.01% |
| 40 | MAL NEOPL PROSTATE | 185 | 2815 | 2.97% | 0.13% |
| 41 | MAL NEOPL TESTIS | 186 | 136 | 0.14% | 0.01% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 54 | 0.06% | 0.00% |
| 43 | MAL NEOPL BLADDER | 188 | 1682 | 1.78% | 0.08% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 978 | 1.03% | 0.04% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 265 | 0.28% | 0.01% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 1722 | 1.82% | 0.08% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 192 | 0.20% | 0.01% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 417 | 0.44% | 0.02% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 299 | 0.32% | 0.01% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 1236 | 1.30% | 0.06% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 449 | 0.47% | 0.02% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 1211 | 1.28% | 0.06% |
| 53 | 2ND MAL NEOPL OTH SITES | 198 | 2095 | 2.21% | 0.10% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 3506 | 3.70% | 0.16% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 430 | 0.45% | 0.02% |
| 56 | HODGKIN'S DISEASE | 201 | 586 | 0.62% | 0.03% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 1771 | 1.87% | 0.08% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 415 | 0.44% | 0.02% |
| 59 | LYMPHOID LEUKEMIA | 204 | 901 | 0.95% | 0.04% |
| 60 | MYELOID LEUKEMIA | 205 | 488 | 0.52% | 0.02% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 63 | 0.07% | 0.00% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 31 | 0.03% | 0.00% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 817 | 0.86% | 0.04% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 362 | 0.38% | 0.02% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 3758 | 3.97% | 0.17% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 472 | 0.50% | 0.02% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 521 | 0.55% | 0.02% |
| 68 | LIPOMA | 214 | 935 | 0.99% | 0.04% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 617 | 0.65% | 0.03% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 4262 | 4.50% | 0.20% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1992
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2182878

A28

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 773 | 0.82% | 0.04% |
| 72 | UTERINE LEIOMYOMA | 218 | 3753 | 3.96% | 0.17% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 293 | 0.31% | 0.01% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 195 | 0.21% | 0.01% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 153 | 0.16% | 0.01% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 182 | 0.19% | 0.01% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 172 | 0.18% | 0.01% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 120 | 0.13% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 683 | 0.72% | 0.03% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 175 | 0.18% | 0.01% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 239 | 0.25% | 0.01% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 570 | 0.60% | 0.03% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 635 | 0.67% | 0.03% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 463 | 0.49% | 0.02% |
| 85 | CA IN SITU RESPIRATORY | 231 | 442 | 0.47% | 0.02% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 502 | 0.53% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 1713 | 1.81% | 0.08% |
| 88 | CA IN SITU NEC/NOS | 234 | 292 | 0.31% | 0.01% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 670 | 0.71% | 0.03% |
| 90 | UNC BEHAV NEOPL GU | 236 | 557 | 0.59% | 0.03% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 560 | 0.59% | 0.03% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 2242 | 2.37% | 0.10% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 9214 | 9.73% | 0.42% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1993
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2110066

A29

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 45 | 0.05% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 379 | 0.39% | 0.02% |
| 3 | MAL NEOPL MAJOR SG | 142 | 108 | 0.11% | 0.01% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 32 | 0.03% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 110 | 0.11% | 0.01% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 313 | 0.32% | 0.01% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 273 | 0.28% | 0.01% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 163 | 0.17% | 0.01% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 128 | 0.13% | 0.01% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 235 | 0.24% | 0.01% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 559 | 0.57% | 0.03% |
| 12 | MAL NEOPL STOMACH | 151 | 451 | 0.46% | 0.02% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 95 | 0.10% | 0.00% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 2949 | 3.03% | 0.14% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 2348 | 2.41% | 0.11% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 574 | 0.59% | 0.03% |
| 17 | MAL NEOPL GB/BD | 156 | 116 | 0.12% | 0.01% |
| 18 | MAL NEOPL PANCREAS | 157 | 536 | 0.55% | 0.03% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 78 | 0.08% | 0.00% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 149 | 0.15% | 0.01% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 117 | 0.12% | 0.01% |
| 22 | MAL NEOPL LARYNX | 161 | 779 | 0.80% | 0.04% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 6904 | 7.10% | 0.33% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 62 | 0.06% | 0.00% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 102 | 0.10% | 0.00% |
| 26 | MAL NEOPL RESP NEC | 165 | 32 | 0.03% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 791 | 0.81% | 0.04% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 667 | 0.69% | 0.03% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 959 | 0.99% | 0.05% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 2934 | 3.02% | 0.14% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 10780 | 11.08% | 0.51% |
| 32 | MAL NEOPL MALE BREAST | 175 | 46 | 0.05% | 0.00% |
| 33 | KAPOSI'S SARCOMA | 176 | 20 | 0.02% | 0.00% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 207 | 0.21% | 0.01% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 1034 | 1.06% | 0.05% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 12 | 0.01% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 635 | 0.65% | 0.03% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 1275 | 1.31% | 0.06% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 187 | 0.19% | 0.01% |
| 40 | MAL NEOPL PROSTATE | 185 | 3414 | 3.51% | 0.16% |
| 41 | MAL NEOPL TESTIS | 186 | 136 | 0.14% | 0.01% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 46 | 0.05% | 0.00% |
| 43 | MAL NEOPL BLADDER | 188 | 1724 | 1.77% | 0.08% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 1031 | 1.06% | 0.05% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 238 | 0.24% | 0.01% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 1766 | 1.82% | 0.08% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 189 | 0.19% | 0.01% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 437 | 0.45% | 0.02% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 306 | 0.31% | 0.01% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 1090 | 1.12% | 0.05% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 423 | 0.43% | 0.02% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 1237 | 1.27% | 0.06% |
| 53 | 2ND MAL NEOPL OTH SITES | 198 | 2241 | 2.30% | 0.11% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 3244 | 3.33% | 0.15% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 628 | 0.65% | 0.03% |
| 56 | HODGKIN'S DISEASE | 201 | 864 | 0.89% | 0.04% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 2572 | 2.64% | 0.12% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 681 | 0.70% | 0.03% |
| 59 | LYMPHOID LEUKEMIA | 204 | 1334 | 1.37% | 0.06% |
| 60 | MYELOID LEUKEMIA | 205 | 688 | 0.71% | 0.03% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 72 | 0.07% | 0.00% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 31 | 0.03% | 0.00% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 956 | 0.98% | 0.05% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 384 | 0.39% | 0.02% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 4106 | 4.22% | 0.19% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 438 | 0.45% | 0.02% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 486 | 0.50% | 0.02% |
| 68 | LIPOMA | 214 | 926 | 0.95% | 0.04% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 515 | 0.53% | 0.02% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 4375 | 4.50% | 0.21% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1993
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2110066

A30

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 663 | 0.68% | 0.03% |
| 72 | UTERINE LEIOMYOMA | 218 | 3469 | 3.57% | 0.16% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 310 | 0.32% | 0.01% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 199 | 0.20% | 0.01% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 134 | 0.14% | 0.01% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 195 | 0.20% | 0.01% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 210 | 0.22% | 0.01% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 130 | 0.13% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 676 | 0.69% | 0.03% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 165 | 0.17% | 0.01% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 261 | 0.27% | 0.01% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 606 | 0.62% | 0.03% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 551 | 0.57% | 0.03% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 460 | 0.47% | 0.02% |
| 85 | CA IN SITU RESPIRATORY | 231 | 432 | 0.44% | 0.02% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 351 | 0.36% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 1739 | 1.79% | 0.08% |
| 88 | CA IN SITU NEC/NOS | 234 | 275 | 0.28% | 0.01% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 707 | 0.73% | 0.03% |
| 90 | UNC BEHAV NEOPL GU | 236 | 613 | 0.63% | 0.03% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 606 | 0.62% | 0.03% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 2331 | 2.40% | 0.11% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 8448 | 8.68% | 0.40% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1994
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2087951

A31

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 63 | 0.06% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 405 | 0.40% | 0.02% |
| 3 | MAL NEOPL MAJOR SG | 142 | 111 | 0.11% | 0.01% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 31 | 0.03% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 128 | 0.13% | 0.01% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 311 | 0.31% | 0.01% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 256 | 0.25% | 0.01% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 182 | 0.18% | 0.01% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 125 | 0.12% | 0.01% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 242 | 0.24% | 0.01% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 596 | 0.59% | 0.03% |
| 12 | MAL NEOPL STOMACH | 151 | 524 | 0.52% | 0.03% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 93 | 0.09% | 0.00% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 3238 | 3.21% | 0.16% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 2480 | 2.46% | 0.12% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 572 | 0.57% | 0.03% |
| 17 | MAL NEOPL GB/BD | 156 | 142 | 0.14% | 0.01% |
| 18 | MAL NEOPL PANCREAS | 157 | 556 | 0.55% | 0.03% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 116 | 0.12% | 0.01% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 130 | 0.13% | 0.01% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 127 | 0.13% | 0.01% |
| 22 | MAL NEOPL LARYNX | 161 | 765 | 0.76% | 0.04% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 7137 | 7.08% | 0.34% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 65 | 0.06% | 0.00% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 99 | 0.10% | 0.00% |
| 26 | MAL NEOPL RESP NEC | 165 | 33 | 0.03% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 778 | 0.77% | 0.04% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 721 | 0.71% | 0.03% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 977 | 0.97% | 0.05% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 3199 | 3.17% | 0.15% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 11692 | 11.59% | 0.56% |
| 32 | MAL NEOPL MALE BREAST | 175 | 46 | 0.05% | 0.00% |
| 33 | KAPOSI'S SARCOMA | 176 | 11 | 0.01% | 0.00% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 237 | 0.23% | 0.01% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 1063 | 1.05% | 0.05% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 11 | 0.01% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 689 | 0.68% | 0.03% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 1370 | 1.36% | 0.07% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 189 | 0.19% | 0.01% |
| 40 | MAL NEOPL PROSTATE | 185 | 3823 | 3.79% | 0.18% |
| 41 | MAL NEOPL TESTIS | 186 | 138 | 0.14% | 0.01% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 52 | 0.05% | 0.00% |
| 43 | MAL NEOPL BLADDER | 188 | 1874 | 1.86% | 0.09% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 986 | 0.98% | 0.05% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 254 | 0.25% | 0.01% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 1866 | 1.85% | 0.09% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 211 | 0.21% | 0.01% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 470 | 0.47% | 0.02% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 297 | 0.29% | 0.01% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 1074 | 1.06% | 0.05% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 460 | 0.46% | 0.02% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 1328 | 1.32% | 0.06% |
| 53 | 2ND MAL NEOPL OTH SITES | 198 | 2196 | 2.18% | 0.11% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 3110 | 3.08% | 0.15% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 529 | 0.52% | 0.03% |
| 56 | HODGKIN'S DISEASE | 201 | 746 | 0.74% | 0.04% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 2188 | 2.17% | 0.10% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 541 | 0.54% | 0.03% |
| 59 | LYMPHOID LEUKEMIA | 204 | 1111 | 1.10% | 0.05% |
| 60 | MYELOID LEUKEMIA | 205 | 648 | 0.64% | 0.03% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 58 | 0.06% | 0.00% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 22 | 0.02% | 0.00% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 870 | 0.86% | 0.04% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 454 | 0.45% | 0.02% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 4451 | 4.41% | 0.21% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 463 | 0.46% | 0.02% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 451 | 0.45% | 0.02% |
| 68 | LIPOMA | 214 | 1001 | 0.99% | 0.05% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 531 | 0.53% | 0.03% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 4321 | 4.28% | 0.21% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1994
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2087951

A32

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 613 | 0.61% | 0.03% |
| 72 | UTERINE LEIOMYOMA | 218 | 3600 | 3.57% | 0.17% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 383 | 0.38% | 0.02% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 183 | 0.18% | 0.01% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 138 | 0.14% | 0.01% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 224 | 0.22% | 0.01% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 229 | 0.23% | 0.01% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 142 | 0.14% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 743 | 0.74% | 0.04% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 158 | 0.16% | 0.01% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 286 | 0.28% | 0.01% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 635 | 0.63% | 0.03% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 533 | 0.53% | 0.03% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 498 | 0.49% | 0.02% |
| 85 | CA IN SITU RESPIRATORY | 231 | 506 | 0.50% | 0.02% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 376 | 0.37% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 1887 | 1.87% | 0.09% |
| 88 | CA IN SITU NEC/NOS | 234 | 239 | 0.24% | 0.01% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 792 | 0.79% | 0.04% |
| 90 | UNC BEHAV NEOPL GU | 236 | 734 | 0.73% | 0.04% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 643 | 0.64% | 0.03% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 2649 | 2.63% | 0.13% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 8634 | 8.56% | 0.41% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1995
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2032367

A33

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 68 | 0.08% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 360 | 0.40% | 0.02% |
| 3 | MAL NEOPL MAJOR SG | 142 | 87 | 0.10% | 0.00% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 27 | 0.03% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 114 | 0.13% | 0.01% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 273 | 0.30% | 0.01% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 265 | 0.30% | 0.01% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 159 | 0.18% | 0.01% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 128 | 0.14% | 0.01% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 214 | 0.24% | 0.01% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 518 | 0.58% | 0.03% |
| 12 | MAL NEOPL STOMACH | 151 | 481 | 0.54% | 0.02% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 77 | 0.09% | 0.00% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 2996 | 3.34% | 0.15% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 2182 | 2.43% | 0.11% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 542 | 0.60% | 0.03% |
| 17 | MAL NEOPL GB/BD | 156 | 127 | 0.14% | 0.01% |
| 18 | MAL NEOPL PANCREAS | 157 | 475 | 0.53% | 0.02% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 88 | 0.10% | 0.00% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 121 | 0.13% | 0.01% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 124 | 0.14% | 0.01% |
| 22 | MAL NEOPL LARYNX | 161 | 725 | 0.81% | 0.04% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 6214 | 6.93% | 0.31% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 61 | 0.07% | 0.00% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 94 | 0.10% | 0.00% |
| 26 | MAL NEOPL RESP NEC | 165 | 23 | 0.03% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 693 | 0.77% | 0.03% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 647 | 0.72% | 0.03% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 828 | 0.92% | 0.04% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 2797 | 3.12% | 0.14% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 11170 | 12.45% | 0.55% |
| 32 | MAL NEOPL MALE BREAST | 175 | 58 | 0.06% | 0.00% |
| 33 | KAPOSI'S SARCOMA | 176 | 17 | 0.02% | 0.00% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 246 | 0.27% | 0.01% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 916 | 1.02% | 0.05% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 5 | 0.01% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 675 | 0.75% | 0.03% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 1243 | 1.39% | 0.06% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 166 | 0.19% | 0.01% |
| 40 | MAL NEOPL PROSTATE | 185 | 3848 | 4.29% | 0.19% |
| 41 | MAL NEOPL TESTIS | 186 | 149 | 0.17% | 0.01% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 46 | 0.05% | 0.00% |
| 43 | MAL NEOPL BLADDER | 188 | 1666 | 1.86% | 0.08% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 939 | 1.05% | 0.05% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 238 | 0.27% | 0.01% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 1683 | 1.88% | 0.08% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 168 | 0.19% | 0.01% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 500 | 0.56% | 0.02% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 261 | 0.29% | 0.01% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 892 | 0.99% | 0.04% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 425 | 0.47% | 0.02% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 1288 | 1.44% | 0.06% |
| 53 | 2ND MAL NEOPL OTH SITES | 198 | 2055 | 2.29% | 0.10% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 2538 | 2.83% | 0.12% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 517 | 0.58% | 0.03% |
| 56 | HODGKIN'S DISEASE | 201 | 607 | 0.68% | 0.03% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 2016 | 2.25% | 0.10% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 474 | 0.53% | 0.02% |
| 59 | LYMPHOID LEUKEMIA | 204 | 964 | 1.07% | 0.05% |
| 60 | MYELOID LEUKEMIA | 205 | 549 | 0.61% | 0.03% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 38 | 0.04% | 0.00% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 16 | 0.02% | 0.00% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 699 | 0.78% | 0.03% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 364 | 0.41% | 0.02% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 3895 | 4.34% | 0.19% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 386 | 0.43% | 0.02% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 375 | 0.42% | 0.02% |
| 68 | LIPOMA | 214 | 881 | 0.98% | 0.04% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 463 | 0.52% | 0.02% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 3890 | 4.34% | 0.19% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1995
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2032367

A34

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 607 | 0.68% | 0.03% |
| 72 | UTERINE LEIOMYOMA | 218 | 2798 | 3.12% | 0.14% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 319 | 0.36% | 0.02% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 183 | 0.20% | 0.01% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 123 | 0.14% | 0.01% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 184 | 0.21% | 0.01% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 183 | 0.20% | 0.01% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 145 | 0.16% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 714 | 0.80% | 0.04% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 192 | 0.21% | 0.01% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 259 | 0.29% | 0.01% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 523 | 0.58% | 0.03% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 475 | 0.53% | 0.02% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 446 | 0.50% | 0.02% |
| 85 | CA IN SITU RESPIRATORY | 231 | 419 | 0.47% | 0.02% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 308 | 0.34% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 1557 | 1.74% | 0.08% |
| 88 | CA IN SITU NEC/NOS | 234 | 157 | 0.17% | 0.01% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 690 | 0.77% | 0.03% |
| 90 | UNC BEHAV NEOPL GU | 236 | 611 | 0.68% | 0.03% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 509 | 0.57% | 0.03% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 2514 | 2.80% | 0.12% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 6971 | 7.77% | 0.34% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1996
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1979137

A35

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 1 | MALIGNANT NEOPLASM LIP | 140 | 51 | 0.06% | 0.00% |
| 2 | MALIGNANT NEOPL TONGUE | 141 | 365 | 0.41% | 0.02% |
| 3 | MAL NEOPL MAJOR SG | 142 | 86 | 0.10% | 0.00% |
| 4 | MALIGNANT NEOPLASM GUM | 143 | 30 | 0.03% | 0.00% |
| 5 | MAL NEOPLASM FLOOR MOUTH | 144 | 115 | 0.13% | 0.01% |
| 6 | MAL NEOPL MOUTH NEC/NOS | 145 | 244 | 0.27% | 0.01% |
| 7 | MAL NEOPLASM OROPHARYNX | 146 | 222 | 0.25% | 0.01% |
| 8 | MAL NEOPLASM NASOPHARYNX | 147 | 158 | 0.18% | 0.01% |
| 9 | MAL NEOPL HYPOPHARYNX | 148 | 118 | 0.13% | 0.01% |
| 10 | OTH MAL NEOPL OROPHARYNX | 149 | 193 | 0.21% | 0.01% |
| 11 | MAL NEOPL ESOPHAGUS | 150 | 541 | 0.60% | 0.03% |
| 12 | MAL NEOPL STOMACH | 151 | 509 | 0.57% | 0.03% |
| 13 | MAL NEOPL SMALL BOWEL | 152 | 86 | 0.10% | 0.00% |
| 14 | MALIGNANT NEOPLASM COLON | 153 | 2935 | 3.26% | 0.15% |
| 15 | MAL NEOPL RECTUM/ANUS | 154 | 2145 | 2.38% | 0.11% |
| 16 | MALIGNANT NEOPLASM LIVER | 155 | 528 | 0.59% | 0.03% |
| 17 | MAL NEOPL GB/BD | 156 | 120 | 0.13% | 0.01% |
| 18 | MAL NEOPL PANCREAS | 157 | 539 | 0.60% | 0.03% |
| 19 | MAL NEOPLASM PERITONEUM | 158 | 102 | 0.11% | 0.01% |
| 20 | OTH DIGEST MAL NEOPL | 159 | 112 | 0.12% | 0.01% |
| 21 | MAL NEOPL NOSE/ME/SINUS | 160 | 132 | 0.15% | 0.01% |
| 22 | MAL NEOPL LARYNX | 161 | 647 | 0.72% | 0.03% |
| 23 | MAL NEOPL TRACHEA/LUNG | 162 | 6281 | 6.98% | 0.32% |
| 24 | MALIGNANT NEOPL PLEURA | 163 | 80 | 0.09% | 0.00% |
| 25 | MAL NEOPL THYMUS/MEDIAST | 164 | 108 | 0.12% | 0.01% |
| 26 | MAL NEOPL RESP NEC | 165 | 28 | 0.03% | 0.00% |
| 27 | MAL NEOPL BONE/CART | 170 | 670 | 0.74% | 0.03% |
| 28 | MAL NEOPL SOFT TISSUE | 171 | 729 | 0.81% | 0.04% |
| 29 | MALIGNANT MELANOMA SKIN | 172 | 879 | 0.98% | 0.04% |
| 30 | OTHER MAL NEOPL SKIN | 173 | 2925 | 3.25% | 0.15% |
| 31 | MAL NEOPL FEMALE BREAST | 174 | 11500 | 12.78% | 0.58% |
| 32 | MAL NEOPL MALE BREAST | 175 | 42 | 0.05% | 0.00% |
| 33 | KAPOSI'S SARCOMA | 176 | 24 | 0.03% | 0.00% |
| 34 | MAL NEOPL UTERUS NOS | 179 | 252 | 0.28% | 0.01% |
| 35 | MAL NEOPL CERVIX UTERI | 180 | 934 | 1.04% | 0.05% |
| 36 | MALIGNANT NEOPL PLACENTA | 181 | 6 | 0.01% | 0.00% |
| 37 | MAL NEOPL UTERUS BODY | 182 | 675 | 0.75% | 0.03% |
| 38 | MAL NEOPL UTERINE ADNEXA | 183 | 1263 | 1.40% | 0.06% |
| 39 | MAL NEOPL FE GENIT NEC | 184 | 170 | 0.19% | 0.01% |
| 40 | MAL NEOPL PROSTATE | 185 | 3888 | 4.32% | 0.20% |
| 41 | MAL NEOPL TESTIS | 186 | 121 | 0.13% | 0.01% |
| 42 | MAL NEOPL MALE GENIT NEC | 187 | 48 | 0.05% | 0.00% |
| 43 | MAL NEOPL BLADDER | 188 | 1618 | 1.80% | 0.08% |
| 44 | MAL GU NEOPL NEC/NOS | 189 | 983 | 1.09% | 0.05% |
| 45 | MALIGNANT NEOPLASM EYE | 190 | 210 | 0.23% | 0.01% |
| 46 | MALIGNANT NEOPLASM BRAIN | 191 | 1627 | 1.81% | 0.08% |
| 47 | MAL NEOPL NERVE NEC/NOS | 192 | 178 | 0.20% | 0.01% |
| 48 | MALIGNANT NEOPL THYROID | 193 | 497 | 0.55% | 0.03% |
| 49 | MAL NEOPL ENDOCRINE NEC | 194 | 245 | 0.27% | 0.01% |
| 50 | MAL NEOPL ILL-DEF SITES | 195 | 921 | 1.02% | 0.05% |
| 51 | SECONDARY MAL NEOPL LN | 196 | 463 | 0.51% | 0.02% |
| 52 | 2ND MAL NEOPLASM GI/RESP | 197 | 1279 | 1.42% | 0.06% |
| 53 | 2ND MAL NEOPL OTH RES | 198 | 2095 | 2.33% | 0.11% |
| 54 | MALIGNANT NEOPLASM NOS | 199 | 2321 | 2.58% | 0.12% |
| 55 | LYMPHOSARC/RETICULOSARC | 200 | 538 | 0.60% | 0.03% |
| 56 | HODGKIN'S DISEASE | 201 | 621 | 0.69% | 0.03% |
| 57 | OTH MAL NEOPL LYMPH/HIST | 202 | 2136 | 2.37% | 0.11% |
| 58 | MULTIPLE MYELOMA ET AL | 203 | 463 | 0.51% | 0.02% |
| 59 | LYMPHOID LEUKEMIA | 204 | 1005 | 1.12% | 0.05% |
| 60 | MYELOID LEUKEMIA | 205 | 569 | 0.63% | 0.03% |
| 61 | MONOCYTIC LEUKEMIA | 206 | 46 | 0.05% | 0.00% |
| 62 | OTHER SPECIFIED LEUKEMIA | 207 | 18 | 0.02% | 0.00% |
| 63 | LEUKEMIA-UNSPECIF CELL | 208 | 640 | 0.71% | 0.03% |
| 64 | BEN NEOPL MOUTH/PHARYNX | 210 | 330 | 0.37% | 0.02% |
| 65 | OTH BENIGN NEOPLASM GI | 211 | 4208 | 4.68% | 0.21% |
| 66 | BEN INTRATHOR NEOPLASM | 212 | 427 | 0.47% | 0.02% |
| 67 | BEN NEOPLASM BONE/CART | 213 | 321 | 0.36% | 0.02% |
| 68 | LIPOMA | 214 | 792 | 0.88% | 0.04% |
| 69 | OTH BEN NEOPL SOFT TISS | 215 | 414 | 0.46% | 0.02% |
| 70 | BENIGN NEOPLASM OF SKIN | 216 | 3828 | 4.25% | 0.19% |

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1996
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1979137

A36

| OBS | ICD9DX Name | ICD9DX | Frequency | Percent | Prevalence |
|-----|--------------------------|--------|-----------|---------|------------|
| 71 | BENIGN NEOPLASM BREAST | 217 | 631 | 0.70% | 0.03% |
| 72 | UTERINE LEIOMYOMA | 218 | 2957 | 3.29% | 0.15% |
| 73 | OTH BENIGN NEOPL UTERUS | 219 | 285 | 0.32% | 0.01% |
| 74 | BENIGN NEOPLASM OVARY | 220 | 164 | 0.18% | 0.01% |
| 75 | BEN NEOPL OTH FEM GENIT | 221 | 135 | 0.15% | 0.01% |
| 76 | BENIGN NEOPL MALE GENIT | 222 | 196 | 0.22% | 0.01% |
| 77 | BENIGN NEOPLASM URINARY | 223 | 190 | 0.21% | 0.01% |
| 78 | BENIGN NEOPLASM OF EYE | 224 | 141 | 0.16% | 0.01% |
| 79 | BENIGN NEOPL NERV SYST | 225 | 752 | 0.84% | 0.04% |
| 80 | BENIGN NEOPLASM THYROID | 226 | 178 | 0.20% | 0.01% |
| 81 | BEN NEOPL OTH ENDOCRINE | 227 | 289 | 0.32% | 0.01% |
| 82 | HEMANGIOMA/LYMPHANGIOMA | 228 | 546 | 0.61% | 0.03% |
| 83 | BENIGN NEOPLASM NEC/NOS | 229 | 445 | 0.49% | 0.02% |
| 84 | CA IN SITU DIGESTIVE ORG | 230 | 408 | 0.45% | 0.02% |
| 85 | CA IN SITU RESPIRATORY | 231 | 375 | 0.42% | 0.02% |
| 86 | CARCINOMA IN SITU SKIN | 232 | 308 | 0.34% | 0.02% |
| 87 | CA IN SITU BREAST/GU | 233 | 1544 | 1.72% | 0.08% |
| 88 | CA IN SITU NEC/NOS | 234 | 151 | 0.17% | 0.01% |
| 89 | UNC BEHAV NEOPL GI/RESP | 235 | 793 | 0.88% | 0.04% |
| 90 | UNC BEHAV NEOPL GU | 236 | 613 | 0.68% | 0.03% |
| 91 | UNC NEOPL ENDOCR/NERV | 237 | 583 | 0.65% | 0.03% |
| 92 | UNC BEHAV NEOPL NEC/NOS | 238 | 2543 | 2.83% | 0.13% |
| 93 | UNSPECIFIED NEOPLASM | 239 | 6352 | 7.06% | 0.32% |